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Preventing the spread of blood-borne infectious diseases is vital to improving 
global health outcomes, particularly for low- and middle-income countries (LMICs). 
Sensitive and accurate diagnosis of infections is vital to this effort. Nucleic acid 
amplification tests (NAATs), which amplify pathogen nucleic acids, are gold-standard 
techniques for detection and quantification of pathogen levels. However, standard 
NAATs such as polymerase chain reaction (PCR) require expensive equipment for blood 
sample processing and DNA/RNA amplification, making them challenging to implement 
in resource-limited areas of LMICs. In this work, I developed two methods to simplify 
sample processing and amplification to make NAATs more accessible for use at the point 
of care in resource-limited areas of LMICs. 
The first method enables instrument-free nucleic acid extraction from whole 
blood. A room temperature lysis chemistry and a paper-and-plastic sample capture device 
were developed to isolate, purify, and store pathogen DNA and RNA on a paper capture 
membrane. Extracted nucleic acids can be eluted and used in standard NAATs or in 
developmental amplification assays. I demonstrated successful isolation of HIV virion 
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RNA and P. falciparum parasite DNA from whole blood samples over several 
concentrations with >60% recovery. Extracted RNA remains stable on the capture 
membrane for two weeks at room temperature and 37°C, alleviating the need for cold 
storage after sample collection. These results are a promising step toward using this 
method for simplified sample extraction and storage in low-resource settings in LMICs.  
The second method I developed is a novel isothermal amplification technique for 
P. falciparum DNA. Sensitive diagnosis of P. falciparum infection is vital to identify and 
treat low-density, asymptomatic infections and move closer to eliminating malaria. 
Highly sensitive PCR assays are difficult to deploy in resource-limited areas of LMICs 
and existing isothermal methods require complex assay design and are often not sensitive 
enough to diagnose asymptomatic infections. Here, I developed a novel isothermal 
technique which amplifies multiple regions of the P. falciparum genome, generating a 
large amount of DNA for better analytical sensitivity. The assay achieves a lower limit of 
detection of ~23.4 fg P. falciparum gDNA/µL (~1 parasite/µL) in 30 minutes, similar 
gold-standard PCR assay while using a fraction of the resources required for PCR.  
Lastly, I adapted the assay for implementation at the point of care. I showed that 
the assay directly amplifies P. falciparum parasite DNA captured on paper with the 
paper-and-plastic device previously developed. I also incorporated visual assay readout 
with lateral flow strips, eliminating the need for specialized equipment to detect 
amplified DNA. I explored methods to eliminate cold storage of reagents by stabilizing 
amplification enzymes at room temperature.   
 The work described in this thesis represents two enhanced methods for point of 
 
 x 
care detection of blood borne pathogens. By simplifying sample extraction, amplification, 
and detection, the methods described here make NAATs more accessible to low-resource 
areas of LMICs. The whole blood nucleic acid extraction device and isothermal assay 
described in this work can be used together for sensitive diagnosis of P. falciparum 
malaria. The methods can also be used independently, or in combination with other 
techniques routinely used in the field. The flexibility built in to these methods enables 
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CHAPTER ONE: INTRODUCTION 
1.1 Overarching goals and thesis aims: 
The purpose of this work was to develop novel methods to simplify the diagnosis 
of blood-borne pathogens in resource-limited settings. I developed a platform technology 
to extract nucleic acids from whole blood and a novel DNA amplification assay for P. 
falciparum malaria, both designed for use at the point of care.  
Specific Aim 1: Develop a paper-based platform for DNA and RNA extraction of 
blood-borne pathogens 
1.1 Development of a paper-based blood extraction device and demonstration with HIV 
RNA and P. falciparum DNA 
1.2 Extraction of HIV-1 virions and P. falciparum parasites from whole blood 
1.3 Demonstration of long-term HIV RNA stability on paper 
In collaboration with MakerHealth, LLC (Cambridge, MA, USA), I developed a 
flexible paper-and-plastic device to extract and purify nucleic acids from whole blood 
without the use of any laboratory equipment (Figure 3). I adapted lysis and precipitation 
chemistry previously developed in the Klapperich Lab, and I showed successful 
extraction of HIV-1 virion RNA and P. falciparum parasite DNA (Figure 5,Figure 8) 
using these disposable devices. Furthermore, I demonstrated extended stability of HIV 
RNA on paper (Figure 6) to show the applicability of this method for long-term sample 





Specific Aim 2: Develop and characterize a novel isothermal assay for P. falciparum 
malaria 
2.1 Development of a novel isothermal DNA amplification assay with comparable 
analytical sensitivity to PCR 
2.2 Demonstration with P. falciparum infected red blood cells in whole blood 
2.3 Assay characterization with next-generation sequencing 
Using a computational method developed by Jigsaw Biosolutions (Bangalore, 
India), to identify repeated primer sites in the malaria genome, I developed a novel 
isothermal amplification assay with a lower limit of detection of ~1 parasite/µL, a similar 
analytical sensitivity to PCR (Figure 45).  The assay uses a novel amplification scheme 
that is simpler than existing isothermal techniques (Figure 43).  I demonstrated the assay 
with several concentrations of P. falciparum parasite-infected red blood cells spiked into 
whole blood (Figure 46).  Next generation sequencing of the amplified products 
demonstrated specificity and helped to elaborate on the new amplification mechanism 
(Figure 48).  
Specific Aim 3: Adapting the novel isothermal assay to point-of-care 
3.1 Assay demonstration with paper-based extraction device from Aim 1 
3.2 On-paper isothermal amplification and visual readout with lateral flow strips 
3.3 Incorporation of dried amplification reagents 
The whole blood extraction device from Aim 1 was used to extract parasite DNA, 




27)—with the novel isothermal assay from Aim 2. The assay was adapted with antigen-
tagged primers and biotinylated dNTPS to enable visual readout with lateral flow strips 
(Figure 53).  I also explored various methods of drying and stabilizing enzymes at room 
temperature to further adapt the assay to the point of care (Figure 62). 
 
1.2 Nucleic acid amplification tests for infectious disease diagnosis 
Sensitive and accurate diagnostics are an important component to combatting the 
spread of infectious diseases. While several methods are available for disease diagnosis, 
molecular testing of pathogen-specific nucleic acids has emerged as one of the most 
reliable categories of diagnostics. Nucleic acid amplification tests (NAATs), for example, 
are widely used diagnostic tools [1].  Amplification and detection of trace amounts of 
pathogen nucleic acids in patient samples enables highly sensitive, quantitative diagnosis 
of infection.   
The most commonly used NAATs are polymerase chain reaction (PCR) for DNA 
amplification and reverse transcription PCR (RT-PCR) for RNA reverse transcription to 
complimentary DNA (cDNA) and cDNA amplification. In both assays, exponential 
replication of a target DNA or RNA sequence can produce millions of copies of the 
original sequence; the increased concentration of target copies can then be detected for 
specific diagnosis [2]. These techniques, which were originally developed in 1987, are 
the cornerstone of many molecular biology methods, and have strongly influenced both 
molecular biology research and disease diagnostics [3].  




reservoirs of disease in a population.  In these cases, the pathogen may be present in such 
low concentration that it does not produce symptoms, which can often mean that the 
infection is not detectable by more traditional clinical diagnosis. However, in many cases, 
even pathogens in low levels in the patient can be transmitted. Identifying, amplifying, 
and detecting trace pathogen nucleic acids can therefore enable accurate diagnosis, even 
in cases where patients do not experience symptoms. Furthermore, NAATs can be used 
to quantify pathogen loads in a patient, even at low infection levels. Quantitative PCR 
(qPCR) and RT PCR methods include fluorescent dyes to monitor real-time DNA 
amplification. Comparing unknown samples against a standard curve of known DNA 
concentration enables quantification of pathogen loads.  
While NAATs have been developed for many, if not most, infectious diseases, 
deploying these tests to resource-limited settings can be challenging. The need for 
expensive equipment, clean laboratory environments, cold storage for samples and for 
reagents, and trained personnel to perform the tests can restrict access to these assays. 
These requirements can be particularly limiting in resource-constrained areas of low- and 
middle-income countries (LMICs), where only a handful of testing facilities across the 
country may be equipped to perform NAATs, thereby limiting testing access to patients 
in more remote areas across the country.  
Three main steps are broadly required for traditional DNA and RNA amplification tests:  
1) Extraction of nucleic acids from patient samples (i.e. whole blood, saliva, 
urine, etc.) 




3) Detection of amplified products (for example, real time amplification 
detection for quantitative diagnosis, or end-point product detection with gel 
electrophoresis or visual detection) 
New methods, such as CRISPR diagnostics, are emerging which may not require 
as many processing steps [4], [5]; however, these methods are not as widely adopted as 
NAATs, particularly in LMICs. In recent years, there have been significant efforts to 
make NAATs more accessible to resource-constrained areas in LMICs by simplifying 
each of these steps for NAATs. In this thesis, I will discuss my contributions to this field: 
a simple nucleic acid extraction device for whole blood, and a novel DNA amplification 
assay paired with a simple visual detection method. The techniques developed in this 
work are platform technologies. Here, I demonstrated them for two pathogens, the 
Human Immunodeficiency Virus (HIV), an RNA virus, and Plasmodium falciparum 
malaria, a parasite with a DNA genome. In both of these cases, identifying and treating 
infections with low pathogenicity is a current and clinically relevant problem.     
 
1.3 HIV viral load monitoring 
HIV is a retrovirus which targets CD4+ cells; once inside the cell, viral RNA is 
reverse transcribed into HIV DNA and integrated into the host cell DNA. The host cell 
machinery is used to transcribe viral mRNAs and translate viral proteins, producing 
mature virions.  Antiretroviral therapies (ART) have been developed to target each of 




significant suppression of viral replication to the point where the patient’s risk of 
developing acquired immune deficiency syndrome (AIDS) is nearly eliminated. 
Importantly, optimal ART drug regimens which effectively suppress viral replication can 
practically eliminate the risk of HIV transmission from the patient [6]. In light of these 
advances, it has become possible to effectively stem the spread of HIV. The Joint United 
Nations Programme on HIV/AIDS has set forth an ambitious milestone to identify 90% 
of people living with HIV, ensure that 90% of all people diagnosed with HIV receive 
sustained ART, and ensure that 90% of people on ART are virologically suppressed [7].  
More than 20 million people living with HIV in LMICs are actively undergoing 
ART, and routine viral load monitoring is necessary for patients to ensure that they 
remain virally suppressed [8]. Patients with detectable viral loads are considered to no 
longer be virally suppressed, indicating potential early treatment failure or lack of patient 
adherence to prescribed regimens. Early identification of these patients is vital for 
clinicians to decide to either intervene in patient adherence, or to switch patients to 
second- and third-line ARTs [9]. According to the World Health Organization (WHO)’s 
recommendation in 2013, patients are considered virally suppressed if their viral loads 
are <1000 copies/mL blood [10], although there is some benefit to identifying and 
quantifying viral loads as low as 200 copies/mL blood [11][8].   
As routine viral load (VL) monitoring of patients undergoing ART treatment is 
recommended at the national level in several LMICs, access to accurate diagnostic 
methods has increasingly become an issue.  RT-qPCR is still considered the gold 




50 virus copies/mL blood [8], [12]. However, due to the high resource needs, 
implementation of these methods in many LMICs is limited to a handful centralized 
testing facilities. For example, in Zambia, 19 central testing facilities serve as the testing 
hubs for the entire country [13], while Uganda has a single central testing facility for the 
entire country [14].  In each case, patient samples from around the country must be 
collected and shipped to the central testing facilities for diagnosis.  
Preparation and transport of blood plasma samples from clinic and hospital 
settings to central testing facilities can be extremely expensive, comprising up to a third 
of testing cost [13].  Dried blood spot (DBS) and dried plasma spot (DPS) samples can be 
collected and shipped in a more cost-effective manner. However, environmental 
conditions and the presence of RNAses can lead to significant RNA degradation in DBS 
and DPS samples, thereby resulting in variable sample integrity [15], [16].  It has been 
shown that extracted RNA stored in dry conditions shows less degradation and more 
consistent amplification results, even when stored at room temperature or elevated 
temperatures over several weeks [17]–[20].  However, RNA extraction from blood in 
field settings prior to shipment to central testing facility can be resource-intensive and 
impractical [21]; while some commercial products are available to stabilize RNA when 
blood is collected, these can be cost-prohibitive or require buffer swapping before 
downstream assays can be performed [22].  
Integrated point-of-care (POC) HIV diagnostics may help alleviate the burden of 
sample collection and shipping to central testing facilities by performing sample 




clinic. Two recent review articles have outlined existing POC diagnostics for HIV VL 
monitoring and their implementation in LMICs [8], [23]. Although POC testing presents 
a promising alternative to the central testing paradigm, there is still a great deal of work 
to be done to evaluate and implement these tests in a sustainable and cost-effective 
manner in LMICs [24], [25].   
Therefore, a need for HIV diagnosis in hospital or clinic settings in LMICs is a 
more reliable sample collection method that can be easily incorporated into the existing 
central testing paradigm. In Aim 1 of this thesis, I developed a field-deployable method 
to extract and preserve nucleic acids from whole blood.  Because RNA degradation in 
particular is a problem (DNA is much more stable at room temperature), I focused on 
demonstrating RNA stability at room temperature and at an elevated temperature over 
multiple weeks. The device was designed to extract and preserve DNA and RNA such 
that they could be eluted and used in standard NAATs (PCR and RT-PCR), enabling use 
of the device in the existing testing workflows in LMICs as an alternative to routine DBS 
or DPS sampling. 
 
1.4 Identifying asymptomatic infections for malaria elimination 
Malaria is caused by red blood cell (RBC) infection by five protozoan parasites.  
Parasites in the asexual multiplication stage within red blood cells are responsible for 
malaria symptoms, including fever, chills, abdominal discomfort, vomiting, and fatigue. 
Artemisinin-combination therapies (ACT) exist to treat all five species of the 




they can make a full recovery, but if left untreated, Plasmodium infection can progress 
rapidly and result in severe, potentially fatal, symptoms [26].  Malaria infection continues 
to be a burden on global health, resulting 425,000 deaths in 2017 alone. The African 
region, which is primarily affected by the P. falciparum species, bears a significant part 
of this burden: 92% of reported malaria cases and 93% of deaths occurred in this region, 
with children under 5 years old accounting for a significant portion of deaths [27].  
Although malaria continues to affect global health outcomes, there has been 
significant progress in fighting the disease. Since the implementation of the WHO’s 
Millennium Development Goals in 2000, malaria control interventions have significantly 
decreased morbidity and mortality over the years [28]. Based on these successes, the 
WHO has implemented new goals to eliminate the disease from 35 countries by 2030 
[29]. An important challenge in malaria elimination efforts is the prevalence of 
asymptomatic infections, which are characterized by low circulating parasite density (≤2 
parasites/µL blood) and lack of the aforementioned symptoms, leading patients not to 
seek treatment [30]. Untreated asymptomatic infections with low parasite loads can serve 
as a silent “infectious reservoir” because they continue to carry parasites that can be 
transmitted to mosquitos. 
To mitigate disease transmission, an important tool for the WHO malaria 
elimination strategy is Mass Screening and Treatment (MSAT) of all people within a 
large geographical area to diagnose and treat all infections. However, current gold 
standard diagnostic methods do not meet the needs for successful MSAT programs. Both 




detection (LLOD) of 50-100 parasites/µL in 5µL of blood [31]–[33], which misses 
approximately 30%-50% of low-density infections [34].  Additionally, microscopy is 
labor-intensive and does not scale easily for large MSAT programs, and there are 
concerns about RDT accuracy in diagnosing active infection [35]. Due to these 
limitations, although MSAT programs show potential for decreasing transmission [36], 
the WHO currently does not recommend MSAT for elimination settings [37]. Instead, 
current efforts are focused on Mass Drug Administration (MDA), which can help 
mitigate transmission, but increases the likelihood of parasites becoming resistant to ACT 
[38].  
To enable the success of MSAT programs to replace MDA programs, there is a 
need for a highly sensitive, affordable, and scalable diagnostic method that can be easily 
operated in screening settings in LMICs. Chapter 3 contains an extensive review of 
existing point-of-care malaria diagnostics developed to move toward elimination. 
Although emerging methods have made malaria diagnosis more accessible, there are still 
several shortcomings that must be addressed. In particular for NAATs, the methods 
reported are complex to design, and are often not sufficiently sensitive to diagnose 
asymptomatic infection. In Aim 2 of this thesis, I focused on developing a novel 
isothermal NAAT that is a much simpler to design than other isothermal methods. I 
developed this method for P. falciparum malaria to show high analytical sensitivity that 
should be capable of diagnosing asymptomatic malaria. In Aim 3, I explored several 
methods to adapt the novel isothermal assay to point-of-care settings, including 








CHAPTER TWO: DEVELOPMENT OF A POINT-OF-CARE WHOLE BLOOD 
NUCLEIC ACID EXTRACTION DEVICE 
 In this chapter, I describe the development of a point-of-care, flexible system for 
nucleic acid preparation (SNAPflex), which comprises Aim 1 of my thesis work. The 
SNAPflex device, which I developed in collaboration with MakerHealth, LLC 
(Cambridge, MA, USA), is a redesign of the Klapperich Lab’s previous pressure-driven 
method for nucleic acid extraction from whole blood [39].  Here, I the adapted chemistry 
for use with a paper-and-plastic device without the need for pressure-driven flow. 
Appendix I covers various prototypes of the device in addition to studies I performed to 
characterize downstream assay inhibition caused by whole blood components, which 
were taken into account when developing the final device. In this chapter, I describe the 
final prototype for the device, which is compatible with roll-to-roll manufacturing. I also 
discuss device performance with HIV-1 RNA and with P. falciparum DNA as two model 
organisms. The latter method was used in conjunction with the novel isothermal 
amplification assay I developed in Chapter 7 of this thesis.  
 
2.1 Significance 
For blood-borne pathogens, amplification and detection of pathogen nucleic acids 
from whole blood enables sensitive disease diagnosis.  While some isothermal NAATs 
amplify nucleic acids in the presence of small amounts of whole blood [40]–[42], more 
traditional methods such as PCR and RT-qPCR are not compatible with direct blood 




quenches fluorescence readout from passive reference dyes and double stranded DNA 
intercalating dyes such as EvaGreen, inhibiting real time amplification readout for qPCR.  
Furthermore, Immunoglobulin G, hemoglobin, and hematin in whole blood have all been 
shown to inhibit polymerization by binding to single stranded DNA and/or affecting 
DNA polymerase activity [43], [44]. Therefore, directly using whole blood as an input 
sample is often not possible, particularly for gold standard NAATs.    
An important first step for PCR and RT-qPCR, therefore, is the extraction, 
isolation, and purification of pathogen nucleic acids from whole blood.  Traditionally, 
this is done using commercially-available solid phase extraction methods, which use 
centrifugation to collect nucleic acids in spin columns with silica membranes [45].  
Typically, these kits use a chaotropic lysis buffer to liberate nucleic acids from the 
sample matrices.  Extracted nucleic acids are then driven to bind to the silica membrane 
in the presence of the chaotrope, further propagated by the introduction of a primary 
alcohol to the solution [45], [46].  Wash buffers are then used to purify the nucleic acids 
on the membrane. A final elution step into an appropriate buffer recovers the nucleic 
acids from the membrane for use in NAATs. 
While spin column-based kits are useful, there are some concerns with 
implementing them in resource-limited field settings, as may be the case for some HIV 
VL monitoring or malaria screening. One concern is that, depending on the target 
pathogen, sample pre-processing may be required to isolate the target nucleic acids. For 
example, in the case of HIV, plasma separation may be required prior to extracting viral 




lysed, as the parasites are intracellular to red blood cells [49]. Additionally, the 
requirement for centrifugation to isolate and purify the nucleic acids makes these 
methods viable only in a clean and well-resourced laboratory environment rather than in 
field-based clinic settings.   
In some low-resource settings, it therefore may be required to collect samples 
from patients in field settings which can then be shipped to central testing facilities 
equipped to perform the necessary processing.  For blood samples, this shipment process 
requires cold storage and fast shipping times, as sample degradation can occur as quickly 
as 24 hours after sample collection [50].  Preparation and transport of blood and plasma 
samples can be extremely expensive; in some instances, it has been estimated that  
shipping samples from clinic and hospital settings in the field to central testing facilities 
can comprise up to a third of testing cost [13]. The lack of cold chain infrastructure and 
high cost of sample shipment can therefore make these gold standard tests inaccessible to 
many patients in remote areas.  
Dried Blood Spot (DBS) and Dried Plasma Spot (DPS) samples can be collected 
as alternatives to whole blood and plasma samples, and transitioning to these sample 
types may be advantageous.  DBS and DPS samples facilitate sample shipment without 
cold storage, thereby enabling simpler sample transport and delayed sample analysis 
[51]–[53]. In the case of HIV viral load monitoring for example, dried samples have the 
potential to increase testing access by 19% in LMICs [54].  For these samples, finger 
prick blood (50µL – 100µL) is collected on specialized cards and dried for approximately 




extraction and analysis. While DBS and DPS simplify sample collection, there are several 
downsides to these methods. Extensive sample processing is still required to extract and 
purify nucleic acids from the samples in the central testing facility, and nucleic acid 
recovery can often be much lower than from fresh samples. Additionally, particularly 
RNA in DBS samples has been shown to degrade over time both from contact with water 
and due to the presence of RNAses in the blood sample and in the environment [15], [16].  
Depending on the drying conditions (i.e. temperature, humidity) and the pathogen loads, 
RNA could degrade at different rates, thereby resulting in variable and potentially 
unreliable test results [15]. For HIV-1 RNA, for example, evaluation of three commercial 
RT-qPCR assays for HIV-1 VL analysis from DBS samples showed extremely variable 
diagnostic accuracy [55].  
Therefore, it is necessary to improve on DBS and DPS sample collection to 
enable more sensitive detection of pathogens. It has been shown that extracted RNA 
stored in dry conditions shows less degradation and more consistent amplification results, 
even when stored at room temperature or elevated temperatures over several weeks [17]–
[20].  However, nucleic acid extraction from blood in field settings prior to shipment to 
central testing facilities can be resource-intensive and impractical [21]; while some 
commercial products are available to stabilize RNA when blood is collected, these can be 
cost-prohibitive [22].  
In this chapter, I describe the development of a novel paper-based device for room 
temperature extraction, purification, and long-term storage of DNA and RNA from whole 




sample preparation (SNAP) we reported previously [39].  Whole blood lysis and nucleic 
acid precipitation are performed in a sample tube at room temperature, and a flexible 
paper-and-plastic device is used to capture and purify nucleic acids on a glass fiber 
membrane. Nucleic acids eluted from the membrane can be used any number of 
downstream NAATs such as qPCR or RT-qPCR in addition to several isothermal 
techniques. I demonstrate the utility of this device with two different types of samples: 
HIV virions in whole blood and P. falciparum parasite-infected red blood cells in whole 
blood. Using these model systems, I show that SNAPflex enables isolation and long-term 
preservation of pathogen DNA and RNA. 
 
2.2 Materials and Methods 
Device materials and equipment: 
The SNAPflex device consists of layers of laminating plastic (Staples thermal 
laminating plastic, 5mil), adhesive plastic (Fellowes self-laminating sheets, 3mil), a 
chromatography paper waste pad (Ahlstrom 320), and a paper capture membrane 
(Millipore 0.7µm glass fiber without binder). Laminating plastic, chromatography paper, 
and adhesive sheets were cut to the appropriate dimensions using a Trotec Speedy 100 
60W laser cutter. The glass fiber capture membrane (Millipore 0.7µm glass fiber without 
binder), was cut to the appropriate dimensions using a Graphtec FCX2000-60VC cutter 
plotter. Laminating plastic was sealed using an Apache AL18P laminator. The final 
device also uses a removable stabilization clip which was printed with polylactic acid 




SNAPflex device design: 
 
Figure 1: Paper and plastic layers for SNAPflex device (Courtesy of MakerHealth). 
The SNAPflex device consists of six layers of paper and plastic (Figure 1). The 
base of the SNAPflex device includes two layers of laminating plastic with 3/8” holes for 
sample application on top of the capture membrane. Chromatography paper cut into a 
triangle with one rounded node (1 1/2” base width, 7/16” diameter node) is used as the 
waste collection pad. A 7/16” diameter protrusion is created at the rounded node of the 
waste pad to improve contact between the capture membrane and waste pad. An 
additional layer of laminating plastic with two holes (3/8” for sample application, 7/16” 
to accommodate waste pad protrusion) is added on top of the waste pad. This 4-layer base 
unit is heated to 320°F using a laminator to seal the waste pad within the layers of 
laminating plastic. 
For RNA capture (HIV samples), the glass fiber capture membrane is washed 
three times in nuclease free water (HyPure) and dried overnight at room temperature.  For 
DNA capture (P. falciparum samples), the glass fiber membrane is submerged for 6-8 




temperature overnight before assembly.  The dried membranes are stored in an airtight 
container with desiccant until use. In both cases, the cleaned membrane is cut into a 1/3” 
circle with arms of 1/8” to stabilize the position of the capture membrane in the device. 
The capture membrane is placed on the waste pad base unit described above and a layer 
of adhesive plastic with two 3/8” holes for is used to secure the capture membrane. 
Nucleic acid extraction chemistry: 
The lysis buffer used in this work was previously developed by the Klapperich 
Lab [39], based on work from Boom et. al.[56] and Chomczynski and Sacchi [57]. The 
chaotropic lysis buffer contains guanidine thiocyanate, N-lauroylsarcosine, and 2-
mercaptoethanol to lyse cells and virions and denature proteins including RNAses.  To 
prepare the lysis buffer, 35.4g of guanidine thiocyanate (Sigma-Aldrich) are dissolved 
into 14mL nuclease-free water (HyPure); the solution is heated at 50°C for 10 minutes 
and vortexed for 1 minute to enable dissolution. 5mL of 1M MOPS (pH 7.0, titrated from 
free acid with 10M NaOH, Sigma-Aldrich) and 1.36mL of 20% N-laurylsarcosine 
(sodium salt) solution (Sigma-Aldrich) are then added to the solution. Once the solution 
is cooled to room temperature, 360µL 2-mercaptoethanol (Sigma-Aldrich) is added to the 
solution, and the final volume is adjusted to 50mL with nuclease free water. 
Prior to sample lysis, a final buffer is prepared containing 68% (v/v) lysis buffer, 
29% (v/v) 10% nonyl phenoxypolyethoxylethanol (NP-40, Sigma-Aldrich), and 3% (v/v) 
GlycoBlue co-precipitant (15mg/mL blue glycogen, Applied Biosystems).  GlycoBlue is 
included in the final lysis solution as a hydrophilic carrier particle which associates with 




enabling capture on the capture membrane. The blood sample (100µL – 200µL) is lysed 
at a ratio of 1:2 (sample:lysis buffer) at room temperature for 15 minutes. After lysis, 
35% (v/v) 1-butanol is added to the solution as a precipitating agent, increasing the 
hydrophobicity of the solution and causing the hydrophilic glycogen-nucleic acid 
complexes to form precipitates while the denatured proteins in the sample remain in the 
hydrophobic phase. For studies to investigate lower sample volume, the precipitation 
solution included chloroform and the total volume used was decreased (90µL 1-butanol + 
10µL chloroform). The sample is applied to the SNAPflex device to isolate and purify the 
precipitated nucleic acid particles. 
Sample application and elution from device: 
The capture membrane portion of the device is divided from the waste pad by a 
perforation in the laminating plastic and adhesive plastic layers. Prior to sample 
application, the top section is first folded over along the perforation to bring the capture 
membrane into contact with the waste pad. A reusable 3D-printed stabilization clip is 
used to keep the capture membrane in contact with the waste pad throughout the sample 
application and washing. The stabilization clip does not come into contact with either the 
sample or lysis buffer, and therefore can be cleaned and used for multiple devices. 
After the addition of 1-butanol, the lysed blood solution is inverted to mix and 
immediately applied to the capture membrane on the device to capture precipitated 
nucleic acid-glycogen particles. 400µL pre-wash buffer containing 70% ethanol and 
12.5% lysis buffer is applied to the capture pad to further solubilize proteins and cell 




nuclease free water is then applied to wash residual salts from the capture membrane, 
followed by 100µL 95% ethanol to enable rapid drying of the preserved nucleic acids on 
the membrane. The 3D printed clip is then removed, and the center circle of the capture 
membrane containing captured nucleic acids is removed from the device and dried for 10 
minutes at ambient temperature.   
Once the capture membrane is completely dry, the sample is immediately eluted 
(recovery studies) or transferred to a zip-top mylar bag containing a silica packet and 
sealed (stability studies).  Sample elution is performed by transferring the capture 
membrane to a 0.2mL PCR tube. 100µL elution buffer (10mM Tris-Cl, pH 8.5, 
QIAGEN) is added to the membrane and the sample is heated at 50°C for 10 minutes. 
The eluted sample is collected via centrifugation and stored at the appropriate storage 
temperature prior to analysis by RT-qPCR (HIV RNA studies) or qPCR (P. falciparum 
DNA studies). For HIV RNA studies, eluted samples are stored at -80°C, while P. 
falciparum DNA samples are stored at -20°C. 
HIV RNA recovery experiments: 
In vitro transcribed RNA for the HIV gag gene was used for RNA recovery 
studies. HIV gag gene DNA was cloned into a pGEM-Teasy plasmid and used as a 
template for in vitro transcription using a RiboMax in vitro transcription kit (Promega) to 
generate RNA (1488nt).  RNA stocks were diluted into elution buffer at concentrations of 
1E4cp/µL, 1E3cp/µL, 1E2cp/µL, and 1E1cp/µL. 10µL RNA sample was added directly 
to 200µL complete lysis buffer, and 90µL whole blood was subsequently added to the 




80°C until qPCR analysis. Three experiment replicates, each with a whole blood sample 
from a different donor, were performed for a total of 6 replicates per concentration. Two 
samples without HIV RNA were included as negative controls for each experiment. 
Samples were quantified using RT-qPCR against an internal standard curve to quantify 
the number of HIV RNA copies in the extracted sample. Percent recovery was calculated 
compared to expected values based on the input RNA concentration. 
HIV RNA Stability experiments:  
In vitro transcribed RNA for the HIV gag gene was prepared at a concentration of 
1E2cp/µL at sufficient volume for 14 devices. 10µL of this sample was added directly to 
200µL lysis buffer and 90µL whole blood was subsequently added to the mixture. Two 
samples without HIV RNA were included as negative controls for each experiment. 
Three experiment replicates, each with a whole blood sample from a different donor, 
were performed. 
Samples were processed on the SNAPflex devices as described above. For Day 0 
and NTC conditions, samples were immediately eluted and stored at -80°C until RT-
qPCR analysis.  For extended time point samples (Days 1 – 14), the dried capture 
membranes were stored in mylar zip-top bags containing silica packets. The samples 
were randomized and divided into two desiccant-containing storage containers.  One 
container was left in a laminar flow hood at room temperature (approximately 25°C) and 
the other was stored in a dry incubator set to 37°C. At Days 1, 7, and 14, two samples 
from each temperature were removed from each container and eluted as described above 




HIV-1 virion recovery experiments: 
AccuSpan HIV-1 RNA linearity panel (SeraCare) cultured virions were used as 
an input for virion recovery experiments. Each panel member was quantified using Roche 
COBAS® AmpliPrep/COBAS® TaqMan® HIV-1 version 2.0 assay prior to purchase 
from SeraCare; the quantification values from the Certificate of Analysis were used as 
the reference point for recovery calculations. SeraCare HIV-1 linearity panel members 2 
– 5 were used as input samples (3.6E7 cp/mL, 2.8E6 cp/mL, 2.7E5 cp/mL, 3.8E4 cp/mL, 
respectively). Each sample was diluted 1:10 in 90µL whole blood and processed on the 
SNAPflex devices as described above.  Three experiment replicates were performed for a 
total of 6 devices per concentration, with 2 negative controls per experiment. For 
comparison, each panel member was diluted 1:10 in plasma and processed by QIAGEN 
QIAamp viral mini kit. The standard protocol was adjusted to accommodate 100µL input 
sample, and the final elution volume was adjusted to 100µL elution buffer to remain 
consistent with the samples tested in our study.  Three experiment replicates were 
performed and all eluted samples were stored at -80°C until RT-qPCR analysis. 
HIV-1 virion stability experiments: 
To demonstrate utility of the SNAPflex system at low concentrations of HIV 
virions, extended stability experiments were performed using virions at an initial 
concentration of 500cp/mL, diluted from panel member 5. 200µL of input sample was 
processed using 400µL lysis buffer and 257µL 1-butanol; wash volumes were kept 
consistent with previously described conditions. Samples were eluted into 100µL elution 




whole blood from different donors, with one device at each temperature and time point 
per experiment (3 replicates per time point). One negative control sample was performed 
for each experiment.  
HIV RT-qPCR analysis:  
The one-step Brilliant II RT-qPCR core kit (Agilent) was used for quantitative 
analysis of extracted HIV RNA; the assay was performed on a Quantstudio 5 
thermocycler. Primers and probes were obtained from Integrated DNA Technologies 
(Commercial Park, Coralville, IA). Gene-specific primers for the HIV gag gene 
(Forward: 5’-GGCTACACTAGAAGAAATGATGACAGCAT-3’, Reverse: 5’-
CCCTTCTTTGCCACAATTGAAACACTT-3’) initiated PCR amplification, with the 
reverse PCR primer also initiating first strand synthesis for the reverse transcription step. 
A Cy5 and Black Hole Quencher dual-labeled species-specific probe was included for 
fluorescence quantification (5’-Cy5-AGTAGGAGGACCCGGCCATA-IAbRQSp-3’). In 
vitro transcribed RNA for the HIV gag gene, was used for standard curve analysis with 
input concentration ranging from 1E4cp/mL to 1E7cp/mL.  10µL sample was added to 
15µL master mix for a final reaction volume of 25µL (final concentrations: 1X SureStart 
Core RT-PCR buffer, 3mM MgCl2, 0.2µM forward primer, 0.2µM reverse primer, 
0.2µM probe, 0.8mM dNTPs, 30nM ROX reference dye, 0.5U/mL Taq polymerase, 1µL 
reverse transcriptase). Samples were incubated at 50°C for one hour for reverse 
transcription, followed by an initial denaturation step at 95°C for 10 min, and 40 cycles 
of 95°C for 30 seconds and 57.5°C for 1:30. Three technical replicates of each samples 




Plasmodium falciparum DNA recovery experiments  
Purified Plasmodium falciparum genomic DNA (BEI resources, MRA-102G) was 
diluted into elution buffer at concentrations of 1E5 fg/µL, 1E4 fg/µL, 1E3 fg/µL, and 1E2 
fg/µL and was diluted ten-fold into whole blood. 100µL of each blood sample was lysed 
with 200µL complete lysis buffer and processed on SNAPflex as described above. 
Samples were eluted into 100µL elution buffer, collected, and stored at -20°C until qPCR 
analysis. Three experiment replicates, each with a different whole blood sample from a 
different donor, were performed for a total of 6 devices per concentration. 2 Samples 
without P. falciparum DNA were processed as negative controls for each experiment.  
Plasmodium falciparum infected red blood cell experiments 
P. falciparum parasites (3D7 strain, BEI Resources, MRA-102), were cultured in 
human red blood cells using standard culturing procedures for malaria parasites [58].  P. 
falciparum parasite culture was maintained in 5% human red blood cells purified from 
whole blood (Research Blood Components) with complete RPMI medium (Gibco) 
supplemented with hypoxanthine (Sigma-Aldrich). Parasite cultures were grown at 37°C, 
5% CO2, 5% O2.  Parasite culture was maintained at high parasitemia levels (>10%) 
infected red blood cells, with daily media change.  The parasites were synchronized to 
ring stage cultures once per week using 5% D-soribitol (Sigma-Aldrich) to ensure that the 
cultures were in a single growth stage for experiments. 
For experimental conditions, two 3µL samples of each culture were collected as a 
thin smear on glass microscopy slides, stained with Giemsa stain, and visualized with a 




primarily in a single culture stage, the percentage of infected red blood cells in 10 fields 
of view on each slide was quantified, and the parasitemia was determined as an average 
of all 20 fields of view. The infected red blood cell cultures were serially diluted into 
whole blood to 10%, 5%, 1%, and 0.1% final parasitemia.  100µL each of the diluted 
samples were processed with QIAGEN Blood & Tissue Kit according to the 
manufacturer’s instructions and the SNAPflex process described above, respectively.  For 
each experiment, a sample of whole blood without parasites was processed on both 
systems as a negative control. The samples were stored at -20°C until further analysis and 
were quantified using TaqMan qPCR.  A total of 9 independent cultures at ring stage and 
3 independent cultures at schizont stage were processed as described.  
Plasmodium falciparum qPCR analysis: 
A previously reported TaqMan qPCR assay was used for quantitative analysis of 
extracted P. falciparum DNA [59]. Amplification was performed with SureStart Taq 
polymerase (Agilent) with primers and probes purchased from Integrated DNA 
Technologies. Gene-specific primers for the 18S rRNA gene (Forward: 5'-
CTTTTGAGAGGTTTTGTTACTTTGAGTAA-3’, Reverse: 5'-
TATTCCATGCTGTAGTATTCAAACACAA-3’) initiated amplification and a HEX and 
Black Hole Quencher dual-labeled species-specific probe was included for fluorescence 
quantification (5’-HEX-TGTTCATAACAGACGGGTAGTCATGATTGAGTTCA-
IAbFQ-3’). Purified P. falciparum genomic DNA was used for standard curve analysis 
with input concentration ranging from 1E1fg/µL to 1E5fg/µL.  5µL of each sample was 




1X SureStart 10X buffer, 3mM MgCl2, 0.3µM forward primer, 0.3µM reverse primer, 
0.2µM probe, 0.8mM dNTPs, 30nM ROX reference dye, 0.025U/mL Taq polymerase). 
Samples were incubated for an initial denaturation step at 95°C for 10 min, and 45 cycles 
of 95°C for 15 seconds and 60°C for 1:00. Three technical replicates of each samples 




As a starting point for device development, DNA recovery from several capture 
membranes was first investigated. For these experiments, 1pg/µL P. falciparum gDNA in 
buffer was added to the lysis buffer and precipitated with 1-butanol and chloroform; the 
precipitates were captured and eluted from several membranes (Table 1). Samples were 
analyzed by qPCR and percent recovery was calculated based on the input concentration.  
Table 1: Membranes evaluated for gDNA capture and elution 






Sterlitech Filtration 0.22µm 









Custom lateral flow 
Not specified 
(est. 2.3µm) [60] 
Vivid Pall Plasma separation 
Asymmetric 
(100µm2µm) 
The results (Figure 2) showed that the most successful recovery resulted from 




Notably, the glass fiber membrane results showed improved recovery compared to the 
control extraction using commercially available QIAGEN kits. Using these results as a 
promising starting point, I moved forward with device development using this membrane. 
 
 
Figure 2: Recovery of P.f. gDNA from several membranes. Glass fiber membrane with 
0.7µL pore size showed the best sample recovery. 
In collaboration with MakerHealth, LLC (Cambridge, MA), I created several 
device prototypes. We endeavored to create a device that was suitable for roll-to-roll 
manufacturing to extract and purify nucleic acids from whole blood.  We aimed to show 
successful elution of nucleic acid samples with comparable recovery to existing 
commercial methods.  Appendix I shows the progression of our prototypes and work 




The final device design for a flexible system for nucleic acid preparation is called 
SNAPflex. The layered paper-and-plastic devices uses hard laminating plastic and a 
flexible adhesive plastic layer to sandwich a 0.7µm pore-size glass fiber capture 
membrane with a chromatography paper waste pad. Contact between the capture 
membrane and the waste pad provides passive wicking force for fluid flow through the 
capture membrane. In its final form, the capture membrane is folded over to come in 
contact with the chromatography paper wicking pad and a 3D printed, reusable 
stabilization clip is used to ensure sufficient contact between the capture membrane and 
the wicking pad throughout the course of sample application. Sample application is 
followed by three separate wash buffers to solubilize remnant blood components and 
remove residual salts, after which the capture membrane is removed from the device to 
dry. From this point, the nucleic acids could either be eluted from the membrane or 
amplified directly from the membrane (Figure 3).  The SNAPflex device works well with 
blood samples: consistent contact between the capture membrane and waste pad ensures 
that the lysed blood is fully washed from the membrane with minimal sample loss (Figure 
4). Blood inhibitors co-eluted from the membrane were previously shown to cause assay 
inhibition (Appendix I); therefore, complete washing of lysed blood from the membrane 





Figure 3: Sample application on SNAPflex device, demonstrated with colored liquid for 
visualization. DNA/RNA can be eluted from the membrane or amplified directly on paper 





Figure 4: Demonstration of SNAPflex with blood samples results in complete purification of 
membrane surface. 
HIV RNA Recovery and Stability 
In order to test the performance of the SNAPflex device, I have demonstrated the 
ability to extract and recover HIV RNA from blood samples over 4 logs.  Using both in 
vitro transcribed RNA for the HIV gag gene (Figure 5A) and HIV-1 virions spiked into 






Figure 5: (a) Recovery if in vitro transcribed RNA from SNAPflex in the presence of whole 
blood over 4 logs; (b) Recovery of HIV-1 virions spiked into whole blood from SNAPflex 
Because whole blood contains RNAses which could degrade unprotected RNA, 
the in vitro transcribed RNA was first introduced to the lysis buffer and whole blood was 




aggressively lyses proteins in the solution (including RNAses) preventing degradation of 
RNA in solution. The results from the RNA recovery experiments indicate that the lysis 
buffer accomplishes the necessary functions: (1) complete lysis of whole blood 
components (proteins and cell debris), (2) precipitation and capture of RNA onto the 
capture membrane surface, (3) purification of captured RNA on the paper membrane, and 
(4) successful elution of captured RNA from the paper membrane.  The results indicate 
successful recovery of RNA across four logs of input concentration. At the lowest 
concentration, some samples show >100% recovery; we hypothesize this is due to known 
stochasticity at the lower limit of quantification for the RT-qPCR assay.  
I further demonstrated the capability of the SNAPflex device to capture HIV-1 
RNA from lysed virions. Using cultured virions obtained from the AccuSpan HIV-1 
Linearity panel (SeraCare) spiked directly into whole blood, I quantified the recovery of 
HIV-1 RNA recovered using SNAPflex compared to the concentrations reported by the 
manufacturer (input sample volume, 100µL).  The data show that, across 4 logs, these 
“mock” patient samples consisting of HIV-1 virions spiked into whole blood can be 
successfully extracted using SNAPflex. Importantly, SNAPflex samples showed 
improved recovery compared to samples extracted using the QIAGEN viral mini kit. Per 
the guidelines of the sample kit, plasma was used as the input sample for the commercial 
extraction method. The data demonstrate successful recovery of HIV RNA from virions 
with SNAPflex using a more complex sample type. 
An additional advantage of the SNAPflex device is the capability to store RNA at 




Long-term storage of RNA on paper enables shipment and storage of collected samples 
without the need for cold storage. In order to demonstrate long-term stability of RNA on 
paper, I first used in vitro transcribed RNA extracted with whole blood to directly 
quantify sample degradation over time (Figure 6).  The results show that, at both 
temperatures, RNA recovery remains within the expected range over time, with minimal 
degradation over two weeks.  ANOVA analysis showed no significant difference between 
stored samples and the samples collected immediately after processing (p = 0.1420).   
 
Figure 6: Two week RNA stability on capture membranes at room temperature (25°C, 
purple) and 37°C (red). 
I further demonstrated that extracted virion RNA at a concentration <500 copies/mL 
could be recovered using SNAPflex devices, in order to demonstrate clinical relevance to 
monitoring viral loads in suppressed patients. For these experiments, I introduced 200µL 




RNA into 100uL elution buffer, resulting in a 2x concentration factor.  Even with this 
concentration factor, I found that the extracted RNA concentration was near the lower 
limit of detection of our RT-qPCR assay, resulting in stochastic amplification for each 
sample (Table 2).  However, I did see successful amplification across all time points at 
both temperatures in at least one technical replicate. These results indicate that, rather 
than sample degradation, it is likely that the lack of amplification because of stochasticity 
at the lower limit of the assay. These results are a good starting point to show that 
SNAPflex extraction of HIV virions results should be relevant for VL monitoring. 
Table 2: Summary of virion stability on capture membrane at room temperature and 37°C 







1 1 37C 
9 6 66.67% 2 1 37C 
3 1 37C 
1 7 37C 
9 6 66.67% 2 7 37C 
3 7 37C 
1 14 37C 
9 7 77.78% 2 14 37C 
3 14 37C 
1 0 RT 
9 7 77.78% 2 0 RT 
3 0 RT 
1 1 RT 
9 5 55.56% 2 1 RT 
3 1 RT 
1 7 RT 
9 5 55.56% 2 7 RT 
3 7 RT 
1 14 RT 
3 3 100.00% 2 14 RT 





Plasmodium DNA recovery: 
In order to test for the successful recovery of DNA from blood using the 
SNAPflex system, I first demonstrated recovery of P. falciparum genomic DNA across 
four logs (Figure 7).  In this case, P. falciparum genomic DNA was introduced directly to 
whole blood, since DNA is generally not susceptible to degradation by blood 
components.  DNA recovery was successful and quantifiable by qPCR across four orders 
of magnitude. 
 
Figure 7: P. falciparum gDNA recovery from whole blood using SNAPflex 
In order to demonstrate successful extraction from malaria parasites, I cultured 
Plasmodium falciparum parasites (3D7 strain) in red blood cells; infected red blood cells 
were first quantified by microscopy and diluted into whole blood at four separate 
concentrations. The malaria parasite life cycle consists of four growth stages once the 




early, ring stage, at which a single parasite copy is present in each red blood cells. For a 
small number of experiments, I also showed successful extraction from parasites in the 
schizont stage, where multiple parasites are present within each red blood cell. The 
growth stages were identified under microscopy and parasite-infected red blood cell 
concentration was quantified. Infected red blood cells were then diluted into whole blood 
to represent “mock” patient samples.  Whole blood samples spiked with infected red 
blood cells were extracted with both SNAPflex and QIAGEN Blood & Tissue kit and 
eluted DNA was quantified by qPCR.  Within each experiment, I found that SNAPflex-
extracted samples showed improved recovery compared to QIAGEN extraction, 
particularly at higher parasitemia (Figure 8).  In other words, the same samples extracted 
with SNAPflex resulted in higher DNA concentration compared to QIAGEN extraction. 
This is can be observed in Figure 8 by comparing the results against the dashed line, 
which represents equal recovery from both QIAGEN and SNAPflex: most samples fall 






Figure 8: P. falciparum DNA recovery with SNAPflex and QIAGEN of both early ring-stage 
(filled circles) and late schizont stage (open squares) parasites from whole blood across four 




The SNAPflex device was designed with a final capacity of 1mL total volume, 
including lysed sample and wash buffers.  Keeping this constraint in mind, we have 
designed the SNAPflex method to enable nucleic acid extraction from up to 200µL whole 




prick blood sampling yields 50-100µL [61], [62]. 
The layered design of the SNAPflex chip is compatible with a roll-to-roll 
manufacturing processes. To prepare the chip components for roll-to-roll manufacturing, 
each of the plastic layers (Figure 9A) will be fabricated on a continuous spool of the 
repeated pattern (Figure 9B). For manufacturing, the proposed assembly of the chip is 
outlined in Figure 9C: 1) the first two layers of laminating plastic will be fed together and 
heat sealed by a heated roll, 2) the triangular waste pad will be introduced and sealed into 
place as the third laminating layer is fed and heated, 3) the capture membrane will be 
placed on top of this base, 4) the layer of adhesive plastic will be fed into the chip to 
secure the capture membrane creating the final SNAPflex chip which will be wound into 







Figure 9: A) SNAPflex layers. (B) All components of the device can be manufactured in 
configurations suitable for roll-to-roll manufacturing. (C) Proposed roll-to-roll 
manufacturing schematic. (Courtesy of MakerHealth) 
Nucleic Acid Extraction and Precipitation Chemistry: 
I developed a lysis buffer that could be used at room temperature without the need 
for centrifugation for nucleic acid extraction. In the development of the buffer, we 
combined components of lysis buffers previously reported by Boom et. al.[56] and 
Chomczynski and Sacchi [57].  Similar to lysis buffers from both works, the custom 




guanidine hydrochloride in combination with proteinase k was also tested, we found that 
this combination required heating and resulted in significant protein precipitation, so did 
not include these in the final formulation (data not shown). In addition to guanidine 
thiocyanate, the buffer includes components of both original buffers to optimize blood 
lysis: the anionic surfactant N-lauryl sarcosine enables complete denaturation of proteins 
and white blood cells, while 2-mercaptoethanol prevents significant protein precipitation.  
NP-40 further enables solubilization of cell membranes and fats in the sample. The 
inclusion of 2-mercaptoethanol make implementation at the point of care more difficult, 
as it is a hazardous reagent; therefore, future work will investigate the removal of this 
component. 
For this work, we adjusted the sample:lysis buffer ratio for the SNAPflex system. 
Here, blood is lysed at a sample:lysis buffer ratio of 1:2 to enable complete degradation 
of blood components, resulting in a homogenous solution without aggregated protein or 





Figure 10: Lysis buffer ratio and sample volume study 
 
The SNAPflex system relies on formation of hydrophilic nucleic acid-glycogen 
complexes, which subsequently form precipitates in the solution mediated by the 
introduction of a hydrophobic primary alcohol. In this work, nucleic acid precipitation is 
induced by the addition of the primary alcohol 1-butanol. While isopropanol or 100% 




significantly more hydrophobic primary alcohol [63]. Using 1-butanol minimizes the 
total alcohol volume necessary to induce nucleic acid precipitation from the solution.  
Here, 35% (v/v) final volume 1-butanol is used as the precipitation reagent, whereas 50% 
isopropanol and 100% ethanol are required for traditional precipitation methods [3].   
It is possible to further reduce the necessary volume of precipitating reagent by 
introducing chloroform in combination with 1-butanol, further increasing the 
hydrophobicity of the precipitating solution. The work presented here is intended for use 
at the point of care, which requires simple waste disposal; because chloroform requires 
specialized hazardous waste disposal, I did not include it in the final sample treatment. 
However, in well-resourced lab environments, including chloroform in the final 
precipitation buffer may be a viable option to further reduce the necessary volume of 
precipitating acid to 25%.  I have performed the RNA experiments described above in the 
presence of chloroform to further demonstrate this point (Figure 11). These results show 
that recovery with a lower volume of precipitating solution including chloroform is 





Figure 11: Comparison of SNAPflex recovery with (blue) and without (green) chloroform 
precipitation 
The original SNAP device used a solid phase capture material without silica, 
relying on capture of nucleic acid-glycogen complexes on porous polymer monoliths 
while the solutions were applied to the unit with a pressurized system [39]. In adapting 
this work to a paper-based system driven by passive wicking, I found that a small pore 
size, silica-based glass fiber capture membrane enabled the best recovery of nucleic acids 
compared to other membranes without silica. I further determined that successful 




12.5% of lysis buffer in addition to 70% ethanol to solubilize and discard any captured 
protein and cell debris on the surface of the capture membrane. Two further ethanol 
washes (70% and 95%) enable removal of residual salts and rapid drying of the capture 
membrane post-processing.  
HIV RNA recovery: 
Here, I have shown successful extraction, stabilization, and elution of HIV RNA 
from a whole blood sample using SNAPflex, using both in vitro transcribed RNA and 
HIV-1 virions. Compared to a commercially available extraction kit which requires 
plasma separation prior to viral RNA extraction, the SNAPflex device showed improved 
recovery over four orders of magnitude with an input of 100-200µL whole blood.  
I also showed that, over two weeks, RNA remained stable on the glass fiber matrix both 
at room temperature and at elevated temperature.  I included desiccant in this study to 
ensure that the RNA remained dry, particularly because contact with water has been 
shown to accelerate RNA degradation [15]. For this preliminary study, I did not 
challenge the storage conditions with increased humidity because I sought to determine 
the initial baseline degradation due to temperature alone. Furthermore, I investigated two 
week stability because we estimated this to be an average shipping time for samples in 
Senegal based on informational interviews with members of the Institute for Health 
Research, Epidemiological Surveillance and Training in Dakar, Senegal. The next step 
for this work is to investigate the effect of elevated humidity and to fully characterize the 
shelf life of extracted RNA in this matrix.  




virion RNA can be successfully extracted and quantified using SNAPflex, and that 
purified RNA remains stable over an extended time period.  Because our device can be 
used at room temperature and without any specialized equipment, the technology we 
describe represents an important step forward in sample collection for HIV VL 
monitoring.  
Plasmodium falciparum DNA recovery. 
In this work, I demonstrated recovery of both RNA and DNA from whole blood, a 
complex sample matrix. While precipitation of both types of nucleic acids was induced 
by the buffer, I found that there were significant differences in the recovery of RNA 
compared to DNA from glass fiber capture membranes used in the device. While HIV 
RNA recovery was >60%, I found that malaria gDNA recovery was consistently lower 
(<20%) with untreated glass fiber capture membranes.   
In order to address this problem, I performed an additional treatment of the glass 
fiber capture membrane with trifluoroacetic acid (TFA), dried the paper at room 
temperature, and kept the paper stored in a dry environment. I found that this treatment 
significantly improved DNA recovery compared to glass fiber membranes washed with 
nuclease-free water (Figure 12A).  I hypothesize that the TFA treatment enabled the 
successful elution of DNA from glass fiber by depositing a hydrophobic layer on the 
surface of the membrane, ensuring that the hydrophilic DNA precipitates did not 
irreversibly bind to the surface of the membrane [64]. Because the RNA samples tested 
are much shorter than genomic DNA, I hypothesize that they did not form as many 




recovery compared to DNA without the need for additional treatment with TFA [46]. I 
further found that storing the TFA-treated membrane in a dry environment was necessary 
to maintain high percentage recovery after treatment of the membrane. Treated 
membranes stored in ambient conditions showed a decrease in sample recovery compared 
to those stored in dry environments (Figure 12B).  
 
Figure 12: A) Recovery of P. falciparum gDNA significantly improved when membranes 
were treated with trifluoroacetic acid. B) Treated membranes stored in a dry environment 
retained their ability to recover malaria gDNA several days after treatment. 
Using the TFA-treated capture membrane, SNAPflex demonstrates excellent 
recovery of P. falciparum DNA with both gDNA spiked into whole blood and parasite-
infected red blood cells spiked into whole blood to simulate patient samples (Figure 7, 
Figure 8). Notably, there was no nonspecific amplification of blood samples, even in the 
presence of human DNA extracted from whole blood, thereby obviating the need for 
isolation of red blood cells prior to parasite DNA extraction. The lysis buffer is capable 
of lysing both the red blood cell membrane and the parasite membrane to liberate parasite 




Given the large difference in DNA recovery compared to RNA recovery, it may 
be possible to take advantage of the differential recovery to isolate HIV RNA alone 
without eluting proviral DNA. Circulating proviral DNA leads to positive PCR 
amplification, even in the absence of active HIV infection.  Therefore, elution of proviral 
DNA and HIV RNA together is known to lead to false positives for viral load monitoring, 
and leading to inaccurate quantification, particularly at low viral loads [8], [65]. Testing 
whether preferential recovery of HIV RNA without interfering proviral DNA is possible 
requires patient samples and therefore was not investigated in this work. However, testing 
this hypothesis would be a promising future direction for this work. 
 
2.5 Conclusion: 
Here, I have presented a paper-and-plastic device for simple, room temperature 
extraction of nucleic acids from whole blood. The SNAPflex system aims to fit the need 
for simple, effective methods that could be adapted to the point of care but still remain 
easily adaptable to existing testing infrastructure and gold-standard diagnostic methods 
used in LMICs. Therefore, I focused on creating a platform technology for nucleic acid 
extraction that could be used with standard NAATs like qPCR and RT-qPCR. However, 
the method should be agnostic to the downstream assay used and should be adaptable to 
isothermal nucleic acid amplification methods or other applications where purified 




CHAPTER THREE: TOWARDS LAB-ON-A-CHIP DIAGNOSTICS FOR 
MALARIA ELIMINATION 
 The remainder of this thesis focuses on the development of a highly sensitive 
diagnostic assay for P. falciparum malaria. Aim 2 focuses on my development of a novel 
isothermal amplification assay for P. falciparum and Aim 3 focuses on adapting this 
assay to the point of care. I pursued this work to address the need for sensitive, affordable 
methods to diagnose malaria for elimination.  
 This chapter is a reproduction of a journal article I recently published in the 
journal Lab on a Chip. The chapter is included to give an overview of the requirements 
for diagnostics for elimination and to review several existing methods to address the need 
these diagnostics.  The article is reproduced from Reference [66] with permission from 
the Royal Society of Chemistry. 
 
3.1 Abstract 
Malaria continues to be one of the most devastating diseases impacting global 
health.  Although there have been significant reductions in global malaria incidence and 
mortality rates over the past 17 years, the disease remains endemic throughout the world, 
especially in low- and middle-income countries.  The World Health Organization has put 
forth ambitious milestones moving toward a world free of malaria as part of the United 
Nations Millennium Goals.  Mass screening and treatment of symptomatic and 
asymptomatic malaria infections in endemic regions is integral to these goals and requires 




path toward sensitive, portable, and affordable diagnostic platforms.  Here, we review 
and compare currently-available and emerging lab-on-a-chip diagnostic approaches in 
three categories: (1) protein-based tests, (2) nucleic acid tests, and (3) cell-based 
detection.  For each category, we highlight the opportunities and challenges in 
diagnostics development for malaria elimination, and comment on their applicability to 
different phases of elimination strategies. 
 
3.2 Introduction 
Malaria affects billions of people around the world, especially in low– and 
middle–income countries.  In the year 2000, the United Nations General Assembly 
identified malaria as an important global health challenge and pledged to halt and reduce 
malaria incidence as a Millennium Development Goal [67].  Although there have been 
strides towards the elimination of malaria, the disease continues to be a major threat to 
world health.  According to the World Health Organization (WHO), there were 212 
million new cases and 429,000 deaths in 2015 and approximately 2.7 billion people 
remain at risk globally, with most of the disease burden falling on resource-constrained 
countries in sub-Saharan Africa or South-East Asia [68]. The WHO has set ambitious 
milestones towards a malaria-free world, including worldwide reduction of 40% in global 
incidence and mortality, and achieving malaria elimination in 10 countries by 2020 [69].   
Malaria is caused by the infection of red blood cells by five protozoan parasites of 
the Plasmodium species.  Malaria infections begin with symptoms similar to a minor 




vomiting. When diagnosed and treated early, patients make a full recovery, but, if left 
untreated, malaria can progress rapidly to a severe, potentially lethal infection within 
hours to days [26].  This is especially true for P. falciparum infections, which are almost 
always fatal without treatment [69], and account for 99% of malaria deaths [68]. The 
recommended treatment for malaria is artemisinin-combination therapy (ACT), which is 
generally effective and well-tolerated by patients [26].  However, ACT therapies can be 
over-prescribed due to lack of access to affordable diagnostics, leading to concerns about 
drug resistance in Plasmodium species. ACT therapy is often prescribed to all patients 
presenting with a fever, even without a definite malaria diagnosis [70], and, in the 
absence of an affordable diagnostic test, patients without any symptoms are often 
prescribed ACTs to prevent initial occurrence or relapse of malaria infection [26], [71].  
ACTs are also used in mass drug administration programs where all healthy members of 
a population are treated with a therapeutic concentration of antimalarial drugs to cure 
possible asymptomatic infections [26].  These programs may be enacted because 
sufficiently sensitive and affordable diagnostics are not yet available.  
Challenges for Malaria Elimination: 
Elimination of malaria is defined as country-wide interruption of mosquito-borne 
transmission of a specific Plasmodium parasite, resulting in zero indigenous cases for 3 
years or more [72].  A significant challenge for elimination efforts is the large number of 
infected patients who are asymptomatic or remain undiagnosed.  Asymptomatic 
infections do not result in a fever or the other acute symptoms described above.  These 




triggered an immune response; chronic infections with small numbers of parasites (low 
parasitemia) that will never trigger an immune response and become symptomatic; or 
infections with mild enough symptoms that lead patients not to seek treatment [30]. 
Current malaria diagnostics lack the sensitivity to identify asymptomatic patients, thereby 
curbing malaria elimination efforts (Figure 13) [30]. 
 
Figure 13: Spectrum of malaria infection. As parasite levels in blood increase, there is an 
increasing risk of morbidity, co-morbidity, mortality, and onward transmission of infection. 
Microscopy and rapid diagnostic tests (RDTs) are sensitive enough to detect symptomatic 
infections at or above the pyrogenic threshold, but are not sensitive enough to detect low parasite 
density infections.  While polymerase chain reaction (PCR) is more sensitive, it is unable to 
detect infections with very low parasite density.  Reproduced with permission from Ref [30] 




These asymptomatic patients constitute infectious reservoirs, where parasite 
transmission continues but is invisible to the health system.  While major gains have been 
made in controlling the disease by timely diagnosis and treatment of symptomatic 
patients and mosquito vector control measures, asymptomatic patients who constitute 
infectious reservoirs must be identified and treated to achieve malaria elimination [69]. 
An additional consideration in diagnostic development is the complex life cycle 
of the malaria parasite and its implications for disease transmission (Figure 14).  Sexual 
stage gametocytes are the only parasites that can transmit from the human host to the 
mosquito vector, and thus must necessarily be a consideration for any diagnostic tool 
aimed at elimination.  Only a small fraction of parasites in the bloodstream are sexual 
stage gametocytes (<5% of the total biomass for P. falciparum infections), and late stage 
gametocytes circulate in the blood stream at extremely low concentrations that cannot be 
detected by current diagnostic techniques (0.1 parasites/µL – 100 parasites/µL) [33].  
Identifying and treating these infections is an important part of malaria elimination 





Figure 14: The majority of circulating parasites in blood are in the asexual stage, found in 
varying concentrations depending on the extent of infection.  A small fraction of asexual parasites 
can produce sexual gametocytes, which are transmissible to mosquitos. The sexual multiplication 
stage (not pictured) occurs in the mosquito. Adapted by permission from Macmillan Publishers 
Ltd: Nature Reviews Microbiology, Ref [33], Copyright 2014. 
The technical challenges presented by asymptomatic infectious reservoirs and 
low-concentration gametocyte infection will need to be overcome to achieve the 
elimination targets set forth by the WHO [69].  Countries in the malaria elimination 
phase employ a targeted strategy to identify, treat, and monitor new and recurring malaria 
infection.  The elimination strategy involves (1) stratifying a geographic area by 
transmission intensity, (2) implementing vector control strategies to prevent further 




further infection transmission [72].  Diagnostic devices for elimination-phase countries 
must therefore meet performance criteria for different purposes: case management of 
symptomatic infections (>100 parasites/µL in blood), parasite screening to monitor low-
density (i.e., asymptomatic and circulating gametocyte) infections and study infection 
transmission (≤2 parasites/µL asexual stage parasites, ≤0.1 parasites/µL sexual stage 
gametocytes), and population surveillance to allow for active intervention to prevent 
transmission (≤2 parasites/µL).  Bell et al. summarized the target product profiles to meet 
the demands for elimination-phase populations in a separate review [73].  Current 
diagnostic methods are mainly focused on P. falciparum and P. vivax infections, as these 
constitute the vast majority of fatal infections in the elimination-phase countries [69].  
There is some advantage to distinguishing between the Plasmodium species for 
epidemiological studies to understand species prevalence and co-infection patterns, but it 
is more important to specifically diagnose P. falciparum, which causes the most severe 
infection [73]. 
Limitations of Current WHO-Recommended Malaria Diagnostic Methods: 
Since 2010, the WHO has recommended laboratory diagnosis of malaria using 
diagnostic light microscopy or rapid diagnostic tests (RDTs) [26].  Microscopic diagnosis 
relies on the collection of finger-prick blood, preparation of thin- or thick-blood smears 
on microscope slides, Giemsa-staining, and manual inspection of stained slides [32].  The 
process is expensive, labor-intensive, and time-consuming, requiring trained operators 
who can accurately identify early-stage parasite infection in red blood cells.  Notably, 




this method is 50-100 parasites/µL [32].  RDTs, the other WHO-recommended diagnostic 
method, rely on immunochromatographic detection of malaria-specific antigens using 
antigen-specific antibodies immobilized onto lateral flow test strips.  Histidine-Rich 
Protein 2 (HRP-2) is the most common target for P. falciparum, while parasite lactate 
dehydrogenase (pLDH) antigen is commonly targeted for pan-Plasmodium detection.  
Although RDTs provide a clinical diagnosis within 15-20 minutes, they have a LLOD 
similar to that of microscopy (50-100 parasites/µL) [31]–[33].      
Microscopy and RDTs are able to diagnose fully-symptomatic patients, and are 
thus still the gold-standard for malaria diagnosis for case management of symptomatic 
infections in many settings. However, as countries move towards malaria elimination, 
these methods will no longer be sufficient for parasite screening or population 
surveillance activities, as parasite loads in these cases are much lower (0.1 – 2 
parasites/µL).  Notably, in areas with low transmission intensity—including countries 
moving towards elimination goals—sub-microscopic infections represent 70-80% of 
diagnosed malaria infections [33].  The WHO strategy for these elimination-phase 
countries involves focused (within a specifically-defined area) or mass (within a broad 
geographical area) screening and treatment.  Therefore, in addition to higher sensitivity, 
diagnostics must be inexpensive, portable, and available in large quantities to ensure the 
success of these mass screening and treatment programs [70].  
Newly developed diagnostics are needed to enable (1) case management of 
symptomatic infections in low-resourced settings, (2) screening for asymptomatic 




monitoring of therapeutic efficacy [73].  Here, we outline advances in the development of 
technologies appropriate for point-of-care (POC) settings, and evaluate these advances 
for suitability to achieve malaria elimination goals.  Most of these technologies aim to 
achieve the target LLOD stated by the WHO for new malaria diagnostics, ≤2 
parasites/µL.  Because different target analytes are measured in different units, Table 3 
provides conversions between reported concentrations for P. falciparum. 
Table 3: Conversions between reported concentrations for P. falciparum 
Target Reported 
Concentration 
Parasite Concentration Reference 
HRP-2 
antigen 
15.3 ± 17.0 ng/mL 200 parasites/µL [74] 
pLDH 
antigen 
15.3 ± 11.3 ng/mL 200 parasites/µL [74] 






0.0235 pg 1 parasite  
(assuming 1 genome 
copy/parasite) 
[76], [77] 
In this Critical Review, we focus on demonstrated technologies that will be 
directly applicable for malaria elimination programs. Emerging and upcoming 
technologies will certainly contribute towards this goal, but are not considered within the 
scope of this review. 
Improving gold standard techniques: 
An active area of research is the improvement of current WHO-recommended 
gold standard techniques for malaria diagnosis, RDTs and microscopy. RDTs are the 
most commonly used malaria diagnostic tests due to their relative ease-of-use and 
availability in public-sector health facilities [78].  RDTs target malaria-specific antigens 




asymptomatic infections.  Current best-in-class RDTs can detect as low as 0.8ng/mL 
HRP-2, and 25ng/mL pLDH for P. falciparum and pan-Plasmodium diagnosis, 
respectively, but most available RDTs do not reach this sensitivity [79].   In addition, if 
the antigen concentration in the sample is too dilute, there is insufficient antigen to bind 
to the test line to enable visual readout, producing a false negative result.  Recent efforts 
have focused on sample preparation and concentration strategies to improve existing 
RDT sensitivity, improving on the existing RDT sample workflow [80], [81].   
Several approaches to improve RDT signal by incorporating signal enhancement 
reagents and enzymes have been reviewed elsewhere [82].  Sample concentration 
strategies have also been developed to improve malaria RDTs. For example, Davis et al. 
have developed several technologies to purify and concentrate target analytes from whole 
blood using nickel nitrilotriacetic acid (Ni-NTA), which selectively binds histidine-rich 
proteins in whole blood. Using Ni-NTA-functionalized agarose beads, the group 
developed a method increase the concentration of malaria-specific HRP-2 antigen in 
blood, and integrated the method with commercially available RDTs [83]–[86].  Their 
most recent device, called mBEADS (Magnetically-enabled Biomarker Extraction And 
Delivery System), is a portable unit designed to concentrate the sample and deposit it 
onto commercially-available RDTs (Figure 15(i)). The device was demonstrated with 
five commonly-used RDT brands, adding minimal processing time and cost per assay, 
and resulting in approximately 10-fold increase in sensitivity compared to conventional 
RDT results.  Other RDT improvement strategies have focused on improving the visual 




RDT test line, allowing for an increase in sensitivity. For example, one technique exploits 
the thermal signature of irradiated gold nanoparticles bound to a test line using thermal 
contrast imaging [87], while other techniques involve the development of adapters for 
cell-phone cameras to better read RDT signal [88].  
Innovative approaches are also in development to improve microscopy, making it 
more portable for field use. A commercially-available handheld light microscope, the 
Newton Nm1, was demonstrated for malaria diagnosis from Giemsa-stained thick blood 
smears from 223 clinical samples from rural Côte d’Ivoire.  The portable microscope 
showed 80.2% sensitivity and 100% specificity, indicating promising results for field 
deployment [89].  In another study, a cell phone-based polarized microscope was 
developed to detect birefringence of the malaria-specific biomarker hemazoin in Giemsa-
stained blood smears, making it an easy-to-deploy solution for standard malaria 
microscopy (Figure 15(ii)) [90]. While not initially used for malaria diagnosis, the 
Foldscope, an origami-based, foldable paper microscope, and the Cellscope, a cell-phone 
based portable optical system [91], could be easily adapted to observe Giemsa-stained 
blood smears for malaria diagnosis in the field. These microscopy-based approaches can 
be deployed in the field to improve malaria case management; although they do not 
improve LLOD of microscopy, they obviate the need for expensive microscopes and 





Figure 15: Improvements for existing gold standard techniques (i) mBEADS system for sample 
concentration of HRP-2 from lysed whole blood.  Lysed whole blood is incubated with Ni-NTA 
beads in a tube, and the concentrated sample is dispensed onto commercial RDTs for more 
sensitive detection. Reproduced from Ref [85] with permission from the Royal Society of 
Chemistry. (ii) Cell-phone based transmission polarized light microscope. The MOPID system 
incorporates an iPhone 5S with polarizer sheets attached to a 3D-printed fitting holding a light 
source, diffuser, sample slide, and microscope attachment. Reproduced in part from Ref [90] 
(2015), license CC BY 4.0 
 
3.3 Emerging Lab-on-a-Chip Point of Care Diagnostics: 
Lab-on-a-chip strategies have the potential to fulfill the need for portable 
diagnostics with improved sensitivity. Over the past 15 years, there has been significant 
research on improving existing diagnostics and developing new microfluidic and paper-
fluidic strategies to meet the needs outlined above.  The solutions can be broadly divided 
into three categories based on the analyte of interest: protein-based tests, nucleic acid 
tests (NATs), and cell-based detection.  
Protein detection tests: 
Protein detection assays in microfluidic cartridges: 
In addition to research on RDT improvement outlined above, recent work has also 




using microfluidics.  ELISA tests have the advantage of better sensitivity compared to 
RDTs, but suffer from the need for expensive equipment and long assay times. 
Several groups have developed ELISA-based microfluidic devices that rely on 
smartphones to power fluid flow and for assay readout.  Lillehoj et al. developed a 
smartphone-compatible microfluidic chip to detect HRP-2 levels in blood.  Capillary flow 
drives the sample through the chip, which is connected to an embedded circuit to measure 
amperometric changes caused by biomolecules of interest [92].  Similarly, Laksanasopin 
et al. developed a triplex ELISA assay to run on a smartphone dongle, driving fluid flow 
and reading the optical output using power from the phone [93]. 
Novel paper-fluidic immunoassays: 
Paper-based immunoassays have been proposed for malaria elimination, moving 
away from the conventional RDT lateral flow format for expanded functionality.  2-
dimensional (2-D) paper-based devices retain the advantages of commercial lateral flow 
tests—low costs, ease-of-use, short sample-to-answer time, and minimal external 
equipment—while incorporating more sophisticated functions on a paper substrate.  By 
incorporating longer lengths of paper orthogonal to the main flow path, reagents can be 
delivered sequentially without the need for user-timed steps, thus allowing for enhanced 
capabilities compared to standard lateral flow formats.  For example, 2-D paper matrices 
have been used to incorporate gold enhancement reagents for signal amplification of gold 
nanoparticles.  Commercially available gold enhancement systems consist of multiple 
reagents that must be mixed together immediately prior to use.  Fridley et al. 




the 2-D paper matrix enabled controlled reagent rehydration to enhance the signal 
produced by HRP-2 antigen binding (Figure 16(i)) [94], [95].  Similarly, Grant et al. 
incorporated a biotin-streptavidin interaction into a 2-D paper matrix to enhance signal 
from HRP-2 compared to RDTs.  Here, controlled fluid flow enabled careful, automated 
delivery and mixing of the sample with biotinylated detection antibody, streptavidin 
horseradish peroxidase, a wash buffer, colorimetric substrate, and a final wash buffer 
[96].   
 
Figure 16: 2-dimensional and 3-dimensional paper-fluidic devices (i) 2-D paper matrix with 
dried and spotted gold enhancement reagents. The 2-D paper matrix allows for in situ mixing of 
the gold enhancement reagents upon sample addition and additional washing prior to incubation 
with detection antibody.  Reproduced with permission from Ref [94]. Copyright 2014, American 
Chemical Society. (ii) DxBox 3-D paper-plastic device for integrated sample processing and 
amplification. The 3-D setup incorporates pneumatic control for pressure regulation (A), allowing 
for controlled reagent storage and rehydration (B), batch mixing (C), and plasma separation (D). 
Reproduced from Ref [97] with permission from the Royal Society of Chemistry. (iii) Expanded 
view of 3-D paper device for integrated sample processing, distribution, and readout. The 
collapsed device enables sample distribution to three channels and multiple assay steps as the 
sample moves through the vertical layers.  Reprinted with permission from Ref [98].  Copyright 




Other groups have proposed novel 3-dimensional (3-D) paperfluidic 
immunoassays for integrated sample concentration and detection or for multiplexed 
detection of multiple targets.  Pereira et al. developed a 3-D paper design to incorporate 
an aqueous two-phase system for simultaneous concentration and detection of pLDH 
[99].  Lafleur et al. developed a combination paper-plastic system, called the DxBox, 
which relies on pneumatic control to regulate pressure and drive fluid flow through a 
custom immunoassay card (Figure 16(ii)).  The system incorporates plasma separation, 
batch mixing for sample dilution and purification, and controlled reagent flow for 
detection of multiple antigens [97].  More recently, Deraney et al. demonstrated a 
completely paper-based 3-D microfluidic device to separate plasma and distribute sample 
to three different test zones, each of which contained reagents for a different target 
analyte, enabling the diagnosis of multiple co-presenting febrile illnesses from a single 
patient sample (Figure 16(iii)) [98].  These devices showed successful detection of 
malaria antigens, along with other target antigens for other diseases. 
Novel protein detection strategies: 
In addition to novel paper-based devices that rely on conventional antibodies, 
alternative antigen capture and detection strategies are also being explored in 
microfluidic and paper-fluidic formats. DNA aptamers have been developed to 
specifically bind malaria antigens with high affinity [100]–[103].  Incorporating these 
aptamers into easy-to-use visual detection systems, such as lateral flow detection, 
provides a highly sensitive point-of-care diagnostic system for malaria [100].  Moving 




captured HRP-2 or pLDH antigens have also been developed.  For example, Kim et al. 
developed an automated droplet-based microfluidic device to detect HRP-2 with quantum 
dot fluorescence.  Here, magnetic beads conjugated with HRP-2 antibodies capture the 
antigen, and HRP-2 antibodies conjugated quantum dots (QDs) are used for detection, 
allowing for more sensitive detection than gold nanoparticles with fluorescent readout 
[104].  Colorimetric dyes are also used for detection: Chakma et al. developed a novel 
detection strategy using competitive binding and displacement of an indicator dye.  
Murexide dye forms a complex with Ni+2, and is displaced from the complex by HRP-2; 
the conformational change results in a color change from orange to pink.  The device’s 
six colorimetric test zones to allow for simple visual detection of HRP-2 [105]. 
The protein-based approaches described above demonstrate important progress 








Table 4: Summary of protein-based LOC devices.  *Original values were reported in parasites/µL; antigen levels were calculated based 
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P. falciparum Human serum HRP-2 16 ng/mL 15 minutes [92] 
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P. falciparum Urine, Serum HRP-2 0.5 ng/mL Not reported [104] 
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Nucleic Acid Tests: 
Molecular techniques that target parasite-specific nucleic acid sequences have 
emerged as alternatives to light microscopy or protein-based immunoassay diagnostics.  
These nucleic acid tests (NATs) are highly sensitive and specific for both pan-
Plasmodium and species-specific targets, making them ideal for detecting low levels of 
parasitemia characteristic in elimination-phase populations. The 18S rRNA gene is the 
most commonly used target for amplification because it is present in multiple copies in 
the Plasmodium genome, is highly conserved, and has consensus regions across all five 
Plasmodium species as well as species-specific regions [106]. Recently, genome-mining 
approaches have identified other targets, such as tandem repeat sequences dispersed 
throughout the genome, as targets for amplification, which significantly improve limits of 
detection of nucleic acid amplification assays for both P. falciparum and P. vivax malaria 
[107]–[109].   
Several NATs, such as polymerase chain reaction (PCR), quantitative PCR 
(qPCR), and nested PCR (nPCR) assays, have been developed for malaria infections, and 
are widely considered the most sensitive diagnostic methods. However, PCR is generally 
thought to be too complex for field applications [26], requiring extensive sample 
preparation, sophisticated equipment for thermal cycling, expensive reagents, and skilled 
personnel.  While PCR assays are currently not recommended by the WHO for case 
management and surveillance [72], microfluidic systems have the potential to bring these 
assays to the field to make them more widely adopted. Modifications to make PCR more 




elsewhere [110]. Additionally, isothermal nucleic acid amplification assays—alternatives 
to PCR which operate at a single temperature, therefore eliminating the need for 
expensive thermal cycling equipment—have also been reviewed elsewhere [111].  The 
approaches described below specifically rely on micro- and paper-fluidics to improve 
traditional NATs.  An important consideration for NAT-based microfluidics is the 
potential for carry-over contamination, in which amplification products from one reaction 
may carry over to subsequent reactions, thereby increasing the likelihood of false positive 
results.  Many microfluidic devices discussed here are proposed as closed systems that 
are disposable, minimizing the potential for contamination. In addition to creating closed 
systems, several techniques have been proposed to minimize cross-contamination, 
including pre- and post-amplification sterilization, enzymatic inactivation of carried over 
amplicons, and chemical inactivation of nucleic acids. These techniques have been 
extensively reviewed elsewhere [112]. 
Microfluidic Approaches for PCR: 
Microfluidic and paper-fluidic methods have been developed to integrate the 
entire diagnostic process, from sampling to readout, into a single device while requiring a 
minimal number of user steps and retaining high sensitivity and specificity with short 
assay time.  Several microfluidics based approaches for various parts of the PCR process 
were previously reviewed by Wu et al. [113]; here, we will provide an overview of 
microfluidic devices specifically for malaria NATs. 
Over the last decade, portable, microfluidics-based PCR assays have become 




developed for malaria diagnosis, they have been successfully demonstrated for similar 
diseases at the point-of-care.  The Palm PCR (Ahram Biosystems Inc.) [114] and the 
TrueNat Uno (Molbio Diagnostics Pvt. Ltd.) [115] systems are examples of portable 
systems with disposable microfluidic chips for PCR reactions, with off-chip DNA 
extraction and purification. The GeneXpert system (Cepheid, Inc.) is a fully-integrated 
system with heating/cooling plates, optical blocks, and an internal processor to drive fluid 
flow through a custom microfluidic cartridge using a syringe barrel (Figure 17(i)).  
Unprocessed patient samples are placed into individual cartridges, and the system 
automatically moves the sample through specified chambers for lysis and nucleic acid 
extraction, purification, and amplification with a real-time fluorescence readout [116]; the 
system has also been demonstrated for blood samples [117].  The Accutas system (Aquila 
Diagnostics Systems, Inc.) was developed specifically for malaria diagnosis and uses a 
high-efficiency Omni KlenTaq enzyme to allow for amplification directly from blood 
without sample processing. In this system, a custom microfluidic chip with embedded 
PCR reagents is inserted into a benchtop unit for amplification and detection (Figure 
17(ii)) [118], [119].  In a small-scale clinical study, the Accutas system showed good 
concordance (97%) with conventional real-time PCR results, and limit of detection of 2 
parasites/µL.  These commercially available techniques have been tested in the field with 
clinical samples; the reported clinical sensitivity and specificity for each commercial 





Figure 17: Commercially available lab-on-a-chip devices for PCR. (i) The Cepheid GeneXpert 
microfluidic PCR cartridge.  The cartridge can be inserted into Cepheid GeneXpert system, which 
enables sample processing, thermal cycling for PCR amplification, and detection.  Reproduced in 
part with permission from Ref [116]. Copyright 2005, Clinical Chemistry. (ii) Microfluidic chip 
for Accutas system. A) Schematic of microfluidic chip for hydrogel PCR. A hydrogel embedded 
with PCR reagents adheres to the surface of the chip; blood flows in the channel underneath by 
capillary flow, and is absorbed by the hydrogel. B) Photo of a wax chip containing trenches 
overlaid with hydrogels bound to a glass coverslip. C) Photo of plastic chip made of two separate 
pieces; hydrogels are housed within wells on the top piece, with the second piece leaving space 
for capillary flow. Reproduced with permission from Ref [119], license CC BY 4.0. 
Microfluidic approaches for isothermal assays: 
Notably, all of the commercially-available devices have been developed for PCR assays, 
and as of yet, no commercial microfluidic devices are available for isothermal NATs 




(LAMP) is the most commonly used isothermal NAT strategy for malaria diagnosis.  
Commercially-available LAMP-based malaria diagnostics exist, but they are not yet fully 
portable, requiring benchtop instrumentation and separate sample processing.  Many of 
these commercial systems rely on turbidity measurements, as LAMP reactions produce a 
large amount of DNA and produce magnesium pyrophosphate precipitate as a byproduct 
[120].  For example, the Illumigene® (Meridian Biosciences, Inc.) uses a custom 
benchtop instrument to heat a sample tube to the required reaction temperature and 
optically measure the turbidity of the post-amplification product [121].  Similarly, the 
Loopamp® assay (Eiken, Inc.) is also based on a turbidity reading, and has been 
demonstrated in field evaluation with a non-instrumented nucleic acid amplification 
system developed for the benchtop [122], [123].   These instruments could be 
miniaturized for portable applications, but they remain benchtop-only at this time. 
Non-commercial, research-grade microfluidic devices are being developed for 
NATs for both sample processing and amplification on-chip.  For example, Liu et al. 
developed a two-stage system with sequential microfluidic devices for sample processing 
and amplification.  The first stage utilizes dimethyl adipimidate/thin film sample 
processing to isolate DNA, while the second utilizes Mach-Zehnder Interferometer-
Isothermal solid-phase DNA amplification and sensing.  In this device, isothermal 
amplification is achieved using recombinase polymerase amplification (RPA).  
Combined, the device has a sensitive LLOD (1 parasite/µL) and requires approximately 1 
hour of assay time [124].   




These systems utilize centrifugal force to move fluids, obviating the need for a pump to 
drive fluid flow.  However, centrifugal systems can have high power requirements, and 
fluid flow can be difficult to control precisely in these systems, making them unsuitable 
for POC applications. Choi et al. developed the AnyMDx system for malaria diagnosis, 
which relies on rotational magnetic interactions rather than centrifugal force.  The 
AnyMDx system (Figure 18) uses a custom-built disposable cartridge containing 
stationary reagent droplets in distinct chambers for nucleic acid extraction and 
purification, amplification, and detection. DNA-carrying magnetic beads move between 
chambers through a passive valve system, which retains the reagent droplets in the 
appropriate chambers while the beads move through.  The system takes 10µL of whole 
blood as an input, amplifies P. falciparum DNA with LAMP, and provides a quantitative 
output within 40 minutes with a LLOD of 0.6 parasites/µL.  For a low-cost and simple 
user interface, the AnyMDx offers both sensitive and quantitative diagnosis, making it 
appropriate for applications in malaria elimination [125].  Other diagnostic devices use 
centrifugal force to separate plasma from whole blood and isolate malaria parasites; this 





Figure 18: AnyMDx benchtop system for malaria LAMP.  A) Each disposable cartridge disc can 
perform three independent tests.  Each test region is designed to integrate sample processing and 
amplification B) The cartridges are placed into a custom unit for amplification. MCU, 
microcontroller unit; LCD, liquid crystal display. Reproduced from Ref [125] with permission of 
The Royal Society of Chemistry. 
Paper-fluidic approaches for NATs: 
The simplest and most inexpensive diagnostics currently in development are 
paper-based devices which benefit from low raw material and shipping costs and require 
relatively few user steps. Another advantage is that paper is commonly used for sample 
collection and storage in the field. The collection of dried blood spots (DBS) onto filter 
paper has been widely adopted in POC screening programs, as these samples are easy to  
collect and store for later analysis [127]. Several groups have developed techniques for 
reliable extraction of nucleic acids from DBS samples, followed by amplification using a 
highly sensitive, benchtop NAT [128]–[132]. The most common incorporation of paper 
into the NAT assay workflow is for visual readout using lateral flow strips: nucleic acid 
amplicons are labeled with molecular tags that can be captured by antibodies 




(YES/NO) sample readout. Several groups have shown lateral flow “dipstick” analysis—
in which lateral flow strips are dipped into post-amplification solutions—to provide 
visual readout of benchtop NATs [99], [133]–[138].  Although there is a lack of 
quantitation, NATs are more sensitive than existing RDTs, providing these “dipstick” 
NATs with an advantage over the existing lateral flow technique. A simple YES/NO 
readout from an assay with high sensitivity and specificity would be useful for mass 
screening and treatment programs. The most promising paper microfluidic devices are 
integrated devices which rely only on passive wicking to move fluids, eliminating the 
need for active pumping required in traditional microfluidic devices.  Fully-integrated 
devices have previously been demonstrated for other disease diagnostics [139]–[142].  
Cordray and Richards-Kortum demonstrated an integrated paper-and-plastic device to 
amplify malaria DNA using RPA (Figure 19(i)) [143].  More recently, Xu et al. 
demonstrated a paper-origami-based device which incorporates all process steps, 
including sample processing and readout (Figure 19(ii)).  The device incorporates a 
simple paper-folding technique to lyse whole blood, and extract and transfer the DNA 
into an amplification region, where multiple LAMP assays can be performed.  After 





Figure 19: Integrated paper-fluidic devices for isothermal amplification (i) Integrated paper-and-
plastic device for amplification with RPA.  a) The Sample slider starts at Position 1 for sample 
mixing with RPA reagents and amplification; b) Sample slider is moved to Position 2 to absorb 
RPA buffer; c) Sample slider is moved to position 3 for dilution with buffer; d) Sample slider is 
moved to position 4 for contact with lateral flow strip and visual readout. Reproduced with 
permission from Ref [143] (2015), license CC BY 4.0. (ii) Paper origami based multiplex LAMP 
assay. A) The device consists of filter paper with 5 distinct panels; hydrophobic wax was printed 
onto the paper to form channels; B) Fully folded device, C) For extraction, panels 2 and 3 are 
folded together and rested on top of panel 1.  The sample is dispensed onto panel 3 and extracted 
using capillary flows vertically from panel 3 to panel 1.  D) The 2-3 panel is flipped over onto the 
4-5 panel to transfer the sample to LAMP spots on panel 5 where the reaction is carried out. E) A 
UV flashlight at 365 nm is used to read out the signal. Reproduced with permission from Ref 
[144] (2016), license CC BY 4.0 
 
There are several techniques in development for benchtop amplification assays 
that can be incorporated into paper-fluidic diagnostics.  One potential avenue for 
improvement is the incorporation of colorimetric dyes onto paper-based tests to enable 
visual readout. Hydroxy naphtol blue (HNB), a metal ion indicator responsive to the 
concentration of Mg+2 ions in the reaction, is commonly used as a colorimetric indicator 
of the LAMP reaction [145] and has been demonstrated for several LAMP-based malaria 
assays [133], [136], [146], [147].  Other colorimetric dyes such as the intercalating dye 
malachite green [148] or custom-made dyes [149], have also been demonstrated in 




than a quantitative readout, which would be best suited for screening programs. 
In addition to improving assay readout, paper-fluidic devices must minimize or 
eliminate sample pre-processing.  It has been demonstrated that robust isothermal assays, 
such as helicase dependent amplification (HDA) or LAMP, are capable of amplifying 
DNA directly from a sample of whole blood with minimal assay inhibition [76], [149], 
[150].  These assays still require some sample processing, such as pre-dilution of the 
whole blood sample, or sample denaturation by boiling.  Still, these technologies obviate 
the need for more complex DNA isolation and purification from biological samples, and 
could therefore be adapted to paper-fluidic devices.   A potential challenge for these 
direct amplification techniques might be their relatively small sample volumes (<5 µL 
blood).  In cases where parasite concentration is relatively dilute, there is a need to 
process larger volumes (60 – 100µL) of sample in order to minimize variability [61].  For 
larger sample volumes with dilute parasite concentrations, benchtop techniques to 
concentrate and purify nucleic acids from biological samples may be adapted to paper-
fluidic formats. These techniques include microwave irradiation from whole blood [151], 
nucleic acid isolation using magnetic beads [152], and filtration through blood separation 
paper [153].   
Non-amplification based NATs: 
An additional class of nucleic acid tests do not rely on amplification of nucleic acids, but 
rather use them as a means for detection. For instance, the Rolling circle Enhanced 
Enzyme Activity Detection (REEAD) system generates a DNA substrate that is 




cleavage, a fluorescent probe binds to the product and results in a quantitative readout 
that can be related to the initial parasite density in the sample.  Juul et al. have developed 
molecular beacons to specifically detect P. falciparum infection using the REEAD 
system [154], [155].  They incorporated their technique into a droplet microfluidics-based 
platform which generates picoliter droplets containing the sample, lysis buffer, and 
enzymes deposited onto a primer-coated glass slide to enable rolling circle amplification 
of the DNA substrate, which is subsequently cleaved by pTopI (Figure 20).  Using this 
system, the authors show an LLOD of 500 parasites/µL [156], [157]. 
 
Figure 20: REEAD microfluidic system. (a) Top: schematic of the microfluidic channel device.  
Sample is loaded into channel I, S1 and S(TopI) are loaded into channel II, and lysis buffer is 
loaded into channel III.  Oil is fed in through channel IV to encapsulate the three components into 
droplets.  The droplets move through a serpentine channel (V) to ensure mixing of droplet content 
and are deposited into the drop-trap device.  Bottom: Drop-trap device confines droplets in 
cavities at the intersections in the drop-trap and exsiccates them onto a primer-coated glass slide 
for RCA. (b) Light-microscopic view of the microfluidic platform showing blood, substrates, and 
lysis buffer encapsulation in picoliter oil droplets. Reprinted with permission from Ref [156]. 
Copyright 2012 American Chemical Society. 
NAT development is an active area of research for malaria diagnostic development; 






Table 5: Summary of nucleic acid based LOC diagnostic devices.  Par/µL, parasites/µL; qPCR, quantitative PCR; nPCR, nested PCR; 
PET-PC, photo-induced electron transfer PCR; *Reference methods used for comparison are listed in parentheses. 
 Technique Parasite Sample 
Sample 
processing 













































































Turbidity 2 par/ µL 
Not 
reported 














































































































Fluorescence 5 par/ µL 
45 
minutes 



















































































































+ Heat lysis, 
Saliva Mobicol 
DNA isolation 
Cox1 gene Fluorescence 1 par/ µL 
30 
minutes 

























Another active field of research for malaria diagnosis is the development of 
diagnostics based on the direct detection of parasites, or of cells infected with parasites.  
Malaria infection is known to alter red blood cell mechanical properties, including shape 
and stiffness, and their magnetic properties. In addition, malaria parasites produce 
hemozoin as a metabolic by-product inside the red blood cells; the biophysical properties 
of this molecule can be exploited to identify infected red blood cells. Several groups have 
developed techniques to distinguish infected red blood cells from uninfected red blood 
cells based on one or more of these cellular characteristics. 
In-vivo, wearable diagnostic devices: 
Another area of research aims to develop non-invasive, wearable devices for 
malaria diagnosis.  For instance, Burnett et al. have developed multiple needle-free 
techniques for in vivo diagnosis based on the optical properties of circulating malaria-
infected red blood cells.  In one case, they used nuclei-binding proflavine stain, applied 
topically to the skin, to identify parasite-infected red blood cells in a chicken embryo 
model using a custom-built confocal microscope [158].  This proof of concept study 
shows promising results for the detection of stained nuclei in circulating parasite-infected 
red blood cells.   Another non-invasive method utilizes optical signatures for 
birefringence and absorbance of hemozoin using a custom-built portable microscope to 
image the superficial vasculature.  Using Plasmodium-infected mice, the researchers 
showed distinct signatures for infected and uninfected red blood cells [159].  Menyaev et 




cytometry.  The technique showed high sensitivity for malaria infection in a mouse 
model, distinguishing low level of parasitemia from uninfected controls in a short amount 
of time [160], [161].   Although still under development, these optical techniques 
represent progress towards wearable, non-invasive diagnostic methods for malaria. They 
are promising for point-of-care elimination settings, as they allow for rapid, real-time 
detection of infection without the need for sample processing or long assay times. 
Microfluidic devices for cell-based diagnosis: 
Other groups have focused on using differences in infected red blood cell 
properties to sort cells in microfluidic devices.  Several techniques have focused on 
exploiting differences in dielectrophoretic and magnetic properties of infected red blood 
cells.  Kasetsirikul et al. extensively reviewed microfluidic devices using both of these 
methods [162].  In the first case, microfluidic devices have been developed which utilize 
an inhomogeneous electrical field to sort and separate cells based on their differences in 
their dielectric properties.  Gascoyne et al. characterized dielectric differences between 
normal and malaria-infected red blood cells, and exploited these properties to separate the 
cell populations in a microfluidic device [163]–[165]. Du et al. expanded on this concept 
to manipulate the dielectric properties of cells to understand mechanical differences in the 
cells.  Here, the authors created a microfluidic device to trap cells using alternating 
current dielectrophoresis and quantitatively determined the force versus deformation 
characteristics of the cells. They demonstrated that healthy, uninfected red blood cells 
were trapped and stretched more significantly than parasite-infected red blood cells due 




It is important to note that the authors worked with samples depleted of contaminating 
leukocytes, as this study aimed to understand biomechanical differences between infected 
and uninfected red blood cells [166].  
Malaria-infected red blood cells can also be sorted based on their magnetic 
properties [167].  Parasite digestion of hemoglobin results in aggregates of haem groups 
which form an insoluble pigment called haemozoin.  Electron paramagnetic resonance 
and Moessbaur spectroscopy have shown that haemozoin has magnetic properties [162]. 
This property of infected red blood cells has been utilized by several groups to develop 
novel microfluidic devices for malaria diagnosis. Several groups have exploited the 
magnetic properties of infected red blood cells to develop microfluidic cell sorters; many 
of these are described in detail elsewhere [162].  In one example of a magnet-based 
microfluidic device, Nam et al. used a ferromagnetic nickel wire was embedded in the 
microfluidic device with a permanent magnet was affixed to the outside to induce an 
external magnetic field.  The cells were first aligned by hydrodynamic focusing, and as 
the sample flowed through the device, infected red blood cells gathered near the nickel 
wire while the remaining cells stayed toward the top of the fluid stream. A separation 
channel at the end of the device allowed sorting and collection of the infected red blood 
cell population (Figure 21). As in other cell-based microfluidic devices, the authors 
demonstrated their device using isolated red blood cells rather than whole blood, and 






Figure 21: Magnetic sorting of malaria-infected red blood cells. A) Schematic of separation 
using paramagnetic characteristics of hemozoin in infected RBCs.  b) Working principle of 
magnetophoretic separation with a ferromagnetic nickel wire in an external magnetic field. 
c) Image of the microfluidic device with affixed permanent magnet. Reprinted with 
permission from Ref [167]. Copyright 2013, American Chemical Society.   
Other groups have investigated alternative approaches to malaria diagnostics 
based on other physical characteristics of malaria-infected cells.  One such property is the 
increased stiffness of malaria-infected red blood cells.  Microfluidic devices have been 
developed to take advantage of the naturally-occurring phenomenon of margination, 
where larger and stiffer leukocytes migrate toward the walls of blood vessels, while 
smaller and more deformable red blood cells migrate toward the center of the vessel.  
Hou et al. mimicked this phenomenon in a one-inlet, three-outlet microfluidic device, in 
which a high-hematocrit, infected blood sample was pumped through a long, straight 
channel (Figure 22(i)) [168].  Due to the margination effect, infected red blood cells, 




and were successfully collected in outlets stemming from the walls.  Uninfected red 
blood cells, which were more deformable and remained in the middle of the straight 
channel, were collected in an outlet stemming from the middle of the channel. The 
authors reported ~75% recovery of early-stage infected red blood cells, and >90% 
recovery of late-stage infected red blood cells from a high-hematocrit sample.  
Additionally, they showed that the presence of leukocytes did not impact the margination 
effect of red blood cells; while the larger leukocytes were also collected into the side 
outlets, their presence did not alter the percent recovery of infected red blood cells.  
Kong et al. expanded on this concept to take advantage of both the increased stiffness and 
magnetic properties of infected red blood cells for diagnosis (Figure 22(ii)).   Here, the 
authors first utilized a microfluidic device to sort and separate infected red blood cells 
through margination, which allowed for increased concentration of the infected blood 
cells in the sample.  Similar to the previously described device, this microfluidic device 
also required high-hematocrit samples to effectively enrich infected red blood cells from 
1.9 to 32.1 times, depending on the stage of the parasite life cycle.  The authors 
subsequently tested the concentrated sample using magnetic resonance relaxometry, in 
which a portable permanent magnet provides a strong polarizing magnetic field and a 
radiofrequency detection probe measures the relaxation rate of the emission signal from 
the sample [169].  The increased magnetic susceptibility of infected red blood cells 
compared to healthy red blood cells resulted in a significant difference in relaxation rate, 
allowing the authors to distinguish between the two cell types with high sensitivity.  




relaxation rate, instead allowing to compare the change in relaxation rate between healthy 
and infected red blood cells within a single sample, since both are collected in the 
microfluidic device [170].  
 
Figure 22: Microfluidic devices for margination of infected red blood cells. (i) Straight 
channel design for microfluidic margination. (a) Outlets 1 and 2 collect infected red blood 
cells, and the center outlet collects uninfected red blood cells. (b) Infected red blood cells 
align along the walls of the microfluidic channel due to the margination effect. Reproduced 
from Ref [168] with permission from The Royal Society of Chemistry.  (ii) Margination 
combined with magnetic relaxometry.  (a) Cells are sorted using a microfluidic device 
according to margination properties (b) Both uninfected red blood cells from the middle 
outlet and infected red blood cells from the side outlets are analyzed using magnetic 
resonance relaxometry to determine a relative relaxation rate for each sample. Reproduced 
with permission from Ref [170] (2015), license CC BY 4.0. 
Infected red blood cells also exhibit characteristic differences in optical 
properties, which can be used to distinguish them from healthy red blood cells. For 
instance, Banoth et al. developed a portable microfluidic device to detect the optical 
absorbance characteristics of red blood cells [171], [172].  In this system, a microfluidic 
chip with a narrow channel allowing for single-cell flow was incorporated into a custom-
built portable optical system.  The device allowed for real-time detection and analysis of 
optical absorbance of cells flowing through the single channel device.  The device was 




in the sample would be distinct from those of red blood cells.  Using the system, the 
authors showed that malaria-infected red blood cells displayed a unique absorbance 
signal, and could be distinguished from other cell types in whole blood. 
Microfluidic optical devices have also been developed to analyze and identify 
infected red blood cells according to their compliance properties.  Mauritz et al. 
developed a microfluidic optical stretcher to identify early-stage infected red blood cells 
in a high-throughput technique. An SU-8 pattern on a glass slide is used to support a 
capillary for sample flow and two optical fibers to deliver laser light.  As cells flow 
through the capillary, they are trapped in the laser light and stretched by modulating the 
light intensity.  The device is placed under a microscope-mounted camera, and analysis 
of cell elongation over time is used to calculate cell compliance.  Infected red blood cells 
have reduced compliance compared to uninfected red blood cells; measuring compliance 
therefore enables single-cell diagnosis of infection [173].  The study described here 
focused on samples containing only red blood cells; however, since the technique works 
at a single-cell level, it is reasonable to predict that leukocytes or other contaminating 
cells would not impact the results, as the mechanical signatures of other cell types would 
be distinct from red blood cells. Furthermore, although the device relies on a microscope 
mounted with a camera and a laser, there is potential for making the device more 
portable, allowing for field deployment, and enabling high-throughput analysis for 
parasite screening with high sensitivity. 
Several studies have also used compliance and deformability characteristics to 




malaria-infected cells based on their decreased deformability and increased 
cytoadherence.  In this study, the authors designed a blood-on-a-chip device to monitor 
biophysical properties of blood using a microfluidic analog of a Wheatstone-bridge 
electric circuit (Figure 23(i)) [174].  Here, the authors incorporate time-resolved 
microparticle image velocimetry to monitor the deformability and the viscosity of blood 
samples in a high-throughput and label-free manner.  Guo et al. developed a similar 
system to sort red blood cells based on deformability [175].  Here, the authors introduce 
two separate flows, one for filtration and a second for declogging as the sample moves 
through a matrix of constrictions.  Uninfected red blood cells, which are more 
deformable, become lodged on the constrictions, while stiffer, infected red blood cells 
move through the device.   Cells of varying deformabilities are collected at various stages 
throughout the device, with the final collection chamber collecting mainly pure infected 
red blood cells (Figure 23(ii)). Bow, et al. also developed a deformability chamber.  In 
this design, images are collected and analyzed as the sample moves through a 
microfluidic device with constrictions.  Deformable healthy red blood cells are able to 
move through the constrictions with greater ease and progress through the chamber 
faster, while uninfected healthy red blood cells take a longer time to pass through [176].  
The proposed devices discussed here were tested with leukocyte-free samples.  However, 
in all cases, it is possible to incorporate an additional chamber to remove contaminating 
leukocytes from a whole blood sample. Additionally, these microfluidic devices are 
proposed as enrichment chambers, to be used in conjunction with RDTs or other 




sensitivity.  However, it is conceivable that they could be used as stand-alone diagnostic 
devices on their own.  
 
Figure 23: Blood on a chip devices to assess red blood cell deformability and viscosity.  (i) 
Deformability chamber based on Wheatstone bridge circuit.  (A) Two syringe pumps 
deliver blood sample and reference fluid into the microfluidic device. (B) All channels 
except the right upper side channels fill with blood. Fluid moves through the bridge channel 
(BRG), and the microfluidic filters in the deformability assessment chamber (DAC) become 
clogged due to RBC deformability. After t3, the blood and reference fluid flow into the 
lower right side channel.  The blood filled width (αBlood) varies depending on viscosity and 
flow rate. C) Time-resolved images are used to calculate average velocities of blood flow in 
DAC and BRG channels. Reproduced in part from Ref [114]. Copyright 2016, American 
Chemical Society. (ii) Deformability chamber using ratchet transport.  (A-B) Each funnel 
constriction experiences oscillation excitation due to upward filtration flow and downward 
declogging flow, enabling unidirectional flow.  (C) Sample is applied through the inlet 
(bottom left). The sample moves across the device in a diagonal trajectory due to the 
combined forces from the cross-flow inlet (CFI) and the oscillation excitation from the two 
oscillation inlets (Osc1 and Osc2).  More deformable (uninfected) cells travel further up the 
chamber, while stiffer (infected) cells become blocked midway; samples are collected into 
outlets throughout the chamber (O1-O9).  Reproduced from Ref [115] with permission from 
The Royal Society of Chemistry. 
Other microfluidic devices utilize the property of hydrodynamic lift forces on 
particles submerged and flowing within a liquid.  Inertial hydrodynamic lift acts on all 
particles under intermediate Reynolds number flows, where shear forces of the moving 




the other hand, are important for compliant, deformable objects at low Reynolds number 
flows, where shear forces are sufficiently low such that inertial effects become negligible 
[177].  Several microfluidic devices have been developed which exploit these 
hydrodynamic lift properties to sort infected red blood cells.  For example, Warkiani et 
al. developed an inertial microfluidic device to sort and isolate parasite-infected red blood 
cells from lysed white blood cells for use in downstream PCR applications. The channels 
were designed with a high aspect ratio to obtain a high shear rate along the width of the 
channel, causing white blood cells to align along the channel walls, and infected red 
blood cells to remain in the center. The red blood cells were collected from the center 
channel for further downstream analysis [178]. Conversely, Geislinger et al. developed a 
simple microfluidic device to sort cells based on non-inertial forces at low Reynolds 
number flows. Here, the stiffer, infected red blood cells would flow along the centerline 
of the flow path while more deformable, uninfected red blood cells would perturb the 
flow path and move away from the centerline [179].  
Cell-based detection strategies have the potential for single-cell level diagnosis 
and for infected red blood cell isolation and concentration using microfluidics. The 






Table 6: Summary of cell-based approaches for LOC devices. Par/µL = parasites/µL 
 Technique Parasite Sample Type Readout 
Limit of 
Detection 




























P. yoelii in mice In vivo 
Photoacoustic signal, 2x 
amplification 
Single cell level 








avian red blood 
cells 
In vivo Fluorescence Not reported Not reported [158] 
Hemozoin detection by 
optical signatures 
P. yoelii in mice In vivo 

























Red blood cells diluted in 
isotonic buffer, 55mS/m 
conductivity 
Post-sort flow cytometry 
1-10% 
parasitemia 





Red blood cells diluted in 
isotonic buffer, 55mS/m 
conductivity 








Magnetic separation of 
iRBCs 
P. falciparum Whole blood + NaNO2 Post-sort Giemsa staining 10% parasitemia ~40 min [167] 
Margination P. falciparum 
Red blood cells, 
40% hematocrit 
Post-sort flow cytometry 













Not reported [170] 
Optofluidic absorption 
of RBCs 
P. falciparum Diluted whole blood Optical absorbance 1% parasitemia <1 min 
[171], 
[172] 
Optical stretching of 
RBCs 
P. falciparum Red blood cells Red blood cell elongation Single-cell level Not reported [173] 
Blood on a chip, RBC 
deformability and 
viscosity 




>2% parasitemia <5 min [174] 
Blood on a chip, RBC 
deformability 
P. falciparum Red blood cells 
Post-sort fluorescence 
microscopy and RDT 
<0.01% 
parasitemia 






Blood on a chip, RBC 
deformability 
P. falciparum Diluted whole blood 
Red blood cell 
deformation 
Single cell-level 









Red blood cells, 
2% hematocrit 
Post-sort flow cytometry 









3.4 Opportunities and Challenges for Lab-on-a-chip strategies in malaria 
elimination efforts 
Lab-on-a-chip strategies have made significant contributions to the development 
of portable and sensitive diagnostics for countries progressing towards malaria 
elimination. As stated previously, diagnostics for elimination-phase countries have 
different performance criteria depending on their use-case (case management of 
symptomatic infections, parasite screening for epidemiological studies, or active 
surveillance and case management to prevent further transmission).  Table 7 summarizes 
some of the important performance criteria for different use cases, including cost, LLOD, 









Table 7: Important considerations for malaria diagnostics for elimination. O = optimal, M = minimum. *Range of blood volumes was 
adapted and combined from multiple sources.  All information presented was adapted from Refs [73], [180] under license CC BY 4.0 and 
with permission from the Royal Society of Chemistry, respectively. 



















(O): ≤ $1.00 
(M): ≤ $1.00 
(O): ≤ 5 
(M): 100–200 
171 million  Finger prick blood (O): 1 – 25µL 
(M): 1 – 50µL 
15 – 30 min 
 











(O): ≤ 2 
(M): < 20 
33 million  (O): non-invasive 
(i.e. saliva, buccal 
swab, urine) 
(M): finger prick 
blood 
(O): 1 – 200µL* 
(M): 1 – 50µL 
15 – 30 min 
 












(O): ≤ 2 




(i.e. saliva, buccal 
swab, urine) 
(M): finger prick 
blood 
(O): 1 – 200µL 
(M): 1 – 50µL 
15 – 30 min 
 









In some scenarios, ease-of-use and fast assay time take precedence over extremely 
low LLOD, while in others, high analytical sensitivity is more critical than device 
simplicity. In each of these cases, it is important to consider the end-user and the purpose 
of the test.   
Diagnostics for case management of symptomatic infections will typically be 
purchased directly by patients showing febrile (fever-like) symptoms.  Recent studies 
have shown that private sector sales—such as local pharmacies and shops—contribute to 
a large percentage of sales of both RDTs and antimalarial drugs for symptomatic patients.  
In order to be widely adopted in endemic regions, new diagnostics must cost less than 
ACT treatments readily available at pharmacies (~$2) [181], must be POC-applicable to 
minimize the patients’ waiting times and number of clinic visits before treatment [182], 
and must be minimally instrumented, high-throughput, simple (≤ 3 user steps), and fast 
(≤60 minutes sample-to-answer time) [183], [184].  Therefore, for case management of 
symptomatic patients, new diagnostic devices must be both simple and inexpensive 
relative to available antimalarial drugs, allowing them to be integrated into a patient’s 
workflow with minimal extra effort.  While cost and simplicity are the most important 
factors, the diagnostics must also have a short sample-to-answer time to incentivize 
patients to use the diagnostic rather than treating with available antimalarials without 
diagnosis.  Notably, because case management typically occurs after symptoms occur, 
having an extremely low LLOD is not necessary for this case.  
For parasite screening and population surveillance, the diagnostic tests are likely 




hours of training with a minimal number of user steps are most appropriate. For these 
purposes, it is more important that the diagnostics are sensitive enough to detect low 
parasite densities characteristic of asymptomatic infections, or circulating gametocyte 
levels to enable effective intervention.  Additionally, mass screening and treatment 
programs require rapid testing and treatment of large populations.  Therefore, diagnostics 
must be appropriate for mass manufacturing and long-term storage to enable for easy 
administration to a large number of people.  Further, the diagnostics must permit health 
workers to screen multiple patients in parallel in a short time to allow for simultaneous 
diagnosis and treatment; in other words, having high-throughput diagnostics in this case 
is key.  It is also critical that these diagnostics have high accuracy, as the epidemiological 
data collected regarding parasite loads and transmission profiles will determine future 
strategy towards elimination.  Finally, it is important that diagnostics for these purposes 
distinguish between Plasmodium species, especially P. falciparum and P. vivax, to enable 
better understanding of malaria transmission patterns and epidemiology. 
Many of the LOC devices reviewed above meet the criteria for the use-cases 
described here.  Protein-based approaches are the simplest point of entry for developing 
diagnostics for elimination settings, as protein-based RDTs are already considered a 
current gold standard for diagnosis.  However, they also have some limitations.  Although 
these methods are highly specific for HRP-2 or pLDH antigens, it has been shown that 
antigen levels may not directly correlate with parasite levels, making it difficult to 
determine parasitemia based on antigen detection alone [79].  For example, HRP-2 can 




results.  Conversely, deletion or mutation of the hrp-2 gene in the parasite may lead to the 
protein not being produced, resulting in false negatives [32].  Therefore, protein-based 
LOC devices are suitable for case management of symptomatic infections due to their 
ease-of-use, but may not be appropriate for mass screening and treatment programs due 
to their potential limitations in determining parasite levels, as they may lead to incorrect 
representation of infection prevalence or transmission. 
Wearable in vivo cell-based diagnostic approaches offer potential for powerful, 
highly sensitive detection of extremely low parasite levels. Similarly, cell-based 
techniques offer the advantage of single-cell precision diagnosis.  However, many of 
these techniques currently require expensive equipment and are difficult to perform in 
parallel, leading to issues with scalability and throughput for mass screening and 
treatment programs.  With more development, wearable diagnostics and cell-based 
microfluidic devices could offer promise in elimination settings. 
NATs, while highly sensitive and specific, require multiple user steps for sample 
preparation. Therefore, in their current state, these tests may be more appropriate for 
parasite screening and surveillance programs, where skilled operators can process 
multiple tests in parallel, rather than for symptomatic case management settings.  Fully-
integrated paper-based devices offer a promising direction for NATs due to their ease of 
use, high accuracy, high throughput, and potential for inexpensive mass manufacturing 
and shipping.  If these integrated devices could be further developed to distinguish not 
only parasite species, but also circulating gametocytes, they would be a powerful tool for 




devices to diagnose infection from non-invasive samples, such as saliva or urine, would 
allow for even simpler mass screening.   
It is also important to note that for all cases, it is imperative that the diagnostic 
does not lose clinical sensitivity or specificity compared to gold standard techniques.  
False positive or false negative readings would impact patient treatment, and would result 
in inaccurate understanding of progress toward malaria elimination.  Many of the 
techniques reviewed here are in the initial proof-of-concept phases, and do not yet report 
clinical sensitivity and specificity; in addition to the factors listed above, comparing these 
devices to current gold standard techniques will be a key step towards commercialization.  
The WHO has set ambitious milestones for malaria elimination in several countries, and 
the development of sensitive and affordable diagnostics is an important component to 
achieve and maintain these goals.  Factors including cost, sensitivity, field-deployability, 
and test throughput are important considerations for mass screening and treatment, or 
case management programs.  Lab-on-a-chip platforms offer solutions to many of the 
challenges for malaria diagnostics for ‘elimination-phase’ settings.  New lab-on-a-chip 
technologies, especially those that can integrate all processing steps and be easily 
incorporated into the existing screening and treatment workflow, have the potential to 







CHAPTER FOUR: VALIDATION OF IMRS, A NOVEL PCR ASSAY 
In this chapter, I focus on the Integrated Multi-Repeat Sequence (IMRS) 
algorithm originally developed by our collaborators at Jigsaw Biosolutions. This 
computational method serves as the cornerstone for the novel isothermal assay 
development I undertook in Aim 2 of my thesis work. This chapter lays out the basics of 
the computational technique and its initial use for traditional PCR.  The chapter describes 
the concept of the algorithm, the work I performed in the Klapperich lab to validate the 
IMRS PCR assay, and an initial demonstration of the assay with non-invasive clinical 
samples, performed in collaboration with Dr. Jesse Gitaka at Mount Kenya University.  
The validation work discussed in this chapter was part of a larger publication 
demonstrating the IMRS PCR technology [185], which included clinical sensitivity and 
specificity, comparison with existing sensitive PCR assays, and demonstration with 
asymptomatic patients.  
 
4.1 Significance  
As I laid out in Chapter 3, highly sensitive analytical methods are a critical 
component in moving toward malaria elimination, particularly because both microscopy 
and protein-based rapid diagnostic tests (RDTs) have a lower limit of detection (LLOD) 
of 50-100 parasites/µL in 5µL of blood [31]–[33], which misses approximately 30%-50% 
of low-density infections [34].   
PCR assays for multi-copy genes in Plasmodium falciparum: 




(PCR), have emerged as sensitive and accurate diagnostics for Plasmodium infection. 
NAATs amplify and detect specific regions of parasite DNA or RNA. Although RNA-
based NAATs are more sensitive due to the high number of RNA transcripts, RNA is less 
stable than DNA, and is therefore not preferred for field-deployable NAATs [186]. 
PCR assays for malaria diagnosis traditionally target multi-copy genes, which 
provide multiple targets for amplification using a single primer set.  The 18S ribosomal 
RNA (rRNA) gene is the most commonly used target for amplification of Plasmodium 
because it is highly conserved and has species-specific regions [59], [75], [106], [187]–
[195]. The gene, which is present in 5-8 copies, has been targeted in several PCR-based 
assays for diagnosis of P. falciparum.  Other multi-copy genes found in higher copy 
numbers have also been targeted for PCR-based amplification and detection [196]–[201] 
(Table 8). Overall, PCR assays targeting multi-copy genes have led to improvement in 
diagnostic sensitivity compared to RDTs and microscopy, but they may not have 
sufficient sensitivity to detect low-density infection characteristic of asymptomatic 





Table 8: Summary of highly sensitive PCR methods for P. falciparum 
 DNA Target 
Number of 
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Pfr364 41 0.1 – 10 [107], [203] 
TARE-2 




0.3 – 0.12 [186] 
varATS 59 0.06-0.15 [186] 
 
Computational genome-mining for more sensitive PCR assays: 
Recently, computational genome-mining approaches used sequence alignment 
strategies to identify conserved, tandem repeat sequences distributed throughout the 
genome.  Traditional primer design tools were then utilized to design PCR amplification 
primers for these tandem repeat targets (Table 8) [107], [186], [203], [204].  However, 
these amplification primers require the insertion of “wobble positions” due to the fact that 
the identified “consensus” sequences are often not exact matches between repeats.  
Therefore, although several copies are computationally identified, these discrepancies 
lead to amplification of only a fraction of the identified targets (40% in one case)[186].  
Unlike other genome-mining techniques, the approach used by our collaborators 




genome that can be used as primer sequences for amplification, rather than consensus 
target sequences for amplification (Figure 24). The heart of the technology is a novel 
concept in de-novo mining of pathogen genomes, called 'Identical Multi-Repeat 
Sequences' (IMRS), which identifies repeated sequences for use as primers. The 
improved sensitivity of the IMRS primers is due to the fact that this strategy is 
fundamentally different than traditional other genome-mining strategies: while 
conventional PCR techniques amplify one specific target region, IMRS primers initiate 
amplification at multiple regions and thus result in a much larger number of amplification 
products.  Further, because the identified sequences are exact repeat sequences 
distributed throughout the genome rather than consensus sequences, the fraction of 
amplifiable regions is also higher than in other genome-mining approaches.  
 
Figure 24: Comparison of traditional genome-mining approaches for PCR assay design 




4.2 Materials and Methods: 
Genome mining with Integrated Multi-Repeat Sequences: 
This work was performed by Jigsaw Biosolutions and is described in more detail 
in our recently published manuscript [185]. Using published, annotated genomic 
sequences as the input, the IMRS algorithm first identifies identical, repetitive sequence 
substrings from multiple loci within the annotated genome sequence.  The algorithm 
generated a library of unique repeat sequences suitable for use as PCR primers. For P. 
falciparum (3D7 strain, GeneDB, version 2013-03-01), the resulting library of repeat 
sequences was screened for primer pairs: sequences that were adjacent to each other, 
between 67 and 3449 base pairs apart, so that they could be used as forward and reverse 
primers in amplification reactions.   
The repeat pairs were evaluated using the NIH’s Basic Local Alignment Search 
Tool (BLAST) to ensure that they were specific to the pathogen genome. These resulting 
primer pairs amplified several fragments of DNA of different sizes due to the distribution 
of the primers throughout the genome.  From this screen, the primer pair resulting in the 
largest amount of DNA amplification was selected for assay development, as this enabled 
the highest possible analytical sensitivity. The primer sequences used in this study were: 
Forward primer 5’- TAACATAGGTCTTAACTTGACTAAC, which repeats 170 times 
in the genome, and Reverse primer 5’- GACCTAAGTTAGTACCTTAATGAC, which 




Real-time quantitative PCR assays:  
Two separate assays were tested head-to-head for each experiment: one assay 
using the P. falciparum IMRS primers, and a second assay using primers targeting the 
18S rRNA gene [190]. The forward and reverse amplification primers for this assay were 
5’-AGTCATCTTTCGAGGTGACTTTTAGATTGCT-3’ and 5’-GCCGCAAGCTC 
CACGCCTGGTGGTGC-3’, respectively. For both assays, a 25µL reaction containing 
5µL DNA sample and 20µL master mix (1X SureStart Buffer (Agilent), 200nM each of 
forward and reverse primers (Integrated DNA Technologies), 800µM dNTPs (Agilent), 
3mM MgCl2, 0.2X EvaGreen, (Biotum) 30mM ROX passive reference dye (Agilent), and 
0.025U SureStart Taq polymerase (Agilent)) was used for amplification.  The cycling 
conditions were as follows: initial denature at 95˚C for 10 minutes; 40 cycles of 95˚C 
denature for 30 seconds, 55˚C annealing for 1 minute, and 72˚C extension for 1 minute; 
and final extension of 72˚C for 10 minutes.  The assay was monitored in real time using a 
QuantStudio5 real time PCR machine, and products were also assessed using gel 
electrophoresis with 10% acrylamide gels and 1% agarose gels. Each sample was tested 
with three technical replicates in the PCR reaction.  
Lower Limit of Detection Characterization, P. falciparum: 
To assess the lower limit of detection in buffer, a serial dilution of P. falciparum 
genomic DNA (gDNA) isolated from the 3D7 lab strain of P. falciparum (BEI 
Resources, MRA-102) was prepared in DNA Elution Buffer (10mM Tris-HCl, pH 8.5, 
QIAGEN).  Three experimental replicates of each concentration were analyzed with the 




Demonstration with P. falciparum parasite-infected red blood cells: 
After the assay was demonstrated in buffer, P. falciparum parasites (3D7 strain, 
BEI Resources, MRA-102) were cultured in human red blood cells using standard 
culturing procedures for malaria parasites [58].  A culture of P. falciparum parasites was 
maintained in 5% human red blood cells in RPMI medium supplemented with 
hypoxanthine and grown at 37°C with 5% CO2 and 5% O2. The culture was maintained at 
high parasitaemia (~30% infected red blood cells) to allow for subsequent dilution; 
parasitaemia level was monitored with routine Giemsa staining and microscopy.  For 
each experiment, the high parasitaemia culture was serially diluted in human whole blood 
(Research Blood Components, Cambridge, MA) according to Table 2.  
In each case, parasite-infected red blood cells were diluted into whole blood 
(Table 9), and 100µL of each sample was extracted with QIAGEN DNeasy Blood & 
Tissue Kit protocols. The eluted DNA was amplified with both the IMRS PCR assay and 
18S rRNA PCR assay as previously described. Three independent cultures were analyzed 
at each concentration.  

















Initial demonstration with non-invasive clinical samples: 
In order to demonstrate the potential of IMRS PCR to identify infections with 
non-invasive clinical samples, I worked with our collaborator Dr. Jesse Gitaka at Mount 
Kenya University (Nairobi, Kenya). Dr. Gitaka performed an initial demonstration of the 
IMRS PCR method with saliva, urine and whole blood samples drawn from the same 
patient. 
Clinical samples were collected from symptomatic patients who submitted for 
routine malaria diagnosis. Patients were first evaluated with routine microscopy and 
RDTs, after which samples of urine, saliva, and venous whole blood were also collected 
for the IMRS PCR study.  
DNA was extracted from whole blood within 48 hours of collection using a silica 
spin column-based method. Urine samples were centrifuged, the supernatant was 
removed, and the pellet was subjected to standard DNA extraction methods. Saliva 
samples were collected and processed using a Saliva DNA and Preservation Kit (Norgen 
Biotek Corp.).   
For each patient, all the extracted samples were tested with the IMRS PCR assay 
as described above. They were also analyzed with a more sensitive nested PCR method 
that was previously successful at detecting P. falciparum DNA in saliva [205]. Briefly, 
the nested PCR assay first used universal PCR primers, rPLU5 (5’- 
CCTGTTGTTGCCTTAAACTTC) and rPLU6 (5’- 
TTAAAATTGTTGCAGTTAAAACG) to amplify 5µL of the input sample, resulting in 




amplified product was used in a second PCR reaction with species-specific primers 
rFAL-1 (5’- TTAAACTGGTTTGGGAAAACCAAATATATT) and rFAL-2 (5’- 
ACACAATGAACTCAATCATGACTACCCGTC), resulting in a final amplicon of ~206 
base pairs.  
 
4.3 Results and Discussion: 
Primer mapping from IMRS software: 
The IMRS algorithm generated several potential primers for amplification; of 
these, a forward-and-reverse primer pair distributed across several chromosomes in the P. 
falciparum genome was selected (Table 10, Figure 25). The primers were mostly 
distributed in the telomeric chromosome regions. The primer sequences represent exact 
matches across the different locations on 13 out of 14 chromosomes, which enables 
specificity to the P. falciparum genome.  
Table 10: IMRS PCR primer sequences and properties 




Forward  5’-TAACATAGGTCTTAACTTGACTAAC 170 32% 





Figure 25: Distribution of forward (blue) and reverse (red) primers across the P. falciparum 
genome. Primers are distributed on all chromosomes except for chromosome 14. Courtesy of 
Jigsaw Biosolutions. 
Lower Limit of Detection in buffer: 
The IMRS qPCR assay was used to amplify P. falciparum gDNA and its 




results showed that IMRS outperformed the gold standard 18SrRNA PCR assays for P. 
falciparum, producing a LLOD that was 65x more sensitive. The IMRS qPCR assay had 
a LLOD of 0.509 fg/µL, compared to a LLOD of 33.3 fg/µL for the qPCR assay with 18S 
primers (Figure 26a).  The increased sensitivity of the IMRS primers was demonstrated in 
two separate laboratories, first in Bengaluru, and subsequently validated at Boston 
University, and was also demonstrated with clinical samples in Bengaluru [185]. 
Notably, the IMRS assay resulted in amplicons of several sizes rather than a single target 
amplicon as produced by the 18S qPCR assay (Figure 26b).  These results are consistent 
with the expectation that the multiple primer binding locations result in the amplification 
of several target amplicons of varied lengths from the genome.  
For this study, positive amplification was determined by monitoring real-time 
fluorescence amplification with a double-stranded DNA intercalating dye or by 
acrylamide gel electrophoresis stained with SYBR green intercalating dye. Because the 
IMRS technique relies on repeated primer sequences which produced multiple products 
of variable length rather than a single amplification target, it was not possible to use a 
target-specific probe for quantitative PCR to characterize the products.  Despite the lack 
of a target-specific probe, the assay showed high specificity for the species, as seen with 
the full clinical study [185]. The 18S PCR assay was used as a representative assay to 
directly compare IMRS to a method using an intercalating dye as the fluorescent readout 





Figure 26: a) IMRS (blue) and 18S rRNA (pink) PCR lower limit of detection with P. falciparum 
genomic DNA diluted in buffer. The IMRS LLOD is ~0.509 fg/µL, and the 18S LLOD is ~33.3 
fg/µL b) Representative 10% acrylamide gels for IMRS PCR (left) and 18S PCR (right) assays; 




Demonstration with P. falciparum parasite-infected red blood cells: 
To further evaluate the IMRS PCR assay I demonstrated parasite-infected red 
blood cells spiked into whole blood to mimic patient samples. The real-time 
amplification results and acrylamide gel analysis both showed that the IMRS PCR assay 
outperformed the 18S PCR assay. For some samples, such as dilutions 4 and 5 in Culture 
1 or dilutions 5 and 6 in Culture 2, IMRS PCR was able to amplify parasite DNA while 
no amplification occurred with the 18S assay (Figure 27a).  In other words, IMRS PCR 
could detect samples with low parasite loads when the 18S PCR assay could not. 
Further analysis of the of the real time fluorescence data showed that IMRS PCR 
amplification occurred earlier than 18S PCR amplification, indicating better assay 
sensitivity. For each assay, the cycle threshold (CT) value—the number of cycles required 
to amplify DNA to a high enough concentration that the fluorescence value increases 
above a baseline threshold—was calculated by the instrument software. In samples where 
both assays successfully amplified, the CT values were compared (18S PCR CT – IMRS 
PCR CT), and the 18S PCR CT values were ~2-4 cycles higher than IMRS PCR (Figure 
27b), indicating later amplification. In other words, for each sample, the 18S PCR assay 
required more cycles to exponentially amplify the same amount of DNA compared to the 
IMRS PCR assay.  
Together, these results demonstrate that the IMRS assay is more sensitive than the 
18S PCR assay.  These results support that the IMRS PCR assay would be able to 





Figure 27: A) CT for IMRS PCR assay (blue) and 18S PCR assay (pink) for several 
concentrations of parasite samples. B) Difference between 18S PCR CT and IMRS PCR CT 
threshold times. IMRS assay consistently amplified earlier than the 18S PCR assay. 
Demonstration with Non-Invasive Patient Samples: 
Our collaborators demonstrated the IMRS assay with clinical samples to show 
excellent clinical sensitivity and specificity, sequenced and characterized the amplified 
products, and further demonstrated its utility in identifying asymptomatic patients in a 
preliminary clinical study [185].  
To further investigate the capabilities of the IMRS PCR assay, I worked with our 
clinical collaborator Dr. Jesse Gitaka at Mount Kenya University (Nairobi, Kenya) to test 
the IMRS PCR assay for non-invasive samples such as saliva and urine. For this study, 
venous blood, saliva, and urine samples were collected from patients who were 




analyzed with IMRS PCR and a nested PCR assay that was previously demonstrated with 
saliva samples [205] and then visualized by agarose gel electrophoresis.  
A summary of the results (Table 11) showed excellent comparability between the 
saliva samples and the blood samples for the IMRS assay. Further, the IMRS assay was 
capable of detecting the same samples as the nested PCR assay, which required a two-
step amplification process as opposed to a single step for the IMRS assay. Overall, this 
study showed good concordance between saliva samples and whole blood samples, both 
for the nested PCR assay and for the IMRS assay. However, amplification of urine 
samples was variable and did not show consistent concordance with the results from 
blood samples.  We hypothesize this is due to the method of DNA extraction: for blood 
and saliva samples, the entire sample volume was extracted using commercially available 
kits while urine samples were first centrifuged and DNA extraction was performed on the 
precipitated components only.  It is therefore possible that P. falciparum DNA was lost in 
the supernatant.  The loss of DNA could be mitigated by using a slurry-based kit for urine 
extraction, which collects DNA from the entire sample instead of the supernatant only, 
resulting in better recovery [206]. Furthermore, there could have been a high carryover of 
urea, residual salts or other inhibitors from the urine samples, as urine samples have 
highly variable solute concentrations. It is known in the literature that inhibitors in urine 
samples can negatively impact PCR amplification [207], [208]; therefore, the variable 





Table 11: Results for field isolates for matched blood and non-invasive samples 
 
Notably, there were two samples which may have had a lower parasite density (7 
and 9, highlighted in Table 11), as indicated by the negative results for initial 
amplification with universal primers followed by positive amplification with P. 
falciparum-specific primers in the nested PCR assay. The IMRS PCR primers 
successfully amplified these samples without the need for two-step amplification, again 
implying excellent assay sensitivity. Additionally, it appears that sample 10 was 
Plasmodium positive, but negative for P. falciparum malaria (universal primers positive, 
P. falciparum primers negative).  In this case, the IMRS PCR assay did not show positive 
amplification, indicating specificity for P. falciparum. For the clinical study 
demonstrated in this chapter, all samples were positive for Plasmodium by microscopy 
and/or RDT; a larger study is in progress to quantify patient parasite loads in positive 




4.4 Conclusion:  
The studies presented in this chapter demonstrated the success of the IMRS PCR 
method for sensitive, specific amplification of P. falciparum DNA. The IMRS primers 
bind in several locations across the genome and each PCR amplification cycle results in a 
large concentration of DNA of varying sizes, thereby increasing the DNA available for 
replication in each cycle.  Comparing the lower limit of detection for IMRS PCR with 
PCR for a multi-copy gene (18S rRNA gene) showed that IMRS had ~65x better 
sensitivity. The improved sensitivity was further shown with parasite-infected red blood 
cell samples, where the IMRS PCR assay was able to identify samples missed by the 18S 
PCR assay. Finally, I presented the potential for IMRS PCR in non-invasive saliva 
samples, which showed the same results as blood samples from the same patient. The 
work presented in this study showed the excellent potential for IMRS as a method for 
more sensitive analytical detection of P. falciparum malaria.  
Using the IMRS algorithm and the PCR primers as a starting point, I next focused 
on translating this assay to an isothermal amplification method that would be more 





CHAPTER FIVE:  
PRELIMINARY DEVELOPMENT OF AN ISOTHERMAL ASSAY USING THE 
IMRS PRIMERS 
 
This chapter describes initial work toward Aim 2, developing a new isothermal 
nucleic acid amplification assay from the original IMRS PCR primers discussed in 
Chapter 4. I aimed to exploit the repetitive nature of the IMRS primer binding sites to 
make a more sensitive isothermal amplification assay than existing methods for P. 
falciparum. I hypothesized that, similar to the IMRS PCR assay, the primer distribution 
would enable generation of more DNA amplicons of varying lengths in an isothermal 
assay, which would increase assay sensitivity. In order to translate the IMRS technology 
to an isothermal assay, I considered several existing isothermal methods, but found that 
they all had design constraints which made the IMRS primers unsuitable. Therefore, my 
goal became, more broadly, to generate a new isothermal assay with simpler design 
constraints than existing methods which would be more suitable to the IMRS technology. 
This chapter discusses the initial proposed strategy, and challenges faced in developing 
and characterizing an isothermal amplification assay using this strategy. The strategy 
described here was ultimately unsuccessful in achieving the analytical sensitivity needed 
to diagnose asymptomatic infections. I pivoted to a more successful amplification scheme 
described in Chapter 6. However, I include this chapter to provide an overview of assay 
optimization and characterization approaches that may be used as a starting point in 





 While PCR amplification is a significant improvement over gold-standard 
diagnostic methods for malaria, it remains difficult to use in field settings for screening 
and POC diagnosis, and therefore has not been widely adopted in these settings [72]. 
PCR assays are difficult to deploy in resource-limited settings in part because they 
require expensive equipment for thermal cycling, optical detection, and cold storage of 
reagents. Isothermal amplification assays operate at a single temperature, obviating the 
need for expensive thermal cycling equipment because they only require a single stable 
heat source, which is easier to implement in resource-constrained settings. These methods 
can also be adapted to visual readout with techniques such as lateral flow or colorimetric 
detection [148], [209], and can be adapted to dry format [40], making them attractive for 
resource-constrained settings.  
Several isothermal methods, including loop-mediated isothermal amplification 
(LAMP), helicase dependent amplification (HDA), and recombinase polymerase 
amplification (RPA) have been developed for P. falciparum, and many of these methods 
have been adapted to POC compatible devices (Table 12).  Currently, two commercially 
available methods utilize LAMP for sensitive diagnosis of P. falciparum malaria. 
Although both commercial isothermal methods demonstrate analytical sensitivity 
sufficient to diagnose asymptomatic patients, remain benchtop methods requiring custom 
equipment to detect turbidity reading or fluorescence. Therefore, adapting the highly 
sensitive IMRS method to an isothermal assay would enable excellent analytical 




Table 12: Existing isothermal amplification methods for P. falciparum 
Technique 
Limit of Detection of  
P. falciparum (parasites/µL) 
Illumigene LAMP (Meridian Bioscience) [121], [210] 0.3 – 2  
Loopamp (Eiken Chemical Co.) [123], [211]–[215] 1 – 20  
RealAmp LAMP assay[216] 10-100 
HDA[150] 200 
RPA [217], [218] 100 fg (4 parasites); 5 copies 
 
Overview of existing isothermal amplification methods:  
While isothermal DNA amplification assays are powerful tools for use in the field, they 
have several constraints that make assay development challenging.  I considered four 
separate methods to adapt the IMRS PCR primers to isothermal methods; the major 
























HDA 80 – 120  24-33 60-74 35-60 65 ± 1 [219] 
RPA 
























F1c/B1c See diagram 




30-35 See diagram 
 
I first considered helicase-dependent amplification (HDA), which requires only 
two primers and incorporates a helicase enzyme to unwind DNA to enable target 
amplification and single stranded binding proteins to keep unwound DNA open (Figure 
28A) [223]. The addition of a helicase enzyme requires optimization of a buffer for two 
enzymes to function in concert, which can be difficult. HDA may be improved by the use 
of a third enzyme, a restriction endonuclease, to cleave DNA into ~200bp fragments to 




as ficoll is often also beneficial to enable molecular clustering to bring the assay elements 
within close proximity for successful amplification [224]. The operating temperature for 
successful HDA assays is narrower than other methods due to the temperature constraints 
of the helicase enzyme. HDA also has strict requirements on target length, typically 
ranging from 70-120 base pairs. Therefore, although only two primers are required for 
HDA, the additional design constraints involving multiple enzymes make HDA a difficult 
assay to design and optimize, particularly for the point of care where the deployment of 
precise temperature control may be difficult to achieve.  
I next considered recombinase polymerase assay (RPA) [225]. In this case, 
primers form complexes with a recombinase enzyme and target homologous DNA; strand 
exchange between the recombinase-primer complex and the target DNA region creates an 
opening in the DNA from which polymerase initiates amplification (Figure 28B). While 
the benefit of this assay is a lower amplification temperature, it also requires an 
additional enzyme to denature DNA. Another important limitation of this technology is 
its limited product size. While the design manual claims that longer products could be 
generated, the assay is designed and optimized for 100-200bp products [220].  
Additionally, I found that adapting the IMRS primers to this technology would be 
difficult due to their location in the telomeric regions. These regions are more difficult to 
target due to the highly repetitive nature of the telomeres, and likely would not be 





Figure 28: A) Helicase Dependent Amplification and B) Recombinase Polymerase 
Amplification schematics 
The third isothermal method I considered for this project was strand displacement 
amplification (SDA) [226], [227].  In this isothermal amplification scheme, a strand 
displacing polymerase is used in combination with four separate primers: a set of bumper 
primers to enable strand displacement, and a set of inner primers with overhang regions 




the nicking site becomes incorporated into the product; once nicks are generated, 
polymerization initiates from the nick site, displacing the rest of the product strand. The 
nicking recognition site is regenerated by polymerization and exponential amplification 
occurs by further nicking and strand displacement (Figure 29). Similar to HDA, SDA 
also requires optimization of multiple enzymes (a nickase and a polymerase), but does 
not require as narrow operating temperature constraints because the functional 
temperature range for these enzymes are wider. However, precise primer design is 
required to incorporate nick recognition sites into the product. Additionally, optimization 
with four different primers is required for successful SDA, which can be challenging and 
may lead to significant nonspecific amplification due to primer-dimer formation or non-
specific annealing by the different primers. The traditional SDA amplification schematic 
requires an initial 95°C denaturation step to enable initial primer annealing; the two-step 
amplification process is more complex and may not be easily adaptable to POC settings.  
Recently, an isothermal SDA method was reported which exploits DNA breathing for 
initial primer annealing [228]. However, this requires precise primer design in locations 
where DNA breathing is more likely to occur. Because the IMRS primers are mainly 
located in the telomeric regions where DNA breathing is less likely to occur, it is unlikely 
that this method would successfully function for isothermal amplification from these 
primer regions. I will discuss the difficulties with DNA breathing in more detail later in 





Figure 29: Strand displacement amplification schematic 
The fourth isothermal amplification method I considered was loop mediated 
isothermal amplification (LAMP). Traditional LAMP [229] requires at least four primers 
to target six distinct DNA regions: forward and backward inner primers (FIP and BIP) 
which anneal to the ends of the target locus and forward and backward outer primers (F3 
and B3) which serve as the “bumper primers” to displace the product strand. Bst 
polymerase-mediated DNA extension from the outer primers results in displacement of 
the single-stranded DNA product initiated from the inner primer. The inner primers are 
designed with self-complementarity to the target locus, resulting in a loop structure 




template for exponential amplification. Although traditional LAMP is a robust assay, a 
major disadvantage is the complexity of primer design, which requires six suitable 
complimentary regions to enable loop formation (Figure 30). LAMP has strict 
requirements on target length, which typically ranges from 120-160 base pairs, limiting 
the number of potential amplification targets in the genome [230]. Also, the presence of 
4-6 of primers can lead to nonspecific amplification of primer dimer complexes. These 
strict primer design constraints make LAMP impractical to adapt the existing IMRS 
primers. 
 
Figure 30: Loop mediated isothermal amplification schematic 
Based on these initial analyses, it became clear that in order to use the repeated primers 





5.2 Materials and Methods: 
Iso-IMRS assay development: 
The isothermal amplification primers used for the proposed strategy were concatamers of 
the initial PCR primers. The primer sequences used are listed in Table 14. 




Several variables were tested to develop and optimize the proposed assay. In lieu 
of listing all permutations, I will list the variables and ranges tested for assay optimization 
(Table 15). Lower limit of detection (LLOD) values were calculated using P. falciparum 
gDNA diluted from 100pg/µL to 10fg/µL; most initial experiments were conducted at 
1pg/µL or 100fg/µL. Real time amplification curves were analyzed by including 0.2X 
EvaGreen and 30mM ROX reference dye in the final master mix. Gel electrophoresis on 
post-amplification products was performed on 1% agarose gels and stained with ethidium 
bromide.  
Both one-step and two-step methods were tested for optimization; for two-step 
methods, DNA was incubated with primers, half of the volume of isothermal buffer, and 
whichever co-factor was being tested (i.e. NaOH). After incubation either at room 
temperature or 95°C, the sample was put on ice and the remaining buffer, strand displacing 





Table 15: Optimization ranges for several variables tested in assay development 
Optimization Factor Range Tested 
Reaction temperature 55°C - 60°C  
Standard master mix components 
Iso-IMRS primers 
[Primer]  1.6uM – 3.2uM 
Isothermal Buffer components 
[MgSO
4
] 2mM – 10mM 
[Betaine] 0M – 1.0M 
[KCl] 0M – 50 mM 
Lysis buffer (0.1%) Tween, Triton X-100, NP-40  
Strand displacing enzyme 
[Bst enzyme]  320 U/mL – 640 U/mL 
[Bioron SD polymerase]  0.3 U/mL – 1 U/mL 
Additional co-factors for denaturation and improved amplification 
Denaturation 
[NaOH] Sample incubation with 0 – 10mM 
(also included in the master mix) 
Enzymatic DNA 
shredding 
Sample incubation with MboI restriction enzyme at 37°C 
overnight; used as an input sample for iso-IMRS 
amplification assay. 
Mechanical shredding DNA passed through an HPLC needle 50x  
Improved amplification 
Ficoll-400 0 – 4% 
BSA 0.4% 








I also changed strategy to attempt NEAR amplification rather than using a strategy 
involving loop formation. For this effort, I modified the IMRS primers to include 
recognition sites for a synthetically generated nicking enzyme. The primers and associated 
nicking enzymes are listed in Table 16. The appropriate enzymes were included in the final 
master mix for two-step amplification. 









Yellow = additional bases, Green = recognition site, ^ = Nick site. 
Although the LLOD was not sufficiently sensitive, I developed an assay method 
to achieve LLOD of ~1pg/µL gDNA. The assay formulation and incubation conditions 
are listed in Table 17: 
Table 17: Final reaction conditions for initial iso-IMRS assay 
Reagent [Stock] [Final] Volume/Reaction (µL) 
Nuclease-Free Water         7.75 
Tris-HCl [pH 8.8] 1000 mM 20 mM 0.5 
Triton X-100 1 % 0.1 % 2.5 
KCl 1000 mM 50 mM 1.25 
MgSO4 100 mM 6 mM 1.5 
IMRS-Pf-FIP 40 uM 3.2 uM 2 
IMRS-Pf-BIP 40 uM 3.2 uM 2 
dNTPs 10 mM 1.4 mM 3.5 
EvaGreen 20 X 0.2 X 0.25 
ROX Reference dye 0.0002 X 0.000006 X 0.75 
Betaine 5 M 0.2 M 1 
Bst 2.0 polymerase  8000 U/mL 320 U/mL 1 
DNA Template      1 
Total     25 




Iso-IMRS assay characterization: 
I pursued a characterization strategy using three plasmids: (a) a positive control 
plasmid containing part of the native genome sequence with a representative distribution 
of iso-IMRS primer binding sites, isolated from the native genome, (b) a positive control 
plasmid with a known distribution of primer binding sites and artificially introduced 
restriction sites, and (c) a negative control plasmid with no binding sites. To create 
plasmids containing the appropriate amplification regions, I first designed cloning 
primers to isolate a 2.8kb region containing a representative distribution of the IMRS 
primer binding sites from P. falciparum genomic DNA (Table 18).   











An amplification matrix with and without 3mM MgSO4 and 3% DMSO was used 
to enable primer annealing, and PCR was carried out with the following cycling 
conditions (Table 19).   
Table 19: Cycling conditions for cloning primers 
Initial Denature 98°C 0:30   
Denature 98°C 0:10 
35 
cycles 
Annealing 65.8°C 0:10 
Extension 72°C 1:25 





Because initial amplification did not work, I varied the annealing temperature 
from 60°C to 66°C, the number of cycles were increased to 40 cycles, and the extension 
time was increased to 4 minutes.  I also attempted a touchdown PCR to home in on a 
more specific annealing temperature (Table 20): 
Table 20: Touchdown PCR conditions 
Temperature (℃) # of Cycles Details 
 76-66 11 Lower 1 ℃ every cycle 
65 3   
64 21   
 
Because these conditions were not successful, I designed new cloning primers for 
a larger, 5kb region outside the highly repetitive regions targeted by the original cloning 
primers. The primers (Table 21) had an annealing temperature of 68°C.  
Table 21: Cloning primers for 5kb telomere region for iso-IMRS characterization 
5kb Fwd cloning primer 5’-ACTCAGGTCATACGTTTACTAACATAGGTCT-3’ 
5kb Rev cloning primer 5’-CGTAGGTCTTAGGTTTTCTAACTTTCGTC-3’ 
 
The ~5kb product from this amplification was extracted using a QIAGEN gel 
extraction kit, and the DNA was used as an input for PCR amplification using the original 





5.3 Results and Discussion: 
Proposed iso-IMRS Amplification Schematic: 
 The four isothermal assays considered here were fundamentally not compatible 
with the IMRS technology because they required specific primer design, meaning the 
IMRS primers could not be adapted for these amplification methods. For example, 
LAMP and SDA require overhang regions that would enable loop structure formation and 
incorporation of nicking regions, respectively, and also require interplay with additional 
outer “bumper” primers to enable strand displacement.  HDA and RPA, on the other 
hand, do not require additional primers but have stringent requirements on temperature 
and priming location to enable helicase activity and recombinase-mediated strand 
exchange.  
 Instead of using existing methods, I instead chose to develop a novel isothermal 
amplification method in collaboration with Jigsaw Biosolutions.  Due to the distribution of 
repeated forward and reverse primer binding sites, we hypothesized that these primers 
could be modified to perform as a LAMP-like assay using only two primers (Figure 31).  
We proposed that overhang regions could be added to the IMRS PCR primers to enable 
loop formation similar to the LAMP amplification schematic. The proposed iso-IMRS 
forward primer consisted of the IMRS PCR reverse primer followed by the forward primer 
(5’3’), and the iso-IMRS reverse primer consisted of the IMRS PCR forward primer 
followed by the reverse primer (5’3’). Because IMRS primer annealing sites are 
distributed adjacent to one another, we hypothesized that outer primers would not be 




lead to displacement of single-stranded DNA product initiated from a downstream primer 
(Figure 31, Steps i-ii). The overhang sequences on each primer would form loop structures 
by binding to the complimentary downstream genome region, generating a template for 
exponential amplification (Figure 31, Step iii). I hypothesized that, unlike the single target 
locus in LAMP, the distribution of the IMRS primer-binding sites across the genome would 
form many products and improve the overall assay sensitivity. 
 




Initial results for the proposed iso-IMRS assay were successful at high DNA 
concentrations (Figure 32). Using P. falciparum genomic DNA, I demonstrated successful 
isothermal amplification down to 1pg/µL genomic DNA in buffer (~42.6 parasites/µL). At 
lower DNA input concentrations, amplification was stochastic.  
 
Figure 32: Amplification curves (left) and representative agarose gel readout (right) for iso-IMRS 
assay. Amplification was consistent through 10pg, but at lower concentrations, became stochastic. 
I also demonstrated successful direct-blood amplification in a two-step assay. By 
incorporating Triton X-100 into the amplification buffer to lyse blood components, 
successful isothermal amplification was possible by including an initial denaturation step 
at 95°C. This initial denaturation step opened up the double stranded DNA to enable primer 
annealing to the target regions, after which isothermal amplification at 63°C could 
successfully occur. I first demonstrated this two-step direct blood assay with 100pg/µL P. 
falciparum gDNA spiked into whole blood (Figure 33A).  I also showed amplification with 
red blood cells spiked with P. falciparum gDNA and with P. falciparum parasite-infected 
red blood cells (Figure 33B,C).  In both cases, although amplification was successful, this 




asymptomatic infections. I therefore attempted several methods to optimize both the iso-
IMRS assay and the direct-blood amplification method to improve analytical sensitivity to 
detect asymptomatic infections.  
 
Figure 33: A) Direct-blood amplification of gDNA spiked into whole blood, amplified with iso-
IMRS. B) Direct amplification of Pf.-infected red blood cells and C) accompanying fluorescence-
based real-time detection.  High concentrations of gDNA and P. falciparum infected red blood 
cells amplified directly with iso-IMRS 
Iso-IMRS assay optimization efforts: 
Several techniques were attempted to improve the assay formulation with the goals 
of (1) improving the limit of detection, and (2) creating a fully isothermal direct-blood 
amplification method without the need for an initial denaturation step.  




more sensitive lower limit of detection for the iso-IMRS assay. Because the proposed assay 
mechanism relied on annealing and looping of two separate primer sites, I hypothesized 
that primer annealing was the most important step for successful amplification. I started 
with optimization of buffer components such as MgSO4 and KCl to enable more favorable 
primer annealing. I also attempted to decrease the amplification temperature to favor 
primer annealing; in concert, I increased the polymerase concentration to maintain 
amplification efficiency at a lower assay temperature. I also incorporated cofactors and 
clustering agents such as ficoll-400 to increase the likelihood of primer annealing to gDNA.  
Unfortunately, these optimization efforts did not improve the assay sensitivity. 
I next attempted to optimize the assay by using a more robust, synthetic polymerase. 
I hypothesized that the template complexity in the telomeric regions may be unfavorable 
for a standard strand-displacing polymerase like Bst. I therefore attempted amplification 
with an engineered strand displacing polymerase (SD polymerase, Bioron). This synthetic 
derivative of Taq polymerase has shown successful DNA amplification of templates with 
complex secondary structures. It has also shown successful isothermal amplification at 
higher temperatures than Bst polymerase [231].  I therefore hypothesized that this synthetic 
polymerase would improve iso-IMRS amplification, but found that this was not the case.  
I then sought to eliminate the need for 95°C denaturation by incorporating alkaline 
hydrolysis with NaOH to make the assay fully isothermal. I hypothesized that initial 
incubation with NaOH would cause DNA denaturation to enable primer annealing without 
the need for additional heating. Although this strategy resulted in successful amplification 




demonstrated by the high variability between triplicates of the same DNA concentration 
(Figure 34). Furthermore, when I adapted this two-step method (initial incubation with 
NaOH followed by isothermal amplification with Bst) to a single step method by 
incorporating NaOH directly into the master mix, there was a significant decrease in 
amplification efficiency, marked by later amplification time (Figure 35).  
 
Figure 34: Two-step, isothermal amplification of gDNA directly in blood with initial denaturation 
by alkaline hydrolysis with 50mM NaOH for 10pg/µL and 1pg/µL input gDNA.  Amplification 





Figure 35: One-step vs. two-step amplification of P. falciparum gDNA using NaOH hydrolysis 
for DNA denaturation. Incorporating NaOH directly into amplification buffer caused a drop in 
assay efficiency, marked by later amplification time. 
Additional methods were attempted to denature DNA without an initial boiling 
step, including incorporation of enzymatic degradation with MboI restriction enzyme 
digest and mechanical shredding with a fine-bore needle. I hypothesized that making DNA 
opening simpler using these methods would improve amplification efficiency, but this was 
not successful. Further efforts to optimize the direct-blood assay included sample dilution 
into phosphate buffered saline to lessen the fluorescence-quenching effects of blood 
components and incorporation of BSA into the amplification mix to reduce potential 
inhibition by blood components [232]. Again, these efforts were ultimately not successful 
to improve real time amplification efficiency.  
In a further attempt to optimize the assay, I hypothesized that the poor amplification 




primer design used in the proposed LAMP-like strategy. Therefore, I changed strategies to 
an amplification scheme more similar to SDA called nicking enzyme amplification reaction 
(NEAR) [233]. This strategy employs the same scheme as SDA; however, rather than using 
modified dNTPs and a specific restriction enzyme, NEAR uses mutant restriction 
endonucleases which can be more readily optimized with other enzymes. To explore this 
assay scheme, I added overhangs to the IMRS primers incorporating recognition sites for 
thermostable mutant nicking enzymes, Nt. BstNBI and Nt. BspQI. In this case, I again 
observed high nonspecific amplification and could not reliably optimize the assay.  
Characterization of iso-IMRS products: 
In concert with the assay optimization strategies for iso-IMRS, I pursued efforts to 
characterize the amplification products generated by the assay.  My initial strategy was to 
create three distinct characterization plasmids: a positive control plasmid containing part 
of the native genome sequence with a representative distribution of iso-IMRS primer 
binding sites, isolated from the native genome, a positive control plasmid with a known 
distribution of primer binding sites and artificially introduced restriction sites, and a 
negative control plasmid with no binding sites. I then proposed to perform Southern blots 
with labeled probes (plasmid 1) and restriction enzyme digest on amplified products 
(plasmid 2); plasmid 3 would be used to confirm the lack of nonspecific amplification.  
We first attempted to generate the characterization plasmids using synthetic DNA 
to insert into the plasmid backbone (Integrated DNA Technologies gBlock), but in silico 
analysis of the region found that the existence of too many repeated sequences meant that 




region from the P. falciparum genomic DNA, which could then be inserted into a plasmid 
backbone for Gibson cloning. However, I found that it was not possible to generate a single, 
distinct amplification product of ~3000bp; instead, amplification of gDNA with cloning 
primers resulted in a smear of multiple products similar to LAMP (Figure 36).  Although I 
attempted the same method with several primers and assay conditions, in all cases I found 
similar non-specific amplification.  
 
Figure 36: PCR cloning primers were not able to isolate a 3000bp product from the telomeric 
regions of P. falciparum gDNA 
I hypothesized that the presence of repeated regions in the telomeric region 
resulted in PCR artifacts due to secondary structure formation [234]. As polymerization 
occurs from the primer sites, the single stranded DNA may loop back on itself, creating a 
hairpin structure that causes the polymerase to fall off, leaving a shorter, partial PCR 




several products of multiple sizes. To address this issue, I attempted several experimental 
fixes: increased extension time to favor synthesis of longer products; touchdown PCR to 
home in on a more precise primer annealing temperature; use of single stranded binding 
proteins to prevent partial fragments from binding to themselves to form hairpin 
structures. These methods were ultimately unsuccessful. I also attempted to design new 
cloning primers to isolate a much longer region from the telomere; the new cloning 
primers targeted a less repetitive region outside of the target region. The longer region 
could be isolated by gel extraction and used as a template for amplification of the 2.8kb 
region. Although a distinct product was generated in the first PCR, the subsequent PCR 
yielded no products (Figure 37). 
 






The results of my initial efforts in assay development and characterization for iso-
IMRS were not successful using the IMRS PCR primers as a starting point. I hypothesized 
that poor amplification was due to the primer distribution being primarily in the telomeric 
region of the chromosomes.  I expect that the highly repetitive and GC-rich complex nature 
of the telomere region results in complex secondary structure formation, making the region 
difficult to isolate for characterization and isothermal amplification.  
Based on the results for one-step isothermal amplification, I further hypothesize 
that the iso-IMRS primers cannot access and bind to the primer binding sites reliably 
without an initial denaturation step. In isothermal amplification with strand displacement, 
access to single-stranded DNA regions for primer binding depends on DNA breathing: as 
the temperature increases, bases unstack and hydrogen bonds between bases break, and 
A/T rich regions break more readily, resulting in partially unwound DNA [235]. The IMRS 
primer binding sites have a high GC content, making DNA breathing less favorable at the 
optimal amplification temperature tested for Bst polymerase (55°C – 65°C). Additionally, 
the proposed strategy relies on loop formation between the Forward and Reverse IMRS 
primer sites, but in almost all cases, the looping distance between these sites is greater than 
100 base pairs, compared to 40-60bp looping distance in traditional LAMP (Figure 38).  
Therefore, it is unlikely that looping would be favorable, due to the large distance between 
the sites and the lack of available single stranded DNA as a result of low DNA breathing 





Figure 38: Looping distance between forward and reverse primer sites was >100bp, which likely 
decreased ability for stable loop formation. 
Based on the results from both the assay optimization experiments and the 
characterization experiments, I determined that the original IMRS PCR primers may not 
be suitable to isothermal amplification using the iso-IMRS strategy proposed.  Therefore, 
I returned to the IMRS algorithm with Jigsaw Biosolutions to identify new, repeated primer 
sites that would be more suitable to isothermal amplification; the new primers and 
amplification strategy are detailed in Chapter 6. I specified the criteria to ensure that the 
regions between primer repeats was ~30 base pairs, and that the span of the primers was 
no more than 3000 base pairs to enable successful strand displacement and favorable 
polymerase activity to generate the full amplicon. Most importantly, the new repeated 
regions would be located within the intragenic chromosomal regions rather than the 
telomeric regions to ensure that DNA breathing and primer binding would be more 





CHAPTER SIX:  
DEVELOPMENT OF A NOVEL STRAND-DISPLACING ISOTHERMAL 
AMPLIFICATION ASSAY, ISO-IMRS 
 
In this chapter, I describe the successful strategy to isothermally amplify P. 
falciparum genomic DNA using the IMRS technology, fulfilling Aim 2 of my thesis. 
Rather than using the overhang strategy proposed in Chapter 5 to adapt the original IMRS 
PCR primers located in the telomeric regions, here we used the IMRS algorithm [236] to 
identify entirely new primer binding sites distributed within the intragenic regions of 
three chromosomes. The distribution of the primer binding sites enabled successful 
simultaneous strand displacement and amplification, resulting in isothermal amplification 
of P. falciparum gDNA within 30 minutes.  In this chapter, I describe the initial 
development of the isothermal assay, characterization with Next Generation Sequencing, 





6.1 Redesigning IMRS primers for isothermal amplification: 
As described in the previous chapter, the initial efforts to adapt the IMRS PCR 
primers to an isothermal format were unsuccessful. I hypothesized that this was primarily 
due to the distribution of the initial primers. Because most of the IMRS primer binding 
sites were located in telomeric regions, the sites were likely unfavorable for DNA 
polymerization. The telomeric regions are known to form complex secondary structures 
and are also characterized by minimal DNA breathing, which likely inhibited polymerase 
activity and access for primer annealing, respectively [237]. Furthermore, the distance 
between primer sites was >100bp in most cases, thereby reducing the likelihood of 
successful amplification by the scheme we proposed. The distance for the loop region for 
standard LAMP amplification is specified as 40-60 bp [222]; because the looping 
distance between forward and reverse primers in the proposed amplification scheme was 
much greater, I hypothesized that loop formation was unlikely to happen. 
In this chapter, I describe efforts to develop an entirely new isothermal 
amplification strategy using the IMRS algorithm. Rather than adapting the IMRS PCR 
primers as before, we used the algorithm to identify new primer binding sites with 
specific constraints more suitable to isothermal amplification. Similar to the initial 
strategy, we still endeavored to identify highly specific, highly repetitive sequences that 
would serve as primer binding sites. I retained the hypothesis that multiple products from 
several locations across the genome would result in high analytical sensitivity by vastly 
increasing the amount of DNA amplified compared to traditional amplification methods. 




to identify primer sites specifically suitable for isothermal amplification with a strand 
displacing polymerase. 
New criteria for isothermal amplification 
First, I specified stricter criteria for the repeated primer binding sequences. I 
hypothesized that repeated sequences with a lower GC content than the original IMRS 
primers would be more successful, as I predicted that this would improve the likelihood 
of DNA breathing and primer invasion [235], [238]. Furthermore, I specified that the 
annealing temperature for the primers should be within the operating temperature range 
for Bst polymerase (50°C – 70°C) [239]. Ensuring that the primer annealing temperature 
fell within this range would allow both primer annealing and strand displacement to 
occur optimally at a single temperature. Next, I focused on the distribution of primer 
binding sites to improve the likelihood of successful isothermal amplification. Based on 
the initial failure of telomeric regions, I limited the search to intragenic regions, since 
these regions should have less secondary structure and therefore more successful primer 
annealing and amplification than the original telomeric regions. In order to enable 
successful strand displacement, I included a criteria that primer binding sites of the same 
orientation should be <30 bases apart from each other, as this would enable strand 
displacement without the need for bumper primers; this distance was based on guidelines 
for bumper primer design for LAMP primers [222]. Finally, I constrained the amplifiable 
region (i.e. the maximal distance between primers of opposite orientation) to be <3000 
base pairs, as I hypothesized that this would ensure successful polymerization before the 




Using these design criteria in the IMRS algorithm, I worked with Jigsaw 
Biosolutions to successfully identify a pair of forward and reverse primers that were both 
highly specific to the P. falciparum genome and highly repetitive. I first tested these 
primers with PCR, and initially attempted to develop an isothermal assay using the 
amplification schematic described in Chapter 5 (Figure 31, LAMP-like amplification 
exploiting looping with concatenated forward-reverse primers). However, I quickly 
realized that strand displacement amplification alone would be sufficient for successful 
isothermal amplification. Therefore, the bulk of this chapter will focus on development 
and validation of a novel amplification scheme using strand displacement as the sole 
mechanism for isothermal amplification.  
 
6.2 Materials and Methods: 
Identification of iso-IMRS primers:  
For this work, I worked with Jigsaw Biosolutions to use the Integrated Multi-
Repeat Sequence (IMRS) algorithm [185] with modified input constraints to identify 
primers suitable for isothermal amplification. Briefly, using the published, annotated 
genomic sequence for P. falciparum (3D7 strain, GeneDB, version 2013-03-01) as the 
input, the IMRS algorithm first identifies identical, repetitive sequence substrings from 
multiple loci within the annotated genome sequence.  It then generates a library of unique 
repeat sequences that can be used as amplification primers.  For the iso-IMRS assay, we 
added two additional constraints: repeats of the same sequence and orientation should be 




be located within an amplifiable region <3000 base pairs apart. This approach would 
choose primers that enable (1) strand displacement and (2) isothermal amplification. The 
repeat pairs identified by the algorithm were evaluated using the NIH’s Basic Local 
Alignment Search Tool (BLAST) to ensure that they were specific to the pathogen 
genome. These resulting primer pairs amplify several fragments of DNA of different 
sizes due to the distribution of the primers throughout the genome.  From this screen, the 
primer pair resulting in the most amplicons was selected for assay development, as this 
pair amplifies the largest amount of DNA, leading to the best possible analytical 
sensitivity.  
The resulting primer pair consisted of a forward primer which repeats in 52 
locations (5’- CTGGAGGTCAGTTCACAGTACCC – 3’) and a reverse primer which 
repeats in 55 locations (5’- CTCTACAATCCGTAGAGTTACTGG-3’); both primers 
occur on in four regions across chromosomes 6, 10, and 11. These primers will be 
referred to as “IMRS 2.0” moving forward.  
Real-time quantitative PCR assays:  
IMRS 1.0 and 18S rRNA PCR [190] amplification were previously carried out in 
Chapter 4, and the data is reproduced here. For IMRS 2.0 PCR amplification, each 25µL 
reaction contained 5µL DNA sample and 20µL master mix (1X SureStart Buffer, 500nM 
forward primers, 200nM reverse primers, 800µM dNTPs, 3.2mM MgCl2, 0.2X 
EvaGreen, 30mM ROX passive reference dye, and 0.025U SureStartTaq polymerase). 
The cycling conditions were as follows: initial denature at 95˚C for 10 minutes; 40 cycles 




2:30 minutes; and final extension of 72˚C for 10 minutes.  The assay was monitored in 
real time using a QuantStudio5 real time PCR machine, and products were also assessed 
using gel electrophoresis with 10% acrylamide gels and 1% agarose gels.  
To assess the lower limit of detection in buffer, a serial dilution of genomic DNA 
(gDNA) isolated from the 3D7 lab strain of P. falciparum (BEI Resources, MRA-102) 
was prepared in DNA Elution Buffer (QIAGEN) at the specified concentrations.  Each 
sample was tested in triplicate using the P. falciparum IMRS assay and the 18S IMRS 
assay as described above. 
Iso-IMRS isothermal amplification: 
The iso-IMRS amplification assay uses one forward and one reverse primer, 
which bind to 52 and 55 sites, respectively (synthesized by Integrated DNA 
Technologies, Coralville, IA). The 25µL reaction mixture uses 640U/µL Bst 2.0 
polymerase (New England Biosciences, Cambridge, MA), with 1X isothermal 
amplification buffer, 3.2mM forward primer and 1.6mM reverse primer combined with 
10mM dNTPs (Agilent), 0.4M Betaine (Sigma-Aldrich), and 2% molecular biology grade 
Ficoll-400 (Sigma-Aldrich).  5µL of sample was included in each 25µL reaction. For real 
time amplification, 0.2X EvaGreen intercalating dye and 30mM ROX reference dye are 
included in the reaction mixture to visualize real time amplification. Amplification is 
carried out at 56°C for 30 minutes, followed by melting curve analysis for real time 
amplifications. For comparison, I also tested a published LAMP amplification assay 
[191] at the same DNA concentrations. Post-amplification products were visualized on 




Lower Limit of Detection:  
In order to determine the LLOD (the concentration at which the sample can be 
detected with 95% confidence), of the P. falciparum 18S rRNA qPCR assay and iso-
IMRS assay, probit analysis was performed in MATLAB using the ratio of successful 
reactions to total number of reactions performed for each assay.  
P. falciparum parasite culture: 
P. falciparum (3D7 strain, BEI Resources, MRA-102) parasites were cultured in 
human red blood cells (Research Blood Components, Boston, MA) using standard 
culturing procedures for malaria parasites [58].  A culture of early ring-stage P. 
falciparum parasites in was maintained in 5% human red blood cells in complete RPMI 
medium in an incubator with 5% O2 and 5% CO2.  Parasites were synchronized with 5% 
D-sorbitol once per week. The culture was maintained at high parasitaemia (>30% 
infected red blood cells) to allow for subsequent dilution; parasitaemia level was 
monitored with routine Giemsa staining and microscopy.   
Parasite DNA extraction from infected Red Blood Cells: 
To test extracted parasite DNA with iso-IMRS and qPCR, 2x3µL of each 
individual culture was collected into a thin blood smear sample on glass slides, fixed with 
methanol, and stained with Giemsa stain to assess the parasitemia. The samples were 
visualized with 100x oil immersion confocal microscopy, parasitemia levels were 
determined for 10 separate fields of view for each slide, and the average parasitemia from 




serially diluted in human whole blood to final concentrations of 10%, 5%, 1%, and 0.1% 
parasitemia.  
For standard DNA extraction experiments, 100µL of the diluted samples were 
subjected to DNA extraction and purification using standard QIAGEN DNeasy Blood & 
Tissue kit protocol.  
18S rRNA TaqMan qPCR assay: 
A previously reported TaqMan qPCR assay was used for quantitative analysis of 
extracted P. falciparum DNA from parasites [59]. Gene-specific primers for the 18S 
rRNA gene (Forward: 5'-CTTTTGAGAGGTTTTGTTACTTTGAGTAA-3’, Reverse: 5'-
TATTCCATGCTGTAGTATTCAAACACAA-3’) initiated amplification and a HEX and 
Black Hole Quencher dual-labeled species-specific probe was included for fluorescence 
quantification (5’-HEX-TGTTCATAACAGACGGGTAGTCATGATTGAGTTCA-
IAbFQ-3’) (Integrated DNA Technologies). Purified P. falciparum genomic DNA was 
used for standard curve analysis with input concentration ranging from 1E1fg/µL to 
1E5fg/µL.  5µL sample was added to 20µL master mix for a final reaction volume of 
25µL (final concentrations: 1X SureStart 10X buffer, 3mM MgCl2, 0.3µM forward 
primer, 0.3µM reverse primer, 0.2µM probe, 0.8mM dNTPs, 30nM ROX reference dye, 
0.025U/mL Taq polymerase). Samples were incubated for an initial denaturation step at 





The IMRS algorithm was used to predict products generated by isothermal 
amplification with the new primers. All predicted product sequences were then aligned 
against the four regions of the chromosome to determine areas where there was 
significant overlap between products. To confirm the IMRS algorithm predictions, next 
generation sequencing (NGS) was performed on amplification products. After iso-IMRS 
amplification, products were size separated by gel electrophoresis on a 3.5% agarose gel.  
Bands of 100bp, 150bp, 250bp, and 300bp were extracted using a QIAGEN gel 
extraction kit, and the bands for each product size were pooled together to generate 
sufficient DNA for analysis.  The products were subsequently sequenced by Illumina 
Direct Amplicon Sequencing (GeneWiz, Cambridge, MA). Data analysis was performed 
by Patrick Lally in the Galagan Lab at BU.  Raw reads were processed through fastqc to 
generate a set of quality metrics and subsequently quality-trimmed with cutadapt with a 
quality score of 20 as the cutoff. Trimmed reads are then aligned to the reference genome 
with BWA and sorted and indexed with samtools. The sorted BAM alignment is 
subsequently converted to a .tdf file of coverage using IGVTools’ count function.  
Alignment was visualized with GenomeView genome browser. For each product size, the 
sequences were aligned to P. falciparum and P. vivax reference genomes available from 




6.3 Results and Discussion: 
PCR demonstration of IMRS 2.0 primers, initial isothermal development: 
We utilized the genome mining algorithm we previously reported  [185] to design 
a pair of short primer sequences to isothermally amplify DNA.  Using the algorithm, we 
identified two unique primers, a forward primer which binds in 55 independent loci and a 
reverse primer which binds in 52 independent loci across four chromosome regions 
within the P. falciparum genome (referred to as IMRS 2.0 primers moving forward) 
(Figure 39). 
 
Figure 39: Distribution of forward (blue) and reverse (red) primer binding sites across 




Using the IMRS 2.0 primers, I first demonstrated their capability for PCR 
amplification and then compared the limit of detection to a PCR assay targeting the 
multi-copy 18S rRNA gene (Figure 40).  The 18S rRNA gene is the most commonly-
used target for sensitive PCR detection.  
 
Figure 40: Probit Limit of Detection analysis of IMRS 1.0 PCR (blue), IMRS 2.0 PCR (green), 
and 18S rRNA gene PCR (pink).  IMRS 2.0 PCR is 10x more sensitive than the 18S PCR but is 
not as sensitive as the original IMRS PCR. 
As expected, the newly identified IMRS 2.0 primers showed approximately 10x 
better analytical sensitivity compared to standard PCR amplification of the multi-copy 
18S rRNA gene. However, the IMRS 2.0 PCR assay was less sensitive than the original 
IMRS PCR assay (Figure 40). These results are consistent with my expectations because 
the IMRS 2.0 primers exist in fewer repeats than the original primers (55 forward sites 
and 52 reverse sites for IMRS 2.0 compared to 152 forward sites and 155 reverse sites for 
IMRS 1.0). Therefore, in a PCR amplification scheme, I would expect that the sensitivity 




better suited to isothermal amplification based on the reasoning for the design criteria 
detailed previously.  
New amplification scheme for iso-IMRS: 
I initially designed the IMRS 2.0 primers based on the original iso-IMRS 
amplification scheme proposed in Chapter 5 (Figure 41). Briefly, the proposed 
amplification scheme would be similar to LAMP, but using only two primers (instead of 
the 4-6 needed for LAMP amplification) by using concatemers of the IMRS forward and 
reverse primers. With the new design criteria outlined above, I expected that the new 
primers would improve amplification with this scheme: primer sites of the same 
orientation would enable strand displacement, and primer sites of opposite orientation 
would enable loop formation.  
 
Figure 41: New IMRS primers (IMRS 2.0) were initially designed to enable amplification with 
the original scheme proposed in Chapter 5. 
However, experimentally, I found that the primers alone—without the 
concatenated overhangs—were sufficient for isothermal amplification (Figure 42). Based 
on these preliminary experimental results, it appears that strand displacement alone is 




a similar fashion as multiple displacement amplification (MDA) [242]–[245]. However, 
while MDA utilizes random hexamers binding to multiple genome locations for whole 
genome amplification, the longer, exact-match primer binding sites identified by the 
algorithm enable the specificity required to utilize this scheme for diagnostic purposes.   
 
 
Figure 42: Amplification was successful and more efficient using primers without overhangs, 




I therefore proposed an alternate amplification scheme using these primers. The 
new proposed amplification scheme takes advantage of individual primers annealing to 
multiple loci across the genome. In each case, the repeated primers are located in close 
proximity (<30 bp) within each genome region. A strand displacing polymerase is used to 
initiate amplification from each of these primer locations; as amplification proceeds, 
single strands are displaced from multiple locations in the genome and serve as templates 
for further amplification (Figure 43).  Due to the distribution of primer sites across the 
genome, this novel method generates multiple products, further increasing assay 
sensitivity without the need for additional primers or enzymes for DNA denaturation as 





Figure 43: Primer alignment enables simultaneous strand displacement and polymerization using 
only two primers and Bst 2.0 polymerase. Amplification from 55 forward and 52 reverse primer 




The isothermal amplification assay I proposed, called “iso-IMRS”, utilizes one 
forward and one reverse primer sequence and a standard Bst 2.0 strand displacing 
polymerase. The assay does not require additional primers or enzymes to enable strand 
displacement or DNA denaturation, thereby significantly reducing the complexity of the 
assay, while generating multiple products of different lengths from a single pair of 
primers.  I tested variations of several assay parameters to enable sensitive and specific 
amplification (Table 22). 
Table 22 Optimization factors for iso-IMRS assay development 
Optimization Factor Range Tested Final value 
Reaction temperature 55°C - 60°C  56°C 
Amplification time 30 – 60 min 30 min 
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Across several DNA concentrations, the optimized assay produces consistent 
products of several sizes.  The products can be visualized by both gel electrophoresis and 
real time amplification using an intercalating dye (Figure 44). Because these products can 




products generated by the assay are double stranded. This matches expectations based the 
prediction from the algorithm performed by my collaborators (discussed below). 
 
Figure 44: Post-amplification products visualized on a 10% acrylamide gel (left) and real 
time amplification curves (right).  Iso-IMRS amplification results in products of multiple 
sizes using only two primers binding in several locations across the genome. 
Using purified P. falciparum genomic DNA in buffer (BEI Resources, MRA 
102G), the iso-IMRS assay was compared to a qPCR assay amplifying the multi-copy 
18S rRNA gene [190].  The 18S qPCR assay I compared to in this work—which was 
previously described in Chapter 4—was optimized using an intercalating dye for real-
time readout. Although more sensitive qPCR methods exist for the 18S gene (using 
TaqMan probes or nested PCR, for example), I chose to compare against this assay 
because it uses an intercalating dye, and therefore has the most directly comparable 
detection method to iso-IMRS. Because iso-IMRS does not amplify a single product, 
generating a product-specific TaqMan probe for this method was not possible, and 
therefore readout could only be acquired using a non-specific intercalating dye. 
Furthermore, the 18S qPCR assay was previously used by our collaborators for P. 




I found that the iso-IMRS assay had a comparable analytical sensitivity to the 18S 
qPCR assay (Figure 45). Probit analysis showed that the lower limit of detection (LLOD) 
with iso-IMRS was 24.5 fg/µL P. falciparum genomic DNA, approximately 1 
parasite/µL (based on the average genome size for P. falciparum [49]).  This analytical 
sensitivity is similar to the 18S qPCR assay, which had a LLOD of 33.3 fg/µL, or 
approximately 1.4 parasites/µL.  Notably, the iso-IMRS assay achieves this sensitivity 
within 30 minutes of amplification time and at a single temperature, representing a 
significant reduction in resource needs compared to qPCR without sacrificing analytical 
sensitivity. I further compared the assay to a commonly used isothermal assay, which 
amplifies the 18S rRNA gene with LAMP amplification, and found that our assay was 
approximately 25x more sensitive (Figure 45).  Importantly, these data support that the 
iso-IMRS method will be sensitive enough to detect asymptomatic infections <2 
parasites/µL.  
 
Figure 45: Probit analysis of iso-IMRS (red), 18S qPCR (light blue), and 18S LAMP (dark blue). 
Iso-IMRS shows comparable sensitivity to qPCR, both using intercalating dyes and gel 




To further demonstrate the efficacy of the iso-IMRS method, I quantified 
successful amplification across several concentrations of parasite-infected red blood cells 
introduced into whole blood. Using synchronized P. falciparum parasites cultured in vitro 
in human red blood cells, I tested several parasite concentrations at varying growth stages 
to mimic patient samples in the lab. DNA was extracted from the spiked blood samples 
using a standard QIAGEN DNeasy Blood & Tissue kit, and subsequently quantified with 
a qPCR for the 18S rRNA gene and analyzed with real time iso-IMRS amplification.  
Across several concentrations ranging from 10fg/µL to 1000fg/µL DNA (0.1% - 10% 
parasitemia), iso-IMRS consistently showed exponential amplification of parasite DNA 
within 30 minutes (Figure 46). As the parasite concentration approached the LLOD of the 
assay (~24 fg/µL), amplification became more stochastic as seen in increased variability 
in iso-IMRS threshold time. However, all concentrations demonstrated successful iso-
IMRS amplification of extracted parasite DNA in at least 2/3 technical replicates. I also 
observed highly stochastic but successful DNA amplification at concentrations <10 
fg/µL; however, these data are not shown as the samples fell outside of the qPCR 





Figure 46: P. falciparum infected red blood cells extracted from whole blood with standard 
QIAGEN extraction kits, quantified with qPCR and analyzed with iso-IMRS.  Across several 
parasitemia levels, iso-IMRS successfully amplifies extracted P. falciparum DNA within 30 
minutes. 
Assay Characterization: 
I first characterized the iso-IMRS assay by comparing the expected product sizes 
to product sizes acquired by gel electrophoresis (Figure 47). Expected product sizes were 
determined by analyzing all possible products between the iso-IMRS binding sites. Based 
on these predictions, I expected there to be an excess of smaller products <1000bp. 
Comparing this prediction to the products sizes determined by acrylamide gel 
electrophoresis, nearly all of the expected product lengths are represented on the gel 
except for products of ~200bp. It is possible that the products are produced, but in much 
lower concentrations compared to the other products, resulting in a band that is not 




or primer binding at these sites is not as favorable as other locations. More experiments 
must be performed to understand the reason for this anomaly. However, it is encouraging 
that the other predicted products are visible on the gel because this corroborates that the 
predicted amplification scheme is correct. 
 





To further characterize amplified products, I performed Illumina next generation 
sequencing (NGS) on amplification products to determine the specificity of the iso-IMRS 
products to the P. falciparum genome.  After amplification, the products were size 
separated by agarose gel electrophoresis and four individual bands of 100 bp, 150bp, 
250bp, and 300bp were extracted and analyzed using Illumina Direct Amplicon 
Sequencing (GeneWiz, Cambridge, MA). The resulting NGS forward and reverse reads 
were computationally aligned to the P. falciparum genome and to the P. vivax genome to 
confirm specificity (alignment performed by Galgan Lab, BU).  
All four bands showed alignment with the P. falciparum genome regions 
predicted by the algorithm, with minimal alignment (<5 reads in either orientation) in 
regions outside of the predicted areas (Table 23). The alignment is presented in Figure 
48. The product sequences showed minimal alignment (<5 reads in either orientation) 
onto the entire P. vivax genome, indicating that the products are specific to P. falciparum. 





region, IMRS algorithm 
NGS sequencing, alignment 
locations 
6 57,296 -59,909 57,220-59,935 
6 1,305,863-1,309,146 1,305,840-1,309,117 
10 1,582,798-1,583,956 1,582,797-1,583,849 








Figure 48: NGS alignment of four products to the P. falciparum genome regions in 




An interesting phenomenon we observed is that all four product bands—of 
varying product sizes—aligned to similar regions on each.  For example, products 
isolated from the 100bp band resulted in sequence alignment >100bp on the genome. To 
better explain this phenomenon, we computationally analyzed all potential products 
found that there was significant overlap in the sequences of the products (Figure 49). 
Notably, the product overlap on all four chromosomes in similar patterns to the alignment 
pattern observed from the NGS sequencing results.  Therefore, the phenomenon 
described earlier, where 100bp fragments align to >100bp sequences on the genome, is 
likely described by the sequence similarity in amplified products. These effects explain 







Figure 49: (a) Alignment of predicted products to chromosomes 6, 10, and 11. 265 total products 
are expected to be formed across these regions, and products of different lengths have significant 
overlapping regions (gray bars). (b) Example of overlapping products for chromosome 10. 





Here, I have developed a novel isothermal assay for amplification and detection 
of P. falciparum genomic DNA.  I first developed more specific design criteria to use the 
IMRS algorithm for a novel isothermal amplification assay. The new design criteria led 
to the discovery of a new amplification scheme similar to MDA, but which used repeated 
primers to enable strand displacement. The assay I developed uses only two primers, each 
of which bind to >50 locations on the genome to generate several DNA products of 
multiple sizes. These products can be detected by traditional methods like real time 
amplification curves using a fluorescent intercalating dye or gel electrophoresis analysis. 
The iso-IMRS assay shows excellent analytical sensitivity comparable to qPCR (~1 
parasite/µL), and successfully amplifies DNA from samples consisting of parasite-
infected red blood cells in whole blood. Comparing the iso-IMRS assay to an existing 
LAMP assay, I found that the iso-IMRS assay was 25x more sensitive. 
To characterize the assay, I first showed that the expected double stranded 
amplification products matched with the predicted sizes of the amplicons. NGS 
sequencing of four distinct products was used to show assay specificity to P. falciparum. 
The product sequences aligned almost exactly with the amplification regions predicted by 
the algorithm. In collaboration with Jigsaw Biosolutions, I was able to further explain and 
illustrate the overlapping amplification products obtained in NGS sequencing.  
Overall, the data presented in this chapter describes the mechanism for a novel 
isothermal amplification scheme. This amplification mechanism was demonstrated for P. 





























CHAPTER SEVEN: ADAPTING ISO-IMRS TO THE POINT OF CARE 
This chapters Aim 3 of my work, adapting the iso-IMRS assay to a point-of-care 
format and bringing together the two pieces of my thesis work for sample extraction and 
amplification.  For this work, I developed each of the following components separately: 
1) Iso-IMRS amplification of SNAPflex-extracted samples with eluted DNA and 
directly on paper 
2) Visual readout of amplified products using lateral flow strips 
3) Dried Bst polymerase for room temperature storage 
In Chapter 2, I presented our point of care nucleic acid extraction device, which 
enables room temperature extraction, storage and shipment of purified nucleic acids from 
blood. In this chapter, I focus on demonstrating compatibility of our novel iso-IMRS 
assay with the SNAPflex device. I will also report developing a visual readout for the 
assay, and initial experiments toward stabilizing Bst polymerase at room temperature. 
Individually, these experiments bring the iso-IMRS method closer to the point of care; 
when combined into an integrated device, I expect that they would enable improved mass 






For the last portion of this thesis work, I pursued strategies to adapt the iso-IMRS 
assay to a field-deployable method. The ultimate goal for this project is to create a 
diagnostic that can be used for mass screening and treatment of symptomatic and 
asymptomatic malaria infection. To this end, it is important for diagnostics to be suitable 
for deployment in field settings: they must be sensitive, portable, affordable, and easy-to-
use. Recently, the Program for Appropriate Technology in Health (PATH) worked with 
the Gates Foundation to suggest criteria for diagnostics suitable for MSAT programs 
[247]; the relevant metrics for this project are included in Table 24.  
Table 24: Diagnostic requirements for mass screening and treatment 
Diagnostic Requirements for Mass Screening and Treatment 
Limit of Detection ≤10 parasites/µL (ideal, 2 parasites/µL) 
Cost per sample $1 - $5 
Sample type/collection Finger prick blood 
Assay time/throughput 15 – 30 min 
>10 tests/hour 
Target end user Community health worker, 
Trained lay person  
 
As I described in the previous chapters, I have successfully developed an assay 
with the necessary analytical sensitivity to identify asymptomatic P. falciparum 
infections within 30 minutes. The iso-IMRS assay was developed as an isothermal 
method, making it easier to adapt to field settings due to the need only for a single heat 
source rather than complex equipment for precise thermal cycling, as with PCR. The iso-




sensitivity with a simple amplification scheme; although several other isothermal 
amplification methods are in development, most do not achieve the analytical sensitivity 
of our assay. There are two commercially-available LAMP-based isothermal 
amplification methods which do achieve similar analytical sensitivity to our assay; 
however, they require specialized equipment to read out turbidity and/or fluorescence 
methods, making them cumbersome to adapt to MSAT settings.  
In order to bring the iso-IMRS assay to screening settings, the next goal was to 
simplify the assay to make it more adaptable to the point of care. Our lab previously 
developed integrated devices for several isothermal amplification methods [142], [248]–
[251]; once we translate iso-IMRS components individually to a field-deployable format, 
we aim to integrate these steps as we have done previously. Toward this goal, I focused 
here on simplifying each step – parasite DNA extraction and assay readout – into more 
field-deployable formats. I first demonstrate that the room temperature, centrifuge-free 
blood extraction device reported in Chapter 2 is compatible with iso-IMRS using both 
eluted DNA and for on-paper amplification. Next, I will show that the iso-IMRS reaction 
can be modified to include components for visual readout of amplified DNA. 
Lastly, I report preliminary efforts to adapt the assay to a dry format without the need for 
any cold storage of assay reagents. Initial experiments for dry reagents were 
demonstrated with technology developed by the Ellington lab at the University of Texas, 
Austin.  In tandem, I also pursued a separate strategy to develop a method to dry 






7.2 Materials and Methods: 
Parasite Culture: 
P. falciparum (3D7 strain, BEI Resources, MRA-102) parasites were cultured in 
human red blood cells (Research Blood Components, Boston, MA) using standard 
culturing procedures for malaria parasites.  A culture of early ring-stage P. falciparum 
parasites in was maintained in 5% human red blood cells in complete RPMI medium with 
hypoxanthine, grown at 37°C at 5% CO2 and 3% O2.  Parasites were synchronized with 
5% D-sorbitol once per week. The culture was maintained at high parasitaemia (>20% 
infected red blood cells) to allow for subsequent dilution; parasitaemia level was 
monitored with routine Giemsa staining and microscopy.   
 
Parasite DNA extraction from infected Red Blood Cells: 
SNAPflex extraction was carried out as described in Chapter 2. The complete 
lysis consists of 68% (v/v) custom lysis buffer, 29% (v/v) 10% nonyl 
phenoxypolyethoxylethanol (Sigma-Aldrich), and 3% (v/v) GlycoBlue (15mg/mL blue 
glycogen, Applied Biosystems). 100µL of parasite-infected red blood cells in whole 
blood were lysed with 200µL complete lysis buffer and the sample was lysed at room 
temperature for 15 minutes. After 15 minutes of room temperature lysis, 129µL of 1-
butanol was added to the lysed sample to enable DNA precipitation. Lysed samples were 
applied to the paper-and-plastic SNAPflex extraction device and washed with three 
separate buffers: 400µL 12.5% BoomD lysis buffer + 70% ethanol, 200µL 70% ethanol, 




For quantification experiments using SNAPflex, the captured DNA was eluted 
into 100µL standard elution buffer (QIAGEN Buffer EB) with 10 minutes of heating at 
50°C. The products were analyzed by qPCR and iso-IMRS. For on-paper amplification 
experiments, the capture membrane was transferred directly to an amplification tube, and 
75µL of iso-IMRS reaction mixture was added to the tube (the sample volume was 
substituted with nuclease free water in the master mix). After amplification, 20µL of 
products were collected for the visual readout protocol described above.  
 
18S rRNA TaqMan qPCR assay: 
A previously reported TaqMan qPCR assay was used for quantitative analysis of 
extracted P. falciparum DNA from parasite-infected red blood cells [59]. Gene-specific 
primers for the 18S rRNA gene (Forward: 5'-
CTTTTGAGAGGTTTTGTTACTTTGAGTAA-3’, Reverse: 5'-
TATTCCATGCTGTAGTATTCAAACACAA-3’) initiated amplification and a HEX and 
Black Hole Quencher dual-labeled species-specific probe was included for fluorescence 
quantification (5’-HEX-TGTTCATAACAGACGGGTAGTCATGATTGAGTTCA-
IAbFQ-3’). Purified P. falciparum genomic DNA was used for standard curve analysis 
with input concentration ranging from 1E1fg/µL to 1E5fg/µL.  5µL sample was added to 
20µL master mix for a final reaction volume of 25µL (final concentrations: 1X SureStart 
10X buffer, 3mM MgCl2, 0.3µM forward primer, 0.3µM reverse primer, 0.2µM probe, 
0.8mM dNTPs, 30nM ROX reference dye, 0.025U/mL Taq polymerase). Samples were 




seconds and 60°C for 1:00. 
 
Lateral Flow readout, iso-IMRS: 
For iso-IMRS visual readout, lateral flow strips with test lines containing a test 
line with anti-FAM antibodies were used (UStar Biotechnologies, Hangzhou, China). 
Forward (5’- CTGGAGGTCAGTTCACAGTACCC) and reverse (5’- 
CTCTACAATCCGTAGAGTTACTGG) iso-IMRS primers were obtained from 
Integrated DNA Technologies, Coralville, IA. A fraction of the forward primers included 
in the reaction mixture were modified on the 5’ end with fluorescein (FAM).  1mM of 5’-
FAM forward primers were used in combination with 2.2mM unmodified forward 
primers. 0.04mM biotin dUTP (Thermo Scientific) was added to the reaction mixture for 
biotin modification of the amplified products. After amplification, 20µL post-
amplification products were precipitated with 2.5M final concentration ammonium 
acetate (Sigma-Aldrich) and 50% (v/v) isopropanol (Thermo Fisher). The solution was 
applied to 0.7µm pore size glass fiber membranes (Millipore) cut into ¼” circles to 
collect amplified DNA and remove unincorporated dNTPs and primers from the solution. 
The paper was washed with 60µL 70% ethanol and 30µL 95% ethanol, dried at room 
temperature, and inverted onto the gold nanoparticle conjugate pad of the lateral flow 







Cellular reagents for Taq polymerase and Bst polymerase were kindly provided 
by Dr. Sanchita Bhadra at the Ellington Lab (University of Texas, Austin).  
Taq cellular reagents were tested with P. falciparum genomic DNA (BEI Resources, 
MRA-102G) which was either 1) diluted into elution buffer (QIAGEN, 10mM Tris-HCl 
buffer, pH 8.5, or 2) diluted into whole blood and extracted and eluted from SNAPflex as 
described above.  
Standard qPCR analysis with an intercalating dye-based assay for the 18S rRNA 
gene [190]. The forward and reverse PCR primer sequences were 5’-
AGTCATCTTTCGAGGTGACTTTTAGATTGCT and 5’-
GCCGCAAGCTCCACGCCTGGTGGTGC, respectively (Integrated DNA 
Technologies, Coralville, IA). 5µL of sample volume was combined with 20µL of a 
master mix for final concentrations, 0.025 U/mL Taq polymerase (Agilent SureStart 
polymerase), 1X SureStart buffer, 0.5mM MgCl2, 0.8mM dNTPs, 0.2µM forward primer, 
0.2µM reverse primer, 0.2X EvaGreen intercalating dye, and 30mM ROX reference dye. 
For Taq cellular reagents, the commercial polymerase was replaced with rehydrated 
cellular reagents. The lyophilized cellular reagent pellet was rehydrated with 20µL of 
nuclease free water (HyPure). 3µL of the rehydrated suspension was added to each 
sample. Cycling conditions were as follows: initial denature at 95˚C for 10 minutes; 40 
cycles of 95˚C denature for 30 seconds, 55˚C annealing for 1 minute, and 72˚C extension 
for 1 minute; and final extension of 72˚C for 10 minutes. For both conditions, three 




amplification on the QuantStudio 5 PCR instrument, and products were analyzed with 
10% acrylamide gel electrophoresis.  
Bst cellular reagents were tested with three separate LAMP assays. The first was a 
previously published LAMP assay for P. falciparum [191], the second was an internally-
developed LAMP assay for the HPV 18 L1 gene [252], and the third was a previously 
published LAMP-OSD assay for GAPDH [253]. The HPV18 and GAPDH assays were 
tested with plasmid templates, sequences are included in Table 25. The HPV18 and 
GAPDH assays were performed with plasmid templates and the plasmid target sequences 
are also listed in Table 25. P. falciparum gDNA was diluted to 50 pg/reaction and 1 
pg/reaction; HPV18 DNA was diluted to 1E7 copies/reaction, 1E6 copies/reaction, and 
1E5 copies/reaction; GAPDH DNA was diluted to 200 fg/reaction; all samples were 








Table 25: Primer sequences for three LAMP assays and plasmid DNA template sequences for HPV 18 and GAPDH. 
 P. falciparum 18S LAMP assay [191] 
(5’3’) 
HPV18 LAMP assay [252] 
(5’3’) 


















LF GCACCAGACTTGCCCT ACGTTGTGGTTCGGCTCGT OSD probe:  
5’FAM – 
CTCACTGGCATGGCCTTCCGTGTCC
CCACTGCCAAC - 3InvdT/ 










































For standard LAMP analysis, the reactions were performed with Bst 2.0 
polymerase (New England Biolabs, Ipswich, MA), according to the standard protocol. 
For cellular reagent samples, the lyophilized pellet was rehydrated with 20µL of nuclease 
free water (HyPure). 3µL of the rehydrated suspension was added to each sample instead 
of commercial polymerase. The master mix composition and amplification conditions are 
listed in Table 26. Results were analyzed by real time amplification on the QuantStudio5 
PCR machine and by 1% agarose gel electrophoresis. 
Table 26: Master mix components and amplification conditions for three LAMP assays 
 P. falciparum 







1X 1X 1X 
dNTPS (mM) 0.4 0.4 0.8 
MgSO4 (mM) 0 0 2 
Betaine (M) 0.5 0.5 0.8 
F3 (µM) 0.2 – 0.4 0.2 0.4 
B3 (µM) 0.2 – 0.4 0.2 0.4 
FIP (µM) 1.6 1.6 1.6 
BIP (µM) 1.6 1.6 1.6 
LF (µM) 0.8 0.8 0.8 
LB (µM) 0.8 0.8  
OSD probe (µM)   0.1 
EvaGreen probe 0.2X 0.2  
ROX reference dye (mM) 30 30  










Dried Bst 2.0: 
The experiments described were performed using the 18S LAMP assay described 




10mM Tris-HCl, pH 8.5. Elution buffer without DNA was used as the negative no 
template control (NTC). The concentrations of the final master mix components were 
kept consistent, but the master mix volume was increased to 50µL.  
 
On-paper Bst 2.0 drying: 
The Bst drying protocol is outlined in Figure 50. 1M trehalose (Sigma-Aldrich), 
1M D-mannitol (Sigma-Aldrich), and 1M erythritol (Sigma-Aldrich) were prepared in 
nuclease free water (HyPure) with gentle heating to enable dissolution. Polyethersulfone 
membrane (PES, 0.45µm pore size, Sterlich) or glass fiber membrane (GF, 0.7µm pore 
size, Millipore) were cut into 0.25” diameter. Bst 2.0 enzyme at the appropriate 
concentration was mixed with either 1M trehalose, 1M D-mannitol, or 1M erythritol by 
gentle pipetting. Approximately 7µL of the Bst-sugar solution was placed onto the paper 
circle and stored in a desiccant-containing dry chamber at room temperature for 2 hours 
(standard) to 48 hours (time course study).  For the time course study, Bst 2.0 without 
stabilizer was added to the paper and stored in the same conditions. 
For endpoint experiments in the thermocycler. The papers were crushed into the 
bottom of the sample tube, and 50µL of the prepared master mix (including sample) was 
added to the tube to fully submerge the paper. The tube was incubated at the appropriate 
temperature in the thermocycler. For real time data collection, the paper was located 
along the side of the well in a cone shape on the inside of the well of a PCR amplification 
plate (instead of crushed) and 50µL of master mix was added to each well. The plate was 





Figure 50: Schematic for Bst drying on paper 
 
Bst 2.0 drying in tube: 
Bst 2.0 enzyme at the appropriate concentration was mixed with either 1M 
trehalose, 1M D-mannitol, or 1M erythritol by gentle pipetting. PCR tubes were placed 
on their side, and approximately 7µL of the Bst-sugar solution was pipetted along the side 
of the tube (Figure 51). The tubes were left open and dried in a desiccant-containing 
chamber for 2 hours at room temperature. 50µL of the reaction master mix (including 
sample) was added directly to the tube and pipetted to mix; the tubes were centrifuged to 
collect the liquid and incubated directly in the thermocycler and incubated at the 





Figure 51: Drying of Bst with trehalose (T), erythritol (E), and mannitol (M) in tube. 
 
 
7.3 Results and Discussion: 
Demonstrating iso-IMRS real-time amplification with SNAPflex-extracted samples: 
In order to make the iso-IMRS assay more adaptable to the point of care, I first 
demonstrated successful amplification of DNA extracted using the POC nucleic acid 
extraction device described in Chapter 2. Using the SNAPflex device, we first extracted 
P. falciparum “mock” patient samples (infected red blood cells spiked into whole blood) 
onto paper and subsequently eluted the extracted DNA into a standard elution buffer, 
10mM Tris-HCl, pH 8.5 (Figure 52a).  The extracted parasite DNA was quantified using 
both qPCR and real-time iso-IMRS. The results demonstrate successful amplification of 
eluted samples across several parasite concentrations, demonstrating that iso-IMRS is 
compatible with the point of care extraction method (Figure 52b). These results support 
that iso-IMRS is compatible with SNAPflex without a significant drop in performance, 





Figure 52: a) Schematic of SNAPflex nucleic acid extraction and elution from whole blood. b) 
Comparison of qPCR quantification with iso-IMRS amplification for SNAPflex extracted 




Interestingly, while all SNAPflex-extracted samples were successfully amplified 
by iso-IMRS, the resulting threshold times shifted later for SNAPflex-extracted samples 
(blue) compared to QIAGEN-extracted samples (red, also presented in Chapter 2). In the 
isothermal assay, later threshold times mean delayed exponential amplification, 
indicating less ideal amplification efficiency. I hypothesize that residual lysed blood 
components or residual salts from the SNAPflex lysis buffer may have impacted the iso-
IMRS amplification efficiency, as I previously determined inhibitory effects of blood on 
amplification assays like qPCR (Appendix I).  However, although amplification occurred 
at a later time than expected for the SNAPflex samples, all DNA extracted from P. 
falciparum infected red blood cells successfully amplified at the concentrations we tested.  
In a pair-wise comparison, SNAPflex-extracted samples showed higher DNA 
concentration relative to the same samples extracted with QIAGEN kits, as quantified by 
both iso-IMRS and qPCR.  These results indicate both that SNAPflex shows excellent 
DNA extraction efficiency, and that iso-IMRS results are consistent with qPCR. In other 
words, both POC friendly methods (SNAPflex and iso-IMRS) are comparable to their 
more resource-intensive counterparts. Importantly, the data support that samples 
representing asymptomatic infections can be extracted with SNAPflex and amplified by 
iso-IMRS (<10 parasites/µL, ~240 fg/µL). 
Adapting iso-IMRS to visual readout with lateral flow strips: 
Next, I adapted the assay to a visual “YES/NO” readout using lateral flow strips. 
Traditionally, lateral flow detection of DNA amplicons can be done using an amplicon 




the lateral flow strip. In this case, the iso-IMRS assay scheme generates multiple products 
across the genome, making it difficult to adapt to a standard lateral flow strip assay with a 
sequence-specific probe, as there isn’t necessarily a specific DNA sequence in the 
multiple products formed.   
To visualize iso-IMRS amplicons on lateral flow strips, I incorporated a fraction 
of biotinylated dNTPs into the assay mix so that all amplified products would contain 
biotin to capture streptavidin-coated gold nanoparticles.  The assay mixture also included 
a fraction of FAM antigen-tagged primers to enable product binding to the antibody-
coated “test line”. Therefore, products would contain FAM on the 5’ end containing the 
primer and gold nanoparticles would bind to the biotin-dNTPs throughout the amplicon 
(Figure 53a). Visualization is enabled by a biotin-tagged primer on the amplicon, which 
binds to streptavidin-coated gold nanoparticles. The “test” line captures antigen- and gold 
nanoparticle-tagged amplicons, appearing red, while the “control line”, coated with 
biotin, captures gold nanoparticles only to indicate successful flow. After amplification, a 
mixture of ammonium acetate and isopropanol was added to the solution to precipitate 
larger, amplified DNA products while leaving unincorporated dNTPs and primers in 
solution. The precipitate was applied to a 0.7µm pore size glass fiber membrane to filter 
out the unincorporated nucleic acids, ensuring that these would not saturate the test line, 
leading to false negative results. The glass fiber membrane containing amplified products 
was placed directly onto the lateral flow strip and products were eluted with a running 
buffer onto the conjugate pad to bind gold nanoparticles and flow across the strip.  




sensitivity to fluorescence-based readout (Figure 53b), demonstrating that the assay 
should not decrease in sensitivity when translating to visual readout. Similar to the 
fluorescence-based results, amplification was stochastic at concentrations ≤10fg/µL. 
Notably, lateral flow strips showed some positive results at 5 fg/µL P. falciparum gDNA, 
which did not show any successful amplification on fluorescent readout with intercalating 
dye. I hypothesize that lateral flow strip capture partial, single stranded amplicons 
containing biotin-dNTP and tagged primer.  Single stranded products would be produced 
by the amplification scheme we propose, but would not be detected by fluorescence 
detection with an intercalating dye, which requires double stranded products.  Therefore, 
they would appear on lateral flow strips, but not on real-time or gel readout. 
 
 
Figure 53: a) Lateral flow strip visualization of iso-IMRS products using biotinylated dUTP and 
FAM-labeled primers, and b) Visualization of products on lateral flow strips at varying 
concentrations. At lower concentrations, amplification is stochastic but visualization of products 




I initially found that including a FAM-tagged forward primer was sufficient to 
enable capture and visualization on lateral flow strips without sacrificing sensitivity. 
However, further optimization studies showed that incorporating a fraction of FAM-
tagged reverse primers in addition to forward primers may improve the analytical 
sensitivity of the lateral flow strip format, further improving the potential to detect 
asymptomatic infection (Figure 54).  
 
Figure 54: Lateral flow strip readouts using combinations of FAM-tagged forward and reverse 





On-paper iso-IMRS amplification with LFS readout: 
I next showed that amplification of DNA captured directly onto paper was 
possible with iso-IMRS.  Using samples consisting of in vitro cultured P. falciparum-
infected red blood cells spiked into whole blood, I processed several parasite cultures 
with SNAPflex devices. I placed the capture paper directly into an iso-IMRS reaction to 
amplify captured parasite DNA. The reaction was visualized with lateral flow strips as 
described above (Figure 55).  
 
Figure 55: Schematic for on-paper amplification of mock patient samples 
The samples were also extracted with QIAGEN Blood & Tissue kits and parasite 
DNA was analyzed by qPCR to determine expected parasite concentration for each 




direct iso-IMRS amplification and detection of parasite DNA on paper was possible 
(Table 27). As expected, samples with QIAGEN extracted DNA concentrations >10 
fg/µL showed strong signal with iso-IMRS and LFS readout.  Notably, however, there 
was also successful lateral flow detection of several samples < 10fg/µL which were not 
always successfully detected by real time readout. These results indicate that the iso-
IMRS amplification and detection and lateral flow detection scheme may be more 
sensitive than fluorescence readout, most likely because partial single stranded amplicons 
are detected in this format.  
An additional important note is the absence of false positive results – for all 
experiments, both with genomic DNA in buffer and with whole blood extracts containing 
human DNA, the negative samples did not show non-specific capture on the test line. 
These results further support that the positive lateral flow strip amplification of samples 










iso-IMRS LFS result 
Ring 3.15 Positive 
Ring 1.74 Positive 
Ring 1.61 Negative 
Ring Undetectable Negative 
Ring 1083.52 Positive 
Ring 460.81 Positive 
Ring 5.90 Positive 
Ring 2.56 Positive 
Tropozoite 913.13 Positive 
Tropozoite 1474.10 Positive 
Tropozoite 238.86 Positive 
Tropozoite 15.46 Positive 
Tropozoite 4016.18 Positive 
Tropozoite 3023.66 Positive 
Tropozoite 1052.48 Positive 
Tropozoite 39.30 Positive 
Schizont 11815.38 Positive 
Schizont 9073.28 Positive 
Schizont 1950.45 Positive 
Schizont 147.95 Positive 
Schizont 27373.39 Positive 
Schizont 13667.72 Positive 
Schizont 2205.57 Positive 




Dried reagents for amplification: 
One major impediment to the implementation of DNA amplification methods at 
the point of care is the requirement for cold storage of reagents. In particular, the 
polymerase used for amplification requires cold storage in order to maintain stability.  
Although Bst polymerase is in many ways more robust than traditionally used Taq 
polymerase, the enzyme does not maintain stability at elevated temperatures for extended 
time periods [254] . 
Cellular Reagents (Ellington lab): 
To address this problem, I first collaborated with the Ellington Lab at University 
of Texas, Austin to demonstrate successful amplification of P. falciparum gDNA using 
their novel assay reagents. The Ellington group has sought to address both production 
costs and cold storage constraints for enzymes by developing a novel production method 
for amplification reagents. They have produced “cellular reagents” by overexpressing 
enzymes in bacteria and lyophilizing the suspension, which both inactivates bacteria and 
stabilizes the enzymes [254].  
The Ellington lab demonstrated successful use of these reagents for several 
diagnostic applications, but in most cases, they did so using synthetic plasmid DNA. 
Therefore, as a starting point, I demonstrated that their Taq cellular reagents successfully 
amplified P. falciparum genomic DNA.  I further showed that P. falciparum genomic 
DNA extracted from whole blood using the SNAPflex device could be successfully 
amplified by Taq cellular reagents (Figure 56). Together, these data support the use of 




for use at the point of care.  
Although amplification was successful, there was some non-specific product that 
appeared on the stained gel outside of the two target products formed by PCR 
amplification. I hypothesize that this background signal is likely caused by non-specific 
binding of SYBR green DNA intercalating dye to all double stranded DNA in the sample, 
including bacterial DNA, which remains in the cellular reagents after lyophilization. The 
presence of bacterial DNA also explains the real-time amplification results for cellular 
reagents (Figure 56b), which show overlapping amplification curves for the positive 
samples and the no template (negative) control (NTC) sample. EvaGreen intercalating 
dye was used as the fluorescence readout for these samples, which is likely why there 
was significant nonspecific amplification observed in the real-time results.  
 
 
Figure 56: A) P. falciparum gDNA in buffer amplified with commercially available Taq 
polymerase compares well with Taq-CR amplification of P.f. gDNA in buffer and P.f. gDNA 
extracted from blood with SNAPflex. (B) Real time amplification with commercial Taq 
polymerase did not show non specific amplification while curves for Taq-CR showed overlap 




These experimental results represent a promising first step toward using the 
SNAPflex point of care blood extraction device with cost-effective dried cellular 
reagents. However, as the PCR assay used to demonstrate Taq cellular reagents still 
required thermal cycling for amplification, I next attempted to use Bst cellular reagents 
for LAMP isothermal amplification.   
Unfortunately, I was unsuccessful in reproducing results from the Ellington lab 
for this reagent. I first attempted to demonstrate standard LAMP amplification of P. 
falciparum genomic DNA with a previously published LAMP assay [191]. I attempted to 
improve amplification by varying the concentration of primers and comparing against 
higher concentrations of Bst. However, as the real time amplification (Figure 57a) and 
agarose gel electrophoresis (Figure 57b) results showed, amplification with Bst-cellular 
reagent was not successful, and resulted in no amplification, even for samples that were 
successfully amplified with commercially available Bst 2.0. Interestingly, the real time 
results showed a dip in the middle of the real time curve at approximately 35 minutes, 
which is not characteristic of exponential amplification. It is possible that the co-factors 
present in the cellular reagent matrix (i.e. byproducts of lyophilization or bacterial lysis) 
may have bound to genomic DNA, inhibiting amplification and leading to this anomalous 





Figure 57: P. falciparum genomic DNA LAMP amplification with commercial Bst 2.0 and Bst 
cellular reagents as measured by A) real time amplification curves and B) agarose gel 




To test this hypothesis, I next attempted amplification with an internally 
developed LAMP assay for the HPV18 L1 gene using plasmid DNA as the input.  Again, 
although there was successful amplification with commercial Bst 2.0, I did not see any 
amplification using Bst-cellular reagents (Figure 58).  In this case, there was no dip in the 
middle of the fluorescence results, leading to the hypothesis that the amplification pattern 
observed previously might have been characteristic of a genomic DNA input. However, I 
did not see successful amplification with this assay either, further leading to the 
hypothesis that the cellular reagents may inhibit amplification. 
 
Figure 58: HPV 18 plasmid LAMP amplification with commercial Bst 2.0 and Bst cellular 
reagents as measured by A) real time amplification curves and B) agarose gel electrophoresis.  




As a last effort toward troubleshooting, I shipped the Bst-cellular reagents I 
received back to the Ellington lab so that their performance could be tested using a 
standard qualification assay in the Ellington lab.  Amplification of a target sequence in 
the human GAPDH gene using a plasmid DNA input was successful in the Ellington lab 
using the shipped reagents (Figure 59a). However, when I then tested the same assay with 
the same cellular reagents in the Klapperich lab using plasmid template provided by the 
Ellington lab, amplification was not successful with Bst-cellular reagents, while the 
commercial Bst 2.0 was successful (Figure 59b).  I therefore speculate that there are 
procedural differences between the two labs that I cannot account for and troubleshoot at 
the moment, and paused on further development with the Bst cellular reagents. 
 
Figure 59: GAPDH plasmid LAMP amplification with commercial Bst cellular reagents was 
successful in the Ellington lab (A) but could not be replicated in the Klapperich lab (B). 
Dried Bst 2.0 to improve room temperature enzyme stability 
In lieu of further development with Bst cellular reagents, I shifted attention to 




Trehalose, which is an osmolyte, is known to be an exceptional protein stabilizer—it has 
been shown to protect enzymes from dehydration and keep the protein conformation 
stable and active by acting as a water substitute [255].  Therefore, as a starting point to 
developing dried Bst, I first adapted a previously published method to stabilize Bst and 
amplification primers using trehalose sugar [256].  Rather than stabilizing the 
components in a reaction tube, I aimed to stabilize them on a polyethersulfone (PES) 
paper matrix, with the expectation that this format would be simpler to incorporate into 
an integrated device. I first demonstrated that the presence of trehalose does not inhibit 
amplification, and successful amplification is possible with both dried iso-IMRS primers 
and trehalose-stabilized dry Bst 2.0 enzymes (Figure 60). Iso-IMRS amplification was 
carried out with a high concentration of purified P. falciparum gDNA (10pg/µL) as an 
initial proof of concept. I was unable to show successful amplification using the dried 
primers and dried Bst enzyme together (data not shown), indicating that further 





Figure 60: Demonstration of trehalose stabilization of Bst and iso-IMRS primers. 
In light of these results, I chose to focus on optimization of dried Bst alone 
because enzyme stabilization could be more broadly applicable than optimization of the 
dried iso-IMRS assay primers. These stabilization studies were performed using a 
published LAMP assay targeting the 18S rRNA gene in the P. falciparum genome [191] 
to remove the variable of using a novel isothermal assay that has not yet been fully 
optimized. 
I first focused on choosing the appropriate stabilization matrix for Bst. In addition 
to trehalose, I investigated erythritol and mannitol as potential stabilizing sugars because 
previous work showed that both sugars have low solubility (<40%) at room temperature, 
but high solubility (>60%) at the operating temperature for Bst amplification [257].  
Therefore, I hypothesized that the sugars would form a crystalline shell around the 
enzyme to retain stability at room temperature, but this structure would dissolve when the 




bottom of an amplification tube rather than on paper to ensure full rehydration and 
dissolution of the enzyme when the master mix was introduced. The results showed that 
all three sugars did not inhibit amplification, but there was more reliable amplification 
down to 1pg/µL P. falciparum gDNA and less non-specific amplification using trehalose 
and erythritol compared to mannitol (Figure 61A).  
Because I already developed a method to dry Bst on paper using trehalose and 
neither mannitol or erythritol showed significant advantages for stabilization, I moved 
forward with trehalose as a stabilization matrix for Bst on paper. I performed further 
optimization experiments to determine the necessary reaction volume and enzyme 
concentrations to ensure sufficient Bst rehydration from paper for successful 
amplification. I then compared the analytical sensitivity of on-paper amplification to the 
assay in the tube with standard reagents, and showed that reliable amplification could be 






Figure 61: A) In-tube amplification of trehalose-, erythritol-, and mannitol-stabilized Bst 2.0. B) 
Trehalose-stabilized Bst 2.0 on PES paper compared to in-tube amplification. 
 
As I previously described, the goal of this portion of the work is to stabilize Bst 
2.0 on paper to preserve enzyme activity for extended periods of time without the need 
for cold storage. To this end, we stabilized Bst on paper and demonstrated that the 
enzyme retains activity for up to 48 hours at room temperature (Figure 62).  The gel 
electrophoresis results show strong amplification across two days for trehalose-stabilized 
Bst, particularly compared to Bst without stabilizer which completely lost activity by 48 
hours at room temperature.  The real-time amplification results further show that the 
threshold time remained consistent across 48 hours at room temperature for trehalose-
stabilized Bst, while the unstabilized Bst showed later amplification at 24 hours, with no 
amplification at all at 48 hours at room temperature.  Further development is needed to 
determine the extended shelf life and performance of trehalose-stabilized Bst on paper 




storage of Bst 2.0. 
 
Figure 62: Room temperature stability of Bst on paper over 48 hours. Trehalose stabilized Bst 
enzyme retains activity at room temperature while unstabilized Bst completely loses activity 
within 48 hours. 
 
7.4 Conclusion: 
In this chapter, I have reported initial experiments to adapt the iso-IMRS assay for 
use at the point of care. The assay is compatible with DNA extracted from SNAPflex, 
both eluted from the device and amplified directly on paper. I also showed that the iso-
IMRS assay could be translated to visual readout with lateral flow strips, and that 
adapting the assay to visual readout did not impact the analytical sensitivity of the assay, 
but made the technique more amenable to the point of care. Finally, I reported initial 
results toward improving room temperature shelf stability of Bst polymerase.   
The next step for this project is to develop an integrated method for sample-to-
answer readout. I will more thoroughly describe the necessary steps to reach this goal in 




CHAPTER EIGHT: CONCLUSIONS AND FUTURE DIRECTIONS 
Sensitive and accurate diagnosis of blood-borne pathogens is important to 
mitigate the spread of infectious diseases. Nucleic acid amplification tests (NAATs) for 
pathogen DNA or RNA have proven to be some of the most effective tests, particularly 
for infections with low pathogen levels. However, many of the NAATs developed for 
infectious diseases are resource-intensive and impractical to implement at the point of 
care in resource-limited areas, particularly in low- and middle-income countries. To help 
address this problem, I developed two separate technologies for point of care diagnosis of 
blood-borne pathogens: an instrument-free extraction device, and a novel isothermal 
DNA amplification assay. Two specific use cases, HIV RNA detection for viral load 
monitoring and P. falciparum DNA detection for asymptomatic infections, were 
investigated in this thesis. 
Although there is potential to integrate these methods into a single device, our 
conversations with scientists in different field settings indicated that accessing each 
method separately has additional advantages. For example, in remote field testing sites or 
mobile screening facilities, it may be advantageous to run the entire process—sample 
extraction, amplification, and visual readout—from start to finish to enable immediate 
response with the patient. On the other hand, extracting nucleic acids separately from the 
developmental assay enables head-to-head comparison of the assay to gold standard 
methods with the same sample to validate the assay prior to implementation. In other 
settings, such as hospitals or clinics without instrumentation for specific testing, there 




analysis at a central testing lab. Similarly, availability of shelf-stable reagents such as 
would increase access both for gold standard tests and for assay development 
experiments in the field by eliminating the need for cold storage.  
In this way, the methods I developed can be used together or separately to 
increase NAAT access to resource-constrained areas. Both methods developed in this 
thesis represent proof-of-concept starting points; a number of additional directions could 
be pursued to improve upon these techniques. 
 
8.1 Future Directions:  
In Aim 3 of this thesis, I demonstrated that the SNAPflex nucleic acid extraction 
device (Aim 1) is compatible with the novel isothermal amplification assay for P. 
falciparum malaria (Aim 2).  While the extraction and amplification steps were 
performed separately in this work, there is potential to integrate these steps into a single 
device. The Klapperich Lab has previously created integrated sample-to-answer devices 
for infectious diseases using several different sample types [142], [248]–[251].  
Developing an integrated device will require optimization of the extraction and 
amplification steps together to function as a single device with a two-dimensional form 
factor. Additional optimization of the visual readout will be required to eliminate the 
need for a separate ammonium acetate precipitation step prior to lateral flow readout—
perhaps alternative detection methods such as electrochemical readout or colorimetric 
readout of amplified DNA could be explored. The preliminary data presented here 




these data, incorporating dried reagents into the integrated device would eliminate the 
need for cold storage, making the device more readily deployable for Mass Screening and 
Treatment of P. falciparum.  
An additional direction for future work would be further exploration of clinical 
performance of the methods with low pathogen load patient samples, particularly with 
finger prick blood. The experiments described in this thesis were performed with small 
volumes of venous blood spiked with in vitro cultured P. falciparum parasites. All 
“mock” patient samples attempted to replicate finger prick samples as closely as possible 
(i.e. initial dilutions were prepared at volumes >700µL and 100µL samples were drawn). 
However, actual finger prick blood samples show high analyte variability, particularly at 
low concentrations [61]. Therefore, performing a clinical study—of both the SNAPflex 
device and of the isothermal assay— with finger prick blood samples would be necessary 
to fully evaluate their utility in field settings.   
Additionally, it would be beneficial to study whether the assay can detect P. 
falciparum from non-invasive patient samples. Plasmodium parasites are not found in 
saliva, but studies have shown that amplifiable parasite DNA is present in saliva, 
although the mechanism is not known [258], [259]. Initial studies with IMRS 1.0 PCR 
showed that the PCR assay is successful from saliva samples (Chapter 4). Although the 
limit of detection for the iso-IMRS assay is not as sensitive as the IMRS 1.0 PCR assay, 
the isothermal assay may still detect DNA from these samples, particularly using the 
more sensitive lateral flow readout. LAMP isothermal amplification has been tested with 




the iso-IMRS assay targets several regions across the parasite genome and therefore may 
be more successful than LAMP because it is more likely that the primer binding regions 
for are present in saliva samples.  It would be interesting to explore this possibility, 
particularly because saliva collection would be more practical for mass screening and 
treatment than finger prick blood collection [247].  
 
8.2 Summary: 
In this thesis, I have outlined two platform technologies to improve access to 
NAATs in resource-constrained settings. To simplify sample preparation, I have 
developed SNAPflex, a flexible paper-and-plastic device for nucleic acid extraction from 
whole blood. The data presented in Chapter 2 show that the equipment-free, room 
temperature extraction device performs comparably with spin-column based extraction 
kits. In this work, I showed successful extraction of HIV virion RNA and P. falciparum 
parasite DNA, demonstrating that the device can be used for multiple pathogen types. 
Furthermore, captured RNA remains stable for up to 2 weeks at elevated temperatures, 
improving on current dried blood spot sampling. The SNAPflex device enables total 
nucleic acid capture from whole blood, and can be used as a point-of-care extraction 
method for a range of target nucleic acids. Extracted nucleic acids can be eluted from the 
capture membrane (Chapter 2) or used directly on the paper (Chapter 7), and can be used 
in a variety of assays ranging from PCR to isothermal NAATs. Although I have not 
tested other methods, I expect SNAPflex extracted nucleic acids could be used in most 




I have also developed a novel isothermal amplification scheme called iso-IMRS.  
Taking advantage of our collaborator’s computational algorithm to identify short, 
repeated regions in the target genome, I designed an isothermal technique requiring only 
two primers and a single enzyme for amplification. I developed an assay for P. 
falciparum which showed excellent analytical sensitivity: in only 30 minutes, the novel 
iso-IMRS assay reached similar limit of detection to a qPCR assay (Chapter 6). To bring 
the assay closer to the point of care, I have shown that it can be adapted to visual readout 
with lateral flow strips, and outlined initial work toward preserving the assay in a dry 
format (Chapter 7). While this initial demonstration was specific to the P. falciparum 
genome, through the development process I have identified critical parameters necessary 
for this amplification scheme. Therefore, any genome could be analyzed with the 
algorithm, and if repeated regions occur within these design constraints, a similar 
isothermal assay can be developed for the genome of interest. This method would be 
most useful in cases where YES/NO readout is the goal, as multiple genome regions are 
amplified rather than a single target, resulting in substantially improved assay sensitivity. 
Overall, the work presented in this thesis contributes to ongoing efforts to make 
accurate and sensitive diagnostics accessible to resource-constrained settings. These 
methods were designed to integrate into current testing systems so that they may be 
readily implemented at the point of care.  We expect that implementing these methods 
would help close the gap in access between resource-rich areas and resource-limited areas 






APPENDIX I: SNAPFLEX PROTOTYPES AND INHIBITOR STUDIES 
Flexible materials for SNAPflex development: 
Our initial conception of the SNAPflex device used a flexible material rather than 
laminating plastic and adhesive plastic film which create a hard plastic shell around the 
waste pad. Over the course of these prototyping experiments, we identified several failure 
modes for the chip design. The previous iterations are listed below:  
1. Silicone tape (X-Treme Tape Silicone Rubber Self Fusing Tape, 2” width) was cut 
with a Trotec Speedy 100 60W laser cutter (100% power, 20% speed, 200ppi). 
Several geometries were tested in which capture membrane and blotting paper were 
sandwiched between layers of the silicone tape. The results showed poor contact 
between the paper and waste pad and a significant amount of sample leakage around 
the edges of the membrane due to large air pockets, resulting in poor washing of the 
membrane (Figure 63). 
 
Figure 63: Examples of silicone tape devices.  In these examples, waste pad and capture 




2. Rather than sandwiching the membrane and waste pad between silicone tape layers, a 
foldable flap was created to separate the membrane from the waste pad. Washing 
improved, but large air pockets were formed during the sample application (Figure 
64A). Several 3D printed clips were tested to improve contact and reduce air pockets 
(for example, Figure 64B), but were not successful. 
 
Figure 64: Examples of silicone tape devices with flap to separate capture membrane and waste 
pad. The silicone material resulted in air pockets (A) even in the presence of 3D printed 
stabilization clips to minimize air pockets, for example (B). 
 
Based on these results, we determined that the flexible silicone tape material 
would not be effective for the SNAPflex device and moved instead to the laminating 
plastic device described in Chapter 2. The layers of the final waste pad are listed in 
Figure 1 in Chapter 2.  
3D printed components for final SNAPflex device: 
In moving to the final design, my collaborators at MakerHealth developed two 3D 




contact between the waste pad and capture membrane. The laser-cut waste pad is placed 
within the mold and pressed using a Carver Press (without heat); the protrusion created 
on the rounded node of the waste pad improves contact with the capture membrane 
(Figure 65). 
 
Figure 65: 3D printed mold to create pressed waste pad. Pressing the waste pad creates a 
protrusion to improve contact between waste pad and capture membrane. Courtesy of 
MakerHealth. 
 
The second 3D printed component is a reusable stabilization clip to maintain 
contact between the capture membrane and the waste pad (Figure 66). The clip helps 
improve contact and minimize sample leakage between the waste pad and capture 
membrane. After sample application, clip is removed to easily separate the membrane 
from the waste pad for drying and sample collection. 
 
 
Figure 66: 3D printed stabilization clip to ensure contact between capture membrane layer 




Analysis of PCR amplification inhibitors from blood: 
Initial experiments with SNAPflex showed a significantly lower DNA recovery 
than expected (~20% recovery of P. f. gDNA spiked into whole blood). Recovered DNA 
was quantified with qPCR [190] and compared to the initial input DNA concentration to 
determine percent recovery.  
 I hypothesized that poor recovery might be due to inhibitors co-eluted with the 
DNA due to poor washing of lysed blood components. To quantify this problem, I 
performed several matrix experiments, in which I used a negative control blood sample 
processed by SNAPflex and eluted as the dilution matrix (i.e. eluent from no template 
control blood samples) and introduced 1pg/µL P. falciparum gDNA. qPCR analysis of 
these samples showed >30% drop in expected concentration compared to the same DNA 
in clean buffer, indicating that the sample matrix contained inhibitors (Figure 67). 
 







In order to counteract these inhibitory effects, I performed several experiments to reduce 
inhibition of the sample matrix.  
1. Addition of BSA to PCR master mix 
Hypothesis: Residual heme components may inhibit polymerase activity. BSA binds 
and sequesters heme, so adding BSA to the master mix may improve amplification. 
Results (Figure 68): Addition of BSA caused the reaction solution to appear cloudy, 
and increased viscosity, which may have interfered with fluorescence readout. The 
qPCR results showed a decrease in recovery with the introduction of BSA to the 
assay matrix. Experimental results were compared to 1pg/µL P. f. gDNA spiked into 
negative blood eluent (left-most sample). 
 
 





2. Introduction of Mineral Oil on top of PCR reaction 
Hypothesis: Surfactants from the lysis buffer may be eluted into the sample matrix 
and interfere with primer annealing. Adding a layer of mineral oil on top of the 
reaction creates an oil/water interface where the surfactants could be sequestered. 
Results (Figure 69): Recovery increased significantly with the addition of a mineral 
oil layer. However, moving forward, I found that this change was difficult to 
implement and did not continue with this practice. Experimental results were 




Figure 69: Adding a layer of mineral oil to sequester inhibitors at oil-water interface 





3. Introduction of EDTA to the lysis buffer 
Hypothesis: EDTA is a known chelator of magnesium ions. Therefore, adding EDTA 
to the lysis buffer should capture magnesium ions in solution and prevent them from 
impacting PCR amplification  
Results (Figure 70): Including EDTA in the lysis buffer did not impact PCR 
amplification results. Experimental results were compared to 1pg/µL P. f. gDNA 
spiked into whole blood, processed by standard SNAPflex lysis (left-most sample). 
 
 







4. Decreasing MgCl2 in the PCR master mix 
Hypothesis: Whole blood has a high concentration of circulating MgCl2. Mg+2 is a 
co-factor for Taq polymerase and impacts primer annealing; therefore, it is possible 
that excess Mg+2 in the sample matrix negatively affected amplification efficiency. 
Results (Figure 71): Decreasing MgCl2 in the PCR master mix from 3mM to 0mM 
improved assay performance to 0.5mM MgCl2, indicating that excess Mg+2 from 
blood may be carried over into the sample eluent. Moving forward, MgCl2 
concentration in the PCR master mix was adjusted to 0.5mM MgCl2. For these 
experiments, standard curve samples were analyzed with 3mM MgCl2 in the master 
mix, which explains >100% recovery as MgCl2 concentration decreases to 0.5mM 
MgCl2. All samples were 1pg/µL P. f. gDNA spiked into negative blood eluent; 










Based on these results, the MgCl2 concentration in the PCR master mix was 
reduced to 0.5mM for all P. falciparum experiments with SNAPflex. Looking at the 
results of gDNA spiked into a negative sample eluent, I found nearly complete recovery 
of inhibition in the negative sample matrix. However, when gDNA was spiked into whole 
blood prior to SNAPflex processing, I found that sample recovery remained low (~20%) 
even with the new PCR master mix (Figure 72).   
 
Figure 72: Decreasing MgCl2
 in the PCR master mix did not improve results for P. 
falciparum gDNA recovery from whole blood but did reduce inhibition from negative 
sample matrix. 
Based on these results, rather than investigating inhibitors, I worked on improving 
the materials. I found that treating the capture membrane with trifluoroacetic acid 
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